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A major challenge affecting the likelihood of a new drug reaching the market is 
poor oral bioavailability derived from low aqueous solubility. Nanocrystals are 
rapidly becoming a platform technology to address poor solubility issues, 
although several challenges including stabilisation and control of particle size 
distribution for nanosuspensions still need to be addressed. The aim of this 
study was to revisit the simplest approach of re-precipitation and to identify the 
critical parameters, including the effect of different stabilisers as well as 
process conditions. We utilised a combined approach of both experiments and 
molecular modelling and simulation, not only to determine the optimum 
parameters but also to gain mechanistic insight. The experimental studies 
utilised three rather distinct, relatively insoluble drugs, the hypoglycaemic 
glibenclamide, the anti-inflammatory ibuprofen, and the anti-malarial 
artemisinin. The choice of crystal growth inhibitors/stabilizers was found to be 
critical and specific for each drug. The effect of the process variables, 
temperature, stirring rate, and the solute solution infusion rate into the anti-
solvent, was rationalized in terms of how these factors influence the local 
supersaturation attained at the earliest stages of precipitation. Coarse grained 
simulation of antisolvent crystallisation confirmed the accepted two step 
mechanism of nucleation at high supersaturation which involves aggregation 
of solute particles followed by nucleation. 
Recovery of nanocrystals from nanosuspensions is also a technical challenge. 
A novel approach involving the use of carrier particles to recovery the 
nanocrystals was developed and shown to be able to recover more than 90% 
of the drug nanocrystals. The phase stability of nanocrystals along with bulk 
crystals for the model compound glycine was explored using molecular 
dynamics simulation. The simulations were consistent with experimental data, 
a highlight being the β phase transforming to the δ phase at 
temperature >400K and 20kbar respectively, as expected. Nanocrystals of α, β 
and γ glycine, however did not show any phase transformation at high 
temperature.  
In summary the study demonstrates that standard crystallization technology is 
effective in producing nanocrystals with the primary challenge being physico-
chemical (rather than mechanical), involving the identification of molecule-
specific crystal growth inhibitors and/or stabilizers. The developed nanocrystal 
recovery method should enable the production of nanocrystals-based solid 
dosage forms. The molecular simulation studies reveal that crystal-crystal 
phase transformations can be predicted for hydrogen-bonded systems. 
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Chapter 1 
 
 
Introduction 
 
1.1 Statement of the Problem 
A major problem affecting the likelihood of a new drug reaching the market is 
poor oral bioavailability derived from low aqueous solubility. Recent 
publications suggest that many drugs identified by high throughput screening 
are poorly water soluble and belong to the BCS class II family of drugs 
(Lipinski, 2002). These drugs although having  greater tendency to pass 
through the lipophilic intestinal membrane often demonstrate low rate and 
extent of  absorption from the gastrointestinal tract (GIT) which  is typically 
limited by slow dissolution rate (Amidon et al., 1995). Amongst the 
technologies developed to address low aqueous solubility, nanocrystals have 
received notable attention and are rapidly becoming a platform solution due 
to the immense surface area that they present. In principle, methods for 
nanocrystal production can be categorized as top down and bottom-up (Horn 
and Rieger, 2001, Rabinow, 2004)  and include milling, high pressure 
homogenisation (Liversidge and Cundy, 1995, Muller and Akkar, 2004) and  
precipitation by compressed antisolvent (PCA) (Bodmeier and McGinity, 
1998). Rapid expansion from supercritical to aqueous solution (RESAS), 
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rapid expansion of supercritical solution (RESS) and spray freezing into liquid 
have been developed over the past decade (Rabinow, 2004, de Waard et al., 
2010). Each of these methods has notable issues which include high energy 
input, long processing times and uncontrolled particle growth. This study 
aimed to investigate the preparation of stable nanocrystals with a uniform 
size distribution using bottom up controlled precipitation coupled with a 
physico-chemical approach where the focus is on crystal growth 
inhibitors/stabilizers. The experimental study is complemented by molecular 
simulation to provide a molecular rationale for the formation and stabilization 
of these systems, and also to explore the phase stability of nanocrystals 
using the glycine as a model compound. 
This chapter presents the broader background to the study including the 
significance of crystal engineering in pharmaceutical development, principles 
of crystallization and crystal growth, and polymorphism and phase stability. 
This is followed by a critical review of our current understanding of the 
fundamental science and associated technology for preparing stable 
nanocrystals as well as their applications in drug delivery. As the study 
combined both experiment and molecular simulation, we also review and 
present the relevant background to molecular modelling and simulation. 
Finally the aims and objectives of the proposed study are given.  
1.2 Crystal Engineering  
The term crystal engineering was probably first used by Schmidt (1971) with 
respect to photodimerisation reactions in crystalline cinnamic acids. A 
modern and more comprehensive definition has been given by Desiraju 
(Desiraju, 2001), who defined crystal engineering as ―the understanding of 
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intermolecular interactions in the context of crystal packing and in the 
utilization of such understanding in the design of new solids with desired 
physical and chemical properties‖. 
Crystal engineering has enabled researchers to design suitable solid state 
structures by optimising the non-covalent interactions which exist between 
the ionic or molecular components of the structures with desired electrical, 
magnetic, and optical attributes. Hippel (1962) had described the detailed 
background of crystal engineering (von Hippel, 1962). It has also become 
evident that the directionality  of intermolecular hydrogen bonds can 
effectively be utilized to assemble supramolecular structures with a controlled 
resultant dimensionality (Subramanian and Zaworotko, 1995). 
Supramolecular chemistry has been described by Lehn  as the chemistry of 
intermolecular bonds between molecules and the atoms within the molecules 
are connected by covalent bonds (Lehn, 1988).  
The discipline of crystalline engineering is maturing and there are many 
successes where crystalline materials with novel properties have been 
prepared by design across a range of industries including the pharmaceutical 
and health care sector (Steed et al., 2000).  
The increasing cost of therapeutic molecules including products recall from 
the market owing to side effects and quality issues have provided notable 
challenges for pharmaceutical companies in their attempts to improve quality. 
As>85% of dosage forms contain the drug in solid state, pharmaceutical 
engineering represents an important approach to ensure quality and 
performance of these drugs and circumvent barriers to commercial success. 
Low aqueous solubility has adversely impacted the performance of multitude 
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of candidate therapies. More than 40% of the drugs in development pipeline 
and 70% coming from synthesis or high-throughput screening are poorly 
water soluble (Shegokar and Müller, 2010). It is known that poorly-water 
soluble drugs are mostly hydrophobic in nature, having greater tendency to 
pass through the lipophilic intestinal membrane more swiftly. In spite of this, 
absorption of these drugs from GI tract has been found to be erratic. 
However, the oral route of administration for these drugs can still be affective, 
if faster dissolution rate from the GI tract can be achieved (Amidon et al., 
1995).  
On the basis of solubility and permeability through biological membranes, 
drugs can be characterised into four classes as defined by the 
Biopharmaceutical Classification System (BCS) (Figure 1.1). 
 
Figure 1.1 Biopharmaceutical classification of drugs 
 
Owing to high permeability but poor solubility, class II compounds pose 
significant challenges during drug development. These compounds can have 
poor dissolution profiles which can delay the drug‘s onset of action and result 
in low bioavailability. It might be possible to address the issue of poor 
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solubility by increasing the drug dose to enhance exposure of the drug to the 
membrane without serious side effects, but in many cases solubility is so 
limited that negligible increases in exposure are experienced through 
increasing dose. This low aqueous solubility also limits the ability to formulate 
these drugs in an injectable form. It is clear therefore, that this crucial 
problem has been a major hurdle in pharmaceutical development. In this 
regard formulation scientists have been struggling to address poor water 
solubility problems by utilising a variety of approaches  including solid 
dispersions (Serajuddin, 1999), solubilisation (Aungst, 1993),  emulsions 
(Floyd, 1999), microemulsions (Lawrence and Rees, 2000), micronisation 
(Charoenchaitrakool et al., 2000), micelles, salts, liposomes (Schwarz et al., 
1994), and inclusion complexes using cyclodextrin (Loftsson and Brewster, 
1996). These approaches have only been modestly successful. Examples of 
crystal engineering approaches employed to address the poorly soluble issue  
include the use of metastable polymorphs, ultra fine particles, crystal habit 
modification and co-crystal design (Blagden et al., 2007).  A particularly 
notable development is the use of nanocrystals with the specific physical and 
chemical attributes. 
1.2.1 Crystallisation     
Crystallisation is the process by which atoms, ions or molecules assemble to 
pack into a regular three dimensional structure under specific conditions. The 
process is controlled by the driving force, which in solution equates to the 
supersaturation. Supersaturation is defined as the concentration of a 
substance in solution relative to its saturation solubility. More precisely, it 
given by  
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Supersaturation ratio     
 
  
                                              Equation 1.2                                                                 
Where, C is the solution concentration and C* is the equilibrium saturation 
solubility. In chemical engineering, high yields of crystalline materials are 
desired and the following relationship for supersaturation is employed. 
 Supersaturation                                                 Equation 1.3                                                    
Where Css is the supersaturation concentration, Ceq is the equilibrium 
concentration. Clearly, the greater the difference between equilibrium and 
supersaturation state, the greater the driving forces for crystallisation to occur. 
Crystallisation occurs under conditions of supersaturation, where solute 
concentration exceeds the equilibrium solubility of the molecule. Figure 1.2 
shows the different regions that exist for a substance in solution in terms of 
its concentration as a function of temperature. Three distinct zones can be 
observed, the first zone being defined as undersaturation where the 
concentration too low for spontaneous crystallisation to occur. In the 
metastable region the solution is above saturation but is still insufficient to 
induce spontaneous nucleation, whilst in the supersaturated region the 
concentration is well in excess of equilibrium solubility and crystal nucleation 
occurs spontaneously.  
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Figure 1.2 The solubility/supersolubility diagram (Garside and Davey, 2000) 
 
Nucleation represents the first step towards crystallisation and refers to the 
formation of a small stable cluster which has the characteristics of the 
emerging crystalline phase upon which further deposition of solute particles 
occurs. Nucleation can be classified into homogeneous, heterogeneous, and 
secondary nucleation. Homogeneous nucleation begins spontaneously 
without foreign particles/surface. Clusters of molecules comprising 10-1000 
molecules (the actual number depends on the supersaturation) are formed 
which continue to grow once a critical size (stable form) has been achieved. 
Gibbs (1928) and Volmer (1939) investigated the change in free energy 
required for the origination of a cluster which is the sum of change in free 
energy related with the phase transformation (       and formation of 
nucleus surface          respectively. 
                                                                   Equation1.4 
Temperature
C
o
n
ce
n
tr
at
io
n
 (
C
)
Supersaturation phase
Metastable phase
Undersaturation
C
o
n
ce
n
tr
at
io
n
 (C
 )
Temperature
8 
 
In crystallisation process supersaturated is followed by spontaneous 
deposition of solute molecules to form a solid. Owing to high stability 
attributes of the solid state compared to liquid,        becomes negative 
which favours crystal growth. Whilst the newly born solid state creates 
solid/liquid interface which increases the free energy of a system. The 
competition between       and         decides growth of nuclei. High value 
of         causes dissolution of the nuclei. Whereas decrease in        
results in crystal growth. It is shown in the Figure 1.3 at a critical size (r*) of 
nuclei ΔG becomes maximum and the solution is likely to be nucleated. The 
nuclei with a size below the critical size would dissolve back into the solution 
because of the high free energy.  
 
Figure 1.3 Gibbs free energy change as a function of nuclei size 
 
Heterogeneous nucleation occurs when nucleation occurs on or is induced 
by foreign surfaces. A lower level of supersaturation and free energy change 
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is required for heterogeneous and secondary nucleation compared to 
homogenous nucleation (Marashall, 1987). A decrease in the energy 
required for nucleation occurs if the foreign particles and crystals have more 
similar structures.  
In secondary nucleation, nuclei form on the solid surface composed of the 
same solute molecules and generally characterises the process of seeding to 
induce nucleation.  There have been reported several theories including dust 
breeding, collision breeding, dendritic growth and needle breeding to 
understand the mechanism of generation of secondary nuclei and its growth. 
Tig and McCab (1934) has investigated that a seed crystal has a larger size 
compared to the size of nuclei which acts as a nucleation site and induce the 
nucleation process at lower supersaturation level.  In addition, at high 
supersaturation levels the formation of needle and dendiritic crystals has also 
been reported which fragment in the solution and these fragments provide 
new nucleation sites (Myerson, 2002a). Some authors propose that 
macroabrasion of crystals because of high stirring speed results in fragments 
with subsequent new nucleation sites (Myerson, 2002b). Cooke (1966) 
proposed that dendritic growth occurs at a seed crystal surface which could 
be broken down due to fluid shear or due to high coarsening of the dendrites, 
resulting fragments in solution which provide new sites for nucleation. The 
rate of nucleation in a supersaturated solution is represented by the equation 
given as follows 
  
  
         
                                                          Equation 1.5 
Where Kn shows the solute nucleation rate, and Ci and C* represent the 
solute concentration on particle surface and saturation concentration 
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respectively. The value of parameter a has been reported to be between 5 
and 18 (J.A. Dirksen, 1991). The diffusion of the solute particles to the 
surface of the particles is represented by the following equation 
 
  
  
         
                                                    Equation 1.6 
Where Kd is the diffusion rate constant of the solute molecules and C shows 
bulk solution concentration.  Nucleation is followed by growth of the particles. 
The growth rate is given as follow 
  
  
  
        
                                                      Equation 1.7                                                 
Where Kg denotes the particle growth constant. Usually the value of 
parameter b is placed between 1 and 3. However there has been reported a 
higher value of parameter b at higher temperature (Chan and Kwok, 2011). 
Equations 1-3 show that supersaturation can affect both nucleation and 
particle growth. Higher supersaturations result in a higher nucleation rate and 
consequently smaller particle size is achieved (Matteucci et al., 2006). 
1.2.1.1 Crystal Growth  
In supersaturated environments, crystal growth is likely to occur through 
diffusion of solute molecules from the bulk solution towards the crystal 
surfaces, followed by de-sorption and diffusion of the solvent away from both 
the crystal surface and from the solvation shell around the solute particles 
leading to consequent incorporation of solute molecules into the crystal 
lattice (Figure 1.4) (Dirksen 1991). Hartman and Perodck have classified 
faces of crystals as Kinked (K), Stepped (S) and Flat (F) depending on the 
bonds/interaction potentially been involved at the crystal surface (Hartman, 
1973). The K, S and F faces involve three, two and single bonds or 
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interactions respectively (Figure 1.5). The kink sites having the most potential 
interactions are the preferred site for incorporation of the solute molecules 
onto the crystal surface. Numerous mechanisms have been reported for 
crystal growth and some of the common ones are described below. 
Convection and Diffusion  
The convection and diffusion mechanism dominates crystal growth when 
either or both these steps of transport of solute molecules to crystal surfaces 
are limiting. The solvation shell diffuses away from crystal surface before 
integration of the solute molecule in the crystal lattice.  
 
Figure 1.4 Mechanism of crystal growth from solution, adopted from (Elwell and 
Scheel, 1975, Dirksen and Ring, 1991). (I) transport of solute molecules to the 
surface of crystal; (II) adsorption onto the surface; (III) diffusion; (IV) coupling at step 
site; (V) diffusion through step site (VI) Diffusing into the crystal lattice. (VII) Solvent 
molecules diffuse away from crystal surface. 
Kink Site
Step site
(I)
(II)
(III)
(IV)
(V)
(VI)
(VII)
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Figure 1.5 Hypothetical crystal with three main faces: flat (F), step (S) and kink (K) 
faces (Dirksen and Ring, 1991) 
 
(b) Surface Nucleation 
Crystal imperfections, surface roughness or the ledges of growth layers can 
provide growth sites for incoming molecules. As the roughness of the crystal 
surface decreases or as the layers become complete, there are few if any 
incorporation sites and the solute molecules return back into solution. For 
further growth to occur a new layer has to be created which requires 2-d 
surface nucleation. Figure 1.6 shows surface nuclei which present new 
kinked sites enabling adsorption of additional units. These nuclei spread 
laterally across the surface with subsequent growth occurring normal to the 
plane of the face. 
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Figure 1.6  Development of crystal nuclei on the surface of growing crystal (Garside 
and Davey, 2000) 
 
 (c) Dislocation or Spiral Growth 
Crystal dislocations generate step and kinked sites on crystal surface which 
provide opportunity for new molecules to be adsorbed on the surface. The 
newly emerging lines of dislocation result in growth patterns while removing 
the need for surface nucleation. In this respect screw dislocations are 
considered paramount as they provide a never ending steps for molecule 
incorporation, producing spiral growth on the crystal surface (see Figure 1.7). 
This mechanism of crystal growth was proposed by (Frank, 1949) and the 
presence of screw dislocations was confirmed only much later by means of 
electron microscopy. Burton,Caberera and Frank also envisaged a theory to 
promote crystal growth using the screw dislocation mechanism where the 
shape of spirals  affect the rate of crystal growth (Burton et al., 1951) 
14 
 
 
Figure 1.7 Development of growth spirals originating from a screw dislocation 
(Mullin, 2001) 
 
1.3 Crystal Polymorphism 
Compounds which can exist in more than one crystalline form are considered 
to polymorphic and the differing phases are termed polymorphs. In 
pharmaceutical products, the existence of polymorphs is critical to product 
development owing to their unique characteristics (Byrn et al., 1994). In 
crystallisation, the most stable form may not be directly produced but is often 
isolated after subsequent transformation in accordance with Ostwald‘s rule of 
successive (Ostwald, 1897).  One of the techniques which is used to obtain 
the required polymorph of a drug is through the choice of specific solvents, 
variation in crystallisation conditions, and by inclusion of specific impurities. 
The inclusion of appropriate impurities may inhibit the transformation of the 
required metastable crystal form to the most stable phase. An example of the 
use of impurities for controlling polymorphism is that involving glutamic acid. 
Trismisic acid has been used as an impurity, which is conformationally similar 
to the stable form of glutamic acid. Rapid growth of the stable form is 
therefore inhibited in the presence of this substance resulting in the 
production of the metastable phases (P.T. Cardew, 1985) 
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Polymorphs can have different physicochemical and mechanical properties 
(Singhal and Curatolo, 2004). In pharmaceutical industries >85% of the 
products contain active pharmaceutical ingredients (APIs) and excipients in 
crystalline forms (Erdemir et al., 2009), therefore it is paramount to 
understand the physicochemical properties of API and excipients before 
there are  formulated into a solid dosage form.  From drug development 
prospective, selection of an appropriate crystalline form of a drug compound 
and its respective polymorphs is considered very important to ensure the 
original crystal form of API is stable in the final product. Polymorphism can 
have significant effect on dissolution and bioavailability of drug compounds 
(Zhang et al., 2004). Aguiar (1967) investigated that different polymorphs of 
chloramphenicol palmitate have different dissolution rate and bioavailability. 
For good economic purposes, pharmaceutical companies are showing 
extensive interest in formulation of solid dosage forms with a polymorph of 
APIs that has enhanced dissolution rate and bioavailability but is stable. How 
polymorphs behave when subjected to certain unit operation processes 
including milling, granulation, compaction, drying and heating is also 
important as these processes can cause phase transitions in the crystalline 
forms of API and excipients (Zhang et al., 2004). Phase transition between 
polymorphs can induced by high pressure, temperature or exposure to high 
humidities  (Kitamura, 2002, Moggach et al., 2008) 
Two types of phase transition in polymorphs have been reported: monotropic 
and enantiotropic (Giron, 2001). The irreversible phase transition in 
polymorphs is known as monotropic. This transition occurs from metastable 
to stable form of a crystal either by heat or stressing the system using 
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mechanical forces including compaction and milling. In monotropic phase 
transitions the polymorph with the high melting point is always the stable form 
(Figure 1.8 (b)). Enantiotropic phase transition is the reversible phase 
transition between a pair of polymorphs which occurs at a transition 
temperature (Tt) and the polymorphs are known as enantiotrophs to each 
other. During a heating process, if a temperature is below the transition 
temperature, the system would be monotropic but above Tt, the more stable 
polymorph is obtained. Figure 1.8 (a) shows that below Tt polymorph A is 
stable while at temperature above Tt  polymorph B becomes 
thermodynamically more stable because of low free energy compared to 
polymorph A.  
 
 
Figure 1.8 Schematic representation of (a) enantiotropic (b) monotropic and phase 
transitions. In enantiotropic phase transition the polymorph A is stable below 
transition temperature (Tt) whereas above Tt the polymorph B becomes more stable 
compared to A. In monotropic phase transition the polymorph B is more stable 
because of high melting point (TB) compared to A which has low melting point (TA). 
 
1.3.1 Nanocrystals and their Method of Preparation 
Nanocrystals have been defined as  crystalline particles with at least one 
dimension less than or equal to 100 nm (Fahlman, 2007). However, there is 
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still no general agreement as to the definition of ―nano‖ (Van Eerdenbrugh et 
al., 2008) in the pharmaceutical literature. According to a number of authors 
nanocrystals are crystalline particles that have a size below 1 micron and 
consist of drug component with minimum amount of surface active agents 
required for its stabilisation (Gao et al., 2008). Owing to particle size being 
below one micron and the resulting high surface area to volume ratio, 
nanocrystals have the potential to improve dissolution rates of hydrophobic 
drugs with consequent increase in bioavailability (Patravale and Kulkarni, 
2004).  
 
Figure 1.9  Distinctive characteristics of nanocrystals after (Muller et al., 2011) 
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Nanocrystals can remove poor solubility issues  of BCS class II drug 
molecules due to their distinctive features which include increased saturation 
solubility, higher dissolution velocity, and fast adhesiveness to cell membrane 
(Müller et al., 2011) (Figure 1.9). 
Nanocrystals can be prepared using a variety of methods which can 
generally be classified into the following two categories. 
(a) Top down approaches (Rabinow, 2004) 
(b) Bottom-up approaches (Patravale and Kulkarni, 2004) 
Top down methods rely upon size reduction by which large particles of drugs 
are broken down by attrition into smaller particles. In contrast, bottom-up 
processes involve building the nanocrystals up from the molecular state 
generally by crystallisation. Figure 1.10 represents the general principle 
employed for production of the nanocrystals by the two approaches. 
 
Figure 1.10 Two commonly used approaches for production of nanocrystals 
 
1.3.1.1 Top down Approaches 
Size reduction methods which utilises top down principles include media 
milling (Nanocrystal R), high pressure homogenization (HPH) in water 
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(Dissocubes, Skype Pharma) and   combined precipitation and HPH 
(Nanoedge, Baxer). In the media milling method, the major forces 
responsible for breaking of the particles are provided by the milling media, 
which can be cross linked polystyrene resin, stainless steel, alumina, 
zirconium stabilized with yttrium, glass or zirconium oxide ((Muller, 2001, 
Liversidge et al., 1992). Typically the size of the starting materials is less than 
the 100 µm whilst the final size of the resultant particle is less than 400nm 
(Liversidge and Cundy, 1995, Liversidge et al., 1992, Merisko-Liversidge et 
al., 2003). The HPH approach produces nanosuspensions by exploitation of 
high shear forces, cavitation and continuous collision of the particles as the 
drug suspension is pushed through a narrow gap of 25µm. The number of 
homogenization cycles and associated homogenization pressure are the key 
parameters that have influence on particle size. A third important approach is 
precipitation combined with HPH (Nanoedge), where the nanosuspension 
produced by a precipitation process is stirred using high stirring forces 
producing a resultant nanosuspension with long term stability. All top-down 
approaches have the capacity to produce low and high concentration (1-
400mg/ml) nanosuspensions with particle size less than 400nm. Drugs which 
are simultaneously poorly soluble in organic and aqueous media however 
have limitations with these methods. Other issues include contamination of 
the final product with milling media and high cost equipment (Patravale and 
Kulkarni, 2004). 
1.3.1.2   Bottom-up Approaches  
The bottom-up approach involves precipitation from solution where the 
hydrophobic drug is dissolved in organic solvent which is then mixed with a 
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stabiliser solution that is typically aqueous. The aqueous stabiliser solution 
acts as an anti-solvent and on mixing and causes supersaturation leading to 
consequent precipitation of the nanocrystals. A number of different methods 
utilise the basic principle of bottom-up approach, a notable one being 
precipitation by compressed antisolvent (PCA) which utilises supercritical 
CO2 as an antisolvent in which drug and polymer solution is injected into the 
chamber which contains CO2 in compressed form to yield nanocrystals 
(Bodmeier and McGinity, 1998). 
Another variation is rapid expansion from supercritical to aqueous solution 
(RESAS) (Rabinow, 2004, de Waard et al., 2010).Poorly soluble drugs in the 
presence of stabiliser solutions are nucleated and consequently stabilised in 
nanosuspension form.  
Spray freezing into liquid process (SFL) was developed by the University of 
Texas at Austin in 2001, in which a drug/excipient is directly atomized into 
compressed liquid, typically CO2, helium, ethane, argon or hydrofluroethane. 
Use of this approach produces frozen nanoparticles which can be isolated as 
a solid by lyophilisation (Williams et al., 2002).  
Evaporative precipitation into aqueous solution (EPAS) utilises organic 
solvents having low boiling points in which the drug is first dissolved before 
being pumped through a heated tube which heats the solution above the 
normal boiling point of the solvent. This heated solution is sprayed through a 
narrow atomized nozzle into a heated aqueous stabiliser solution which 
results in precipitation of a nanosuspension (Williams et al., 2002). Physical 
instability has been a major issue with nanosuspensions prepared using 
bottom approach. Nanosuspensions with broader size distribution result in 
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differential dissolution rate of API. Smaller particles are thermodynamically 
unstable relative to larger particles which results in dissolution of the small 
particles in favour of deposition over the surface of the large particles. This 
phenomenon is referred to as Ostwald‘s ripening and results in physical 
instability of nanosuspensions. Lindfors (2004) developed a novel bottom-up 
process to control Ostwald ripening process. Miglyol (a medium chain 
triglyceride) was selected as a crystal growth inhibitor and dissolved in the 
solvent containing the drug, which when mixed with the anti-solvent resulted 
in a stable nanosuspension (Lindfors, 2004). 
Microchannel reactors (MCR) have also been investigated for production of 
stable nanocrystals, where solutions containing hydrophobic drug and 
aqueous stabiliser solutions are passed through the microchannel feeds from 
their respective storage containers. Mixing of the two solutions at the contact 
points of the two channels results in precipitation and consequent production 
of the nanoparticles (Buzea et al., 2007). Nanosuspension with narrow size 
distribution can be produced by controlled parameters of the MCR set up 
(Zhao et al., 2007). The methodology however does not readily scale up and 
the reactors are prone to blockages. 
Perhaps the simplest and cost-efficient bottom-up method is controlled re-
precipitation. The challenge here is to obtain stable nanocrystals for a range 
of drugs, and also to be able to deal with drugs that have a low solubility in 
both aqueous and organic media.  
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1.4  Characteristics and Performance of Nanocrystals 
1.4.1  Stabilisation of Nanocrystals 
When particle size is reduced new surfaces are formed leading to increased 
surface area and consequent increases in free energy. The rate of 
agglomeration is directly proportional to the free energy of the particles. 
Equation 1.8 represents this relationship 
                                                                    Equation 1.8 
Where γs/l the interfacial tension which determines the stability of the particles 
but can be reduced by inclusion of a suitable surface active agents and ΔA 
represents the change in surface area associated with reduction in particle 
size (Rabinow, 2004). It has been reported previously that lack of Ostwald 
ripening is a favourable condition for long term stabilisation of 
nanosuspensions (Peter and Muller 1996). Ostwald ripening is one of the 
challenging issues associated with the crystal growth in nanosuspensions 
prepared by both top down and bottom up methods. The broader size 
distribution of nanosuspensions is one of the well-known reasons which 
cause crystal growth by Ostwald ripening (Patravale et al., 2004). Owing to 
high saturation solubility the small particles are diffused towards the 
surroundings of larger particles. The relationship between the saturation 
solubility and particle size has been described by Ostwald Freundlich‘s 
equation (Equation 1.10) which shows that smaller particles have high 
saturation solubility compared to the larger particles. Additionally the smaller 
particles have high surface to volume ratio and free energy which tend to 
diffuse towards the large particles. The solution around the large particles 
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becomes supersaturated because of the high concentration of the small 
particles in the surroundings with subsequent integration into the large 
particles and crystal growth. In addition due to depletion of the area 
surrounding the small particles the solution is no longer saturated resulting in 
dissolution of the drug and complete elimination of the small particle zone. 
Inhibition of Ostwald ripening in nanosuspensions is still an issue which 
needs to be addressed. Selection of appropriate polymers and surfactants 
can play an imperative role to address this issue. Moreover, surfactants and 
polymers can stabilise nanosuspensions by electrostatic and steric 
mechanisms of stabilisation. Non-ionic surfactants or polymers form a layer 
on the surface of nanoparticles and prevents their agglomeration by blocking 
motion towards one another. When the two particles surrounded by an 
adsorbed no ionic surfactants or polymers approach each other there would 
be increase in polymeric or non-ionic surfactant concentration between the 
particles which will increase the total energy with a subsequent repulsion of 
the particles (Van Eerdenbrugh et al., 2008). Electrostatic stabilisation by 
charged surfactants provides a barrier to agglomeration which is achieved by 
repulsive interactions between the electrical double layers around the 
approaching particles in nanosuspension. The concept of the energy barrier 
and its prevention of interactions between  particles has been described by 
the DLVO theory (Derjaguin, 1941) (Figure 1.11). The interactions of the solid 
particles in liquid dispersion are described by this theory in two ways. Either 
attraction or repulsion forces among the components of the dispersion can 
occur. Forces of attraction between particles include, van der Waals forces 
alongside repulsion forces resulting from the electrical double layers. In 
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addition there is another type of force that can also exist which comes from 
the shell of solvent molecules around the drug particles which could either be 
attractive or repulsive. 
In electrostatic stabilization the stabilizer will affect the repulsive electrostatic 
energy (vel). It has been shown clearly in the classical DLVO diagram that a 
perfect barrier does not allow the particles to agglomerate by achieving the 
required Lifshitz-van der Waals energy (Vlw). Thus repulsive force is 
produced due to this barrier. 
 
Figure 1.11  Variation in potential energy against the inter particles distance. Vlw = 
Lifshitz van der Waals energy and Vel shows electrostatic energy (Classical DLVO 
theory). 
 
1.4.2  Absorption and Bioavailability  
The rate of dissolution of solid substance can be described by the Noyes–
Whitney dissolution model (Noyes and Whitney, 1897). 
Energy barrier
V total
Vlw
Distance
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                                                        Equation 1.9 
 Here dc/dt shows the dissolution rate, A is the drug surface area to be 
dissolved, D represents the diffusion coefficient, Cs is the saturation 
solubility , Cx and h show the bulk concentration of drug and thickness of the 
diffusion pathway respectively. Unquestionably, the above model indicates 
that the greater the surface area of drug particles, the faster the dissolution of 
the drug with subsequent quick release of drug resulting in faster absorption 
through intestinal membrane. Owing to the smaller particles size, 
nanocrystals having immense surface area which can lead to higher 
dissolution rates and result in faster absorption and consequently higher 
bioavailability for therapeutic agents. Although the benefits of nanocrystals 
are primarily accrued from vastly increased surface area, increases in 
saturation solubility are also believed to be possible, especially in the sub 
100 nm size range, with consequent increases in dissolution rate as 
described by the Freundlich Ostwald equation (Müller and Peters, 1998) as 
shown in Equation 1.10 
                                                                 Equation 1.10 
where   is the saturation solubility of the nanoparticle,   is the saturation 
solubility of the large crystals, γ is the interfacial tension of the crystal-
medium interface, M is the molecular weight of the compound, r is radius of 
the particle, ρ  is the density, R is the gas constant and T is the temperature. 
At particle sizes of ≤100 nm the stated equation predicts increases in 
solubility of approximately 10-15 %. Increases in solubility in excess of 50% 
have however been reported as the particle size is reduced from 2.5 µm to 
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300 nm (Müller and Peters, 1998). Additional relationships between surface 
curvature, vapour pressure and particle size are also described by the Kelvin 
equation (Böhm and Müller, 1999). According to this relationship, smaller 
particles with increased surface curvature have been shown to demonstrate 
markedly higher vapour pressure compared to coarser micron sized particles. 
The transfer of molecules from liquid to gas has been reported to be identical 
to transformation of molecules from solid phase to liquid medium. The 
dissolution pressure therefore becomes equivalent to vapour pressure which 
is likely to be increased for smaller sub-micron particles (Junghanns and 
Müller, 2008).  
 
Figure 1.12 Comparative absorption mechanism of micro and nanocrystals from gut 
lumen. Adopted from (Mauludin et al., 2008). 
The use of nanocrystals in particular for increasing surface area, dissolution 
rate and bioavailability is fast becoming a platform solution (Muller, 1999) 
(Figure 1.12).   
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1.5 Molecular Modelling and Simulation 
Molecular modelling and simulation is the application of computational 
techniques to model the behaviour of molecules and molecular systems 
using atomic theory and inter-molecular forces.  
The paramount feature of molecular simulations is to provide insight into the 
molecular level description of a system. Additionally molecular simulation can 
yield dynamical information e.g. diffusion coefficient and thermodynamics 
quantities such as free energies.  
The methodology provides insights into how molecules react or interact and 
hence in a way provides atomic resolution in the behaviour of collections of 
molecules comprising complex systems. The technique is receiving 
increasing attention in computational biology, computational chemistry and 
material sciences complementing the traditional experimental approaches. In 
combination with experiments, the simulations help to rationalise 
experimental results and also aid the design of better experiments.  
There are different levels to describe the intermolecular forces in molecular 
simulations. For example when electronic structures become important then 
quantum mechanics which is computationally more expensive approach is 
likely to be employed.  On the other hand, in molecular simulations using 
molecular mechanics approach, no bond formation and breaking occurs and 
integrity of the molecules are retained.  Therefore it is worthwhile to employ 
molecular mechanics approximation which is the less expensive 
computational approach while enabling the simulation of 100000 atoms using 
standard computing laboratory facilities.  
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1.5.1 Quantum Mechanics                                                                                          
Quantum mechanics models focus on electrons and their distributions 
towards describing molecular structures and the derived properties of these 
systems including energies. Quantum mechanics models are considered 
paramount for investigating chemical reactions in which covalent bonds are 
broken and formed. The basic quantum mechanics model for a molecular 
system is based on the time dependent Schrödinger's equation which takes 
the following form (see Equation 1.11). 
                                                                                Equation 1.11 
where H is the Hamiltonian of the system, Ψ is the wave function, which is 
considered to represent the coordinates of the electrons and nucleus and E 
is the energy of the system. The Hamiltonian represents the sum of the 
kinetic and potential energies arising from the interaction of nuclei n (A+B) 
and electrons and takes the form  
                                                      Equation 1.12 
Where Kn and Ke are the kinetic energies of the nuclei and electrons 
respectively. Whilst Une, Uee and Unn are the nucleus – electron, electron – 
electron and nucleus –nucleus potential energy terms respectively.  
Schrödinger's wave equation is a many-body equation and can only be 
solved exactly for hydrogen and for helium. For more complex atoms which 
have more than one electron and molecular systems it is necessary to use 
approximations. For example Born–Oppenheimer approximation suggested 
that the equilibration of electrons is not dependent on the movement of nuclei. 
Nuclei can be considered as static objects being heavier and which move 
very slowly compared to the electrons (Goodman, 1998). Nevertheless these 
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methods are computationally intensive which restricts this approach to 
systems that involve bond making and breaking and where the electronic 
structure is important.  
1.5.2 Molecular Mechanics 
Molecular mechanics utilises the principle of classical mechanics to model 
the geometry and dynamics of the molecules. In molecular mechanics, atoms 
are considered as spheres whose effective radii are determined either by 
theoretical or experimental approaches. Whereas bonds are treated as 
springs which can be stretched, bended and twisted. The stiffness attributes 
of the bonds rely on the bonded elements and types of bonds which include 
single, double and covalent bonds. In addition the non bonded interactions 
including van der Waals and electrostatic interactions are also considered. 
Molecular mechanics models give the static energy or the total potential 
energy which is obtained by adding up all the potential terms describing the 
bonded and non-bonded interactions. The potential function takes the 
following form  
                                                                 
                                                                                         (Equation 1.13)              
This set of bonded and non-bonded interaction energy terms together with 
associated parameters for the different atom types is called a force field 
(Figure 1.13). The important interaction potentials are described as follow. 
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Figure 1.13 Common potential terms representing a typical force field 
 
(a)  Bond Stretching 
The bond stretching energy, Ustretching, is that required to stretch the bond 
between two given atoms from the equilibrium bond length lo (see Figure 
1.14). It is represented by 
            
 
 
       
                                            Equation 1.14 
Where K shows the force constant for the bond, and lo is the equilibrium bond 
length. For calculation of Ustretching two parameters (lo and K) must be 
known (Jensen, 2007).  
 
Figure 1.14 Representation of bond stretching 
 
Torsion
Van der Walls and 
Electrostatic Interactions
A B
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(b)  Angle Bending 
Ubending is the energy associated with bending of the angle between three 
atoms ABC (see Figure 1.15) and takes the following form: 
         
 
 
        
                                         Equation 1.15 
Where   is angle between atoms I, j and k. At least two parameters KΦ and 
Φ0 are required to determine Ubending , which can be obtained by IR 
spectroscopy and x-ray diffraction respectively. 
 
Figure 1.15 Representation of valence angle bending 
 
(c)  Bond Torsion 
Utorsion is the energy associated with the rotation of a single bond in a chain 
of four atoms (I, j, k, l) connected each other. Rotation about bonds gives rise 
to the different conformations that a molecule can adopt. For example ethane 
has two conformations namely staggered and eclipsed. The stable conformer 
of ethane is the staggered form with lower energy in which the hydrogen 
atoms do not exist in the same plane on carbon atom, owing to repulsion 
between the electrons orbitals of the hydrogen atoms (see Figure 1.16).  
 
 
i
j
k
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Figure 1.16  Conformation in ethane molecule 
 
The value of torsion energy is usually low compared to the bending and 
stretching energy (Jensen, 2007). Utorsion is represented as follow (Equation 
1.16).  
                                                              Equation 1.16 
Where A is the barrier for rotating around the bond, m is the periodicity 
parameter and ζ shows reference angle. For instance m = 3 in sp3-sp3 bond 
and ζ =0, and m = 2 and ζ = 180 in sp2-sp2 bond (Ullmann, 2007).   shows 
torsional angle between I, j, k and l. 
(e) Van der Waals Energy 
Van der Waals interactions represent the sum of attractive and repulsive 
forces between non bonded atoms. Atomic nuclei are surrounded by a cloud 
of electrons and the respective size of the atom is measured by van der 
Waal‘s radius. When two atoms are at equilibrium distance which is equal to 
the sum of their van der Waals radii, a substantial energy will be required to 
bring them more closer (Figure 1.17 a). This is because of the repulsive 
forces resulting from interaction of the electronic clouds. Whereas when two 
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atoms are at optimum distance from each other, energy will also be required 
to pull them apart owing to induced dipole interactions (Figure 1.17 c).  
 
Figure.1.1 Van der Waals interactions 
 
Various potentials are employed to establish the van der Waals potential 
energy relationship between atoms as a function of separation distance. The 
Lennard-Jones potential (Smit, 1992, Verlet, 1967) is however the most 
efficient and computationally acceptable term which takes the following form   
         
 
   
        
                                        Equation 1.17 
Herein 1/r12 represents the repulsive term which is likely to be dominated at a 
short distance. Whilst 1/r6 shows the attractive part which dominates more at 
longer distances, ζ is the collision diameter at a distance where the energy is 
zero and ε is the magnitude of the maximum attraction energy (Jensen, 
2007)(see Figure 1.18). 
 
Atoms far apart attracted 
With van der Walls forces
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Figure 1.18 The Lennard-Jones potential. 
 (d) Electrostatic Potential 
Atoms within molecules exist with partial charges due to different 
electronegativity values that result in electrostatic interactions between 
molecules. These forces of interactions include charge –charge interactions, 
charge – dipole interactions and dipoledipole interactions. For example, in 
the carbonyl functional group there is a partial negative charge on the oxygen 
and a partial positive charge on the carbon atom. The positive head group of 
one molecule is attracted by negative group of the other molecule. 
Electrostatic potential is based on Columbic equation which takes the form: 
     
    
       
                                                  Equation 1.18 
Where QiQj are the charges on atoms i and j respectively, ε0 is the dielectric 
constant and rij is the separation distance between. 
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1.5.3 Molecular Simulation Methods 
There are two important methods of molecular simulations: Monte Carlo and 
molecular dynamics simulation.  
1.5.3.1 Monte Carlo Method 
At the end of Second World War von Neuman, Ulam and Metropolis 
developed the Monte Carlo method to investigate the diffusion of neutrons in 
fissionable materials (Meteopolis and Ulam, 1949). This method was named 
after the well known casino ―Monte Carlo casino‖ in the capital city of Monaco. 
This method utilises random numbers and probability to solve a range 
problems. This method has widespread application which includes evaluation 
of definite integrals in mathematics to calculations of risk in business. In 
molecular simulations, this method is used to determine the equilibrium 
structure and properties of molecular systems by moving individual atoms or 
molecule randomly and calculating the energy of the new configuration to 
assess the feasibility of the configuration. The choice of accepting or 
rejecting a move is based on criteria, which for molecular simulations is 
typically that of Metropolis(Metropolis et al., 1953). Thermodynamic 
properties of the system are calculated by taking the average of the physical 
properties of all molecular configurations generated over the entire period of 
simulation once the system has equilibrated.  
1.5.3.2  Molecular Dynamics (MD) Simulation 
During the 1970s molecular dynamic simulations received widespread 
attention owing to the emergence of powerful computers. Molecular 
dynamics simulations employ Newton‘s equations of motion to generate a 
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trajectory of the molecular motion of interacting molecules, the interactions 
being described by a forcefield.  At the heart of the method is Newton‘s 
second law: 
                                                                     Equation 1.19                                                                
F is the force acting on the atom, whereas m and a show mass and 
acceleration of the atoms respectively.  
The most widely used integration algorithm to solve the equations of motion 
is Verlet algorithm which takes the following form 
                            
      
  
               Equation 1.20 
This algorithm enables the calculation of the new positions of atoms ri (t + Δt) 
at time t + Δt using the positions ri (t) and acceleration ai (t) at the present 
time t and the positions ri (t –Δt) from previous time (t - Δt).  
The initial atomic positions usually come from either by X-ray or neutron 
diffraction or may be generated based on intuition. In principle, if the system 
has no strong barriers the system should converge from any starting 
configuration to the equilibrium structure in the simulation. 
1.5.3.3  Statistical Mechanics 
The MD simulations explore the molecular level behaviour whilst our interest 
is primarily on the macroscopic properties of the system which include 
average structure and dynamics, and also thermodynamic quantities such 
enthalpy and free energy. The link between the microscopic level information 
such as atomic position and velocities and the macroscopic properties is 
statistical mechanics (Leach 2001). The macroscopic properties are actually 
the averages of microscopic properties which are obtained from the 
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instantaneous state of the system. In statistical mechanics, an ensemble is 
an assembly of all the possible configurations that a system can exist in. A 
configuration here is defined here as a microstate for which the atomic 
positions and momenta of all the atoms in the system have a given set of 
values. If the momentum or coordinates of one of the particles is changed, 
we have a new configuration. To link the microstates to thermodynamics a 
number of statistical mechanical ensembles have been defined, which enable 
the comparison of calculated thermodynamic quantities to be with real world 
experimental values. The important ensembles are given below:  
(a) NVE; This ensemble is also called microcanonical ensemble where 
the number of atoms (N), volume (V), and energy (E) are fixed. 
(b) NPT;   Isobaric –isochoric ensemble ( in this ensemble the number of 
atoms (N), pressure (P) and temperature (T) are fixed. This 
corresponds to experiments at constant temperature and pressure. 
(c)  NVT ;    Canonical ensemble (a system where the number of atoms (N), 
volume (V) and  temperature (T) are constant. 
(d) NST; This ensemble is characterised as a system where (a number of atoms 
N,  stress ζ and temperature T are kept constant ) 
 
 
1.5.3.4  Simulation Cell and Periodic Boundary Conditions 
In MD simulations the atoms to be simulated are contained in a three 
dimensional container which is termed a simulation cell. Such a simulation 
cell does not have solid interacting walls and hence has surfaces. Therefore 
the collection of molecules contained in the cell will be exposed to vacuum. 
For a typical simulation, the volume element comprising the molecules will be 
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small and surface effects will dominate. In view of this the molecular system 
being simulated cannot be seen as bulk. To remove surface effects, the 
simulation system has periodic boundary conditions wherein the cell is 
effectively replicated all round the original simulation cell.  Figure 1.19 shows 
a simulation cell with a dark background surrounded by eight identical cells 
which are formed by replication of the central simulation cell. Each of these 
cells contains periodic images of the atoms present in the original simulation 
cell. If some of the atoms leave the central simulation cell they re enters to 
the central simulation cell from the replicate cell at the opposite side. For 
example in Figure 1.19 the simulation cell shown with red lines does not have 
atoms 1 and 2 but atoms 1‘ and 1‘ which are images of the 1 and 2 re enters 
from the left side. Nonetheless PBCs can cause complication where, for 
example, an atom interacts twice either its own image or the same atom. An 
interaction cut off radius rcut is considered to be important to overcome this 
problem. The interaction cut off should not be more than half of the 
dimension of the simulation cell. Cut off radius plays an important role in MD 
simulation to minimise the necessary calculations with subsequent accurate 
model (Leach, 2001).  
During MD simulations the particles move by a time stepping procedure 
which is based on a characteristic time step. The simulation time step should 
neither be too small nor large, because a small time step will require a large 
number of steps to sample a trajectory of a system for a fixed time period. 
Whilst using too large time step can cause high energy overlaps between 
atoms with consequent instability of the system (Leach, 2001). Constraints 
can be employed to fix the bond lengths and angles of flexible molecules to 
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allow the users to run a simulation for a large time step. The bond stretching 
frequencies and bond angle bending frequencies are of the order of 30ps-1 
and 10ps-1respectively. Therefore to eliminate  the high frequency 
components of the molecules, the bond lengths are often constrained (Van 
Gunsteren and Karplus, 1982) . As a result of this, the time step for 
integrating equations of motion can be increased with consequent improved 
efficiency of the MD simulation. 
 
Figure 1.19 Simulation cell showing periodic boundary conditions in two 
dimensions. The central shaded box is surrounded by its periodic images. In the 
central box there are five molecules and the sky blue circle shows cut off for 
interaction. If some molecules for example 1 and 2 leave the central box then the 
counterparts (1' and 2') renter from the surrounding box.    
 
1.6 Molecular Simulation of Crystal Growth and Nucleation 
It is extremely difficult to investigate the crystal nucleation and growth, 
particularly the earliest stages of crystallisation, at the molecular level using 
experimental approaches. Molecular dynamics simulations can therefore be 
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employed to investigate the mechanics of crystallisation processes (Anwar 
and Boateng, 1998). According to classical homogeneous nucleation theory, 
the formation clusters of solute molecules occur before nucleation (Bennema, 
1974). It has been inferred from  experiments that order in solute molecules 
occurs prior to nucleation and crystal growth (Sohnel and Garside, 1988, 
Larson and Garside, 1986). There have been different arguments towards 
the structure of prenucleation clusters. Weisbuch (1994). Ya and Velikov 
have concluded that the arrangement of molecules within the prenucleation 
clusters were similar to that associated with the newly formed crystals. 
However other researchers do believe that composition and structure of the 
prenucleation clusters are rather different than the eventual crystalline phase 
of the compound (Oxtoby, 1998). To date, there is little proper understanding 
to investigate the origin of secondary nucleation (Myerson, 2002a). In 
addition, the effect of impurities and additives on crystallisation is still the 
focus of experimental studies. It is possible that the nucleation process could 
be promoted, inhibited or retarded by appropriate additives (Weissbuch et al., 
2003). Nucleation in solution is followed by crystal growth which involves 
different processes in bulk solution, adsorption layer near to the crystal 
surface and crystal surface itself. For example diffusion of solute molecules 
to the adsorbed layer around the crystal surface and subsequently 
incorporation of the adsorbed molecules into the crystal lattice (Weissbuch et 
al., 2003). Hypotheses which include surface roughening  and solvent 
adsorption on crystal surface have been reported to influence the molecular 
level interactions and the effects of solvent on crystal growth (Bourne et al., 
1978). However explanation of these mechanisms still remains challenging 
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using experimental approaches.  MD simulations have therefore been 
employed to investigate the interaction of solvents at crystal surfaces 
(Hussain and Anwar, 1999), processes in adsorption layer near to the crystal 
surface (Huitema et al., 1999) and crystal growth and dissolution (Piana and 
Gale, 2005, Cheong and Boon, 2010)  
1.7 Simulation Approaches to Nanocrystal Stability and 
Phase Transformation 
Stability of nanocrystals has become a major hurdle in exploiting their special 
properties. In this regards molecular simulations could help to improve the 
methodology for nanoparticle production. As the crystal size decreases its 
surface area and interfacial free energy increase compared to its bulk free 
energy which can result in aggregation and crystal growth in suspension. 
Typically a range of experiments are employed to rationalise surfactants and 
polymers for stabilisation of nanocrystals in a required phase.  Molecular 
simulation could be used to ascertain the key factors and develop strategies 
for stabilisation.  
Phase stability is another issue associated with nanocrystals. When a particle 
size is reduced, the surface free energy becomes more significant and the 
difference in surface energies between different polymorphic forms could 
determine which phase is the stable one on the nanoscale range. Thus a 
particular phase could be stable in the bulk and yet be unstable in the 
nanoscale range. The effect of size particularly at the scale down to 
nanocrystals on phase stability has been investigated for a number of 
compounds including TiO2, ZrO2 and Al2O3 (Ranade et al., 2002, McHale et 
al., 1997, Garvie, 1978). The key issue with the observed nanocrystal phase 
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is however to investigate whether this is just a highly metastable phase or it 
is thermodynamically the real stable phase. Molecular simulation approaches 
could be used to calculate both the surface and bulk free energies to address 
this issue (Anwar and Zahn, 2011). 
1.8 Aims and Objectives 
Crystalline nanosuspensions have been identified as a promising technology 
to address poor solubility issues, although several challenges including 
stabilisation and control of particle size distribution for nanosuspensions and 
scale up issues still need to be addressed. Much of earlier studies used high 
energy nanoparticle preparation methods and these have particular issues. 
The intention of this study was to revisit the simplest approach of re-
precipitation and to identify the critical parameters including effect of 
stabilisers types and concentration as well as process conditions. We utilise 
a combined approach of both experiments and molecular modelling and 
simulation not only to determine the optimum parameters but also to gain 
mechanistic insight. The experimental studies utilised the three rather distinct, 
relatively insoluble drugs, the hypoglycaemic glibenclamide, the anti-
inflammatory ibuprofen, and the anti-malarial artemisinin. These drug 
molecules were chosen as they all could potentially benefit in terms of their 
bioavailability from being formulated as nanocrystals. Recovery of 
nanocrystals in the solid form from nanosuspensions is also a technical 
challenge. The goal is is to recover the nanocrystals in the dry form which 
when incorporated in a solid dosage form can yield the near original 
nanocrystal characteristics e.g. dissolution rate. We have developed a 
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method that utilises large single crystals as carriers for adsorbing 
nanocrystals from nanosuspension.  
Crystallisation of the drug molecules occurs by nucleation which is the key 
step to control the particle size distribution and size of the crystal. As this 
process takes place at atomistic level which is difficult to be visualised using 
experimental approaches (Schüth et al., 2001). Computer simulation 
approaches including Monte Carlo and molecular dynamics simulation have 
been used to investigate this process. However these methods are limited 
only to crystallisation processes which take place from melt. Also large cpu 
usage and long simulation time is required which limit these methods. In view 
of this the coarse grained molecular dynamics simulation method was 
employed to explore the earliest stages of the anti-solvent precipitation.  
The phase stability of nanocrystals was investigated using molecular 
simulation for the model compound glycine (Chapter 5). Phase stability of 
nanocrystals is a challenge to investigate since nanocrystals can persist in 
metastable states and it becomes difficult to identify whether the stabilized 
phase is thermodynamically stable or metastable because of large barriers 
(Zahn & Anwar, Chem. Eur. J. 2011, 17, 11186 – 11192). The stability of the 
glycine crystals was investigated for both bulk and nanocrystals as function 
of both temperature and pressure.  
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Chapter 2  
 
 
Nanocrystal Preparation: Low-Energy 
Precipitation Method Revisited 
 
2.1  Introduction 
Nanocrystals and their composites can exhibit markedly different properties 
with respect to bulk phases and hence offer new opportunities (Moriarty, 
2001, Parak et al., 2003, Horn and Rieger, 2001, Paul and Robeson, 2008, 
Choi and Awaji, 2005). For pharmaceuticals, nanocrystals promise to resolve 
the issue of poor bioavailability of poorly soluble drugs (Rabinow, 2004, 
Müller and Keck, 2012, Müller et al., 2011b, Müller et al., 2011a, Gao et al., 
Jinno et al., 2006, Merisko-Liversidge et al., 1996). The immense surface 
area of the particles, increased saturation solubility, and the decreased 
diffusional pathway adjacent to the nanocrystal surface all converge to 
enhance the bioavailability (Müller et al., 2011a, Buckton and Beezer, 1992, 
Wu and Nancollas, 1998, Moeschwitzer and Mueller, 2006, C.M. Keck, 2010). 
The difficulty in exploiting this technology is the technical challenge of 
generating and stabilising nano crystalline products. Nanocrystals can be 
prepared by a variety of methods, which in general terms can be categorized 
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as comminution (top down) or controlled precipitation (bottom up) (Müller et 
al., 2011a).  Although the technology is maturing, there are still important 
issues and limitations. Top down processes which include milling (Merisko-
Liversidge et al., 2003, Peltonen and Hirvonen, 2010, Plakkot et al., 2011) 
and high pressure homogenization (Majuru and Oyewumi, 2009, Zhang et al., 
2007) usually require long processing times, high energy input, and tend to 
yield a broad particle size distribution. There is also a concern with regards to 
contamination of the products from the milling media (Keck and Müller, 
2006) . With respect to the precipitation methods, there are many variants 
including simple precipitation (Chan and Kwok, 2011, Matteucci et al., 2006, 
Hu et al., 2010), spray freezing into a liquid(Williams et al., 2002, de Waard 
et al., 2008) precipitation from a supercritical fluid using an anti-solvent (Tom 
and Debenedetti, 1991, Cansell et al., 2003, Byrappa et al., 2008), and 
microfluidics (Panagiotou et al., 2009, Ali et al., 2011, Panagiotou et al., 
2007). Precipitation has also been employed in combination with 
homogenization (Kipp et al., 2003). The major limitations with precipitation 
are considered to be uncontrolled particle growth which has resulted in its 
adoption for only a few selected molecules (Gao et al., 2008, Müller et al., 
2001). 
Top-down technology for nanocrystal preparation has undergone rapid 
innovation with recently emerging methods such as Baxter‘s NANOEDGE 
technology being termed as 2nd generation methods (Müller and Keck, 2008). 
Furthermore these methods have been actively adopted by the 
pharmaceutical industry with an increasing number of commercial products 
supplemented by those in development pipelines (Rabinow, 2004). In 
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contrast, the precipitation approach has had relatively little interest with only 
a handful of publications (Chan and Kwok, 2011) and to our knowledge, no 
commercial exploitation, which raises some questions. Do precipitation 
methods suffer from major technical challenges? Are such methods unable to 
reproducibly yield crystals in the low nanometre range? Do the resulting 
nanocrystals show physical instability? The simple precipitation method is 
patented under the trade name Hydrosol, the patent being owned by 
Sandoz/Novartis (List and Sucker, 1995) which might act as a barrier to 
further commercial interest. As for the lack of exploitation, could it be that the 
patent holders do not have appropriate applications? Or have they 
encountered significant technical challenges? 
Here we revisit the precipitation method in its simplest form, re-precipitation 
using an anti-solvent without any high-energy input (no high speed shear 
mixing or sonication, just a stirrer). Probably the major perceived limitation of 
precipitation approaches is that they may work for some specific molecules 
but are not general, being unable to accommodate a wide range of molecules. 
The implication is that the few published studies present only the successes. 
We report a systematic study where we have prepared stable crystalline 
nanocrystals with uniform size distributions by precipitation of three rather 
distinct (see molecular structures in Figure 2.2) relatively insoluble drugs 
including the hypoglycaemic glibenclamide, the anti-inflammatory ibuprofen, 
and the anti-malarial artemisinin.  
These drug molecules were chosen as there is potential to enhance the rate 
and/or extent of drug absorption through presentation in the form of 
nanocrystals. No other molecules were considered and hence there are no 
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unreported ‗failures‘. For each of the drug molecules, systematic experiments 
have been carried out to identify the key formulation and process variables 
that influence the particle size and the physical stability of the resulting 
nanosuspensions. What becomes clear is that the challenge is physico-
chemical rather than mechanical, involving the identification of molecule-
specific crystal growth inhibitors and/or stabilizers, an issue which appears to 
be at the heart of preparing stable nanocrystals irrespective of how they are 
generated (Van Eerdenbrugh et al., 2008, Verma et al., 2010, Wu et al., 2011, 
Lindfors, 2004). To identify what determines the choice of stabilizer(s) for a 
particular compound it is necessary to understand their mechanism of action. 
Towards this particular objective we have attempted to rationalise the 
molecular interactions at the dominant crystal surfaces with the 
inhibitors/stabilizers and carried out molecular modelling studies using 
Material studio software. 
 
2.2 Materials and Methods 
2.2.1 Materials 
Glibenclamide (Batch No: PPC/08/GLB/057) was purchased from Anzen 
Exports Kolkata India. Ibuprofen (Batch No: 7050-1077) was purchased from 
Anzen Exports Kolkata India Hypromellose USP 
(hydroxypropylmethylcellulose) (Batch No: 7068037, 8028213, grades: 605 
and 615 and viscosity: 6cps and 15cps) were obtained from Shin-etsu-Japan 
Chemical Ltd. PVP K-30 (Batch No: 08297047GO) was provided for free by 
BASF Germany. PEG-400 (Catalogue No: P/3676/08 and Batch No: 
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0742478) was purchased from Fisher Scientific UK limited. Acetonitrile 
(Catalogue No: A/0626/17 and Batch No: 0809411) was purchased from 
Fischer Scientific. Ammonium di hydrogen phosphate monobasic, (Catalogue 
No: 1382384 and batch number: 09717), progesterone (Catalogue No: 
1262521 and Batch No: 81702), calcium phosphate dibasic (Catalogue No: 
C7263-500G and Batch No: 047K0035), monobasic potassium 
phosphate >99% (Catalogue No: P5655 and Batch No: 097K0067) and 
calcium phosphate dibasic (Catalogue No: C7263-500g and Batch No: 
047K0035) were purchased from Sigma Aldrich. NaOH pellets (Catalogue No: 
B882848 127 and Batch No: 301675N) were purchased from BDH 
Laboratory England. Sodium deoxycholate (NaDC) (Batch No: D6750), 
pluronic F127 (Batch No: 038K0113) and pluronic F68 (Batch No: 018K0029) 
were purchased from Sigma Aldrich. Copper grid (200 mesh) coated with 
Formvar/Carbon (Code No: S162) purchased from Agar Scientific.  
Artemisinin (Batch No: 100916, supplier: Chengdu Wagott Pharmaceutical 
Co, Ltd) was gifted by Institute of Material Medica China. 
 
2.2.2 Methods 
2.2.2.1 Preparation of Glibenclamide, Iburprofen and 
Artemisinin Nanosuspensions 
The methodology is based on standard precipitation using an anti-solvent 
(Figure 2.1). The drug is dissolved in a solvent and then injected at a defined 
rate into the anti-solvent (being water for the three drug substances 
investigated) containing growth inhibitors/stabilizers. For each drug, a series 
of precipitations were carried out at a millilitre scale (batch size: 3ml) to 
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identify the most appropriate stabilizers and process conditions (temperature, 
agitation rate and infusion rate) to yield stable nanocrystals. For the 3ml 
batch size, the amount of anti-solvent stabilizer solution was 2.7ml while the 
solvent solution was 0.3ml. The respective solvent solutions comprised 
ibuprofen at a concentration of 30 mg/ml in ethanol (0.3ml),  
 
 
Figure 2.1 Schematic representation of a typical antisolvent method 
 
glibenclamide at 5 mg/ml in polyethylene glycol 400 (PEG400), and 
artemisinin at 15 mg/ml in ethanol. Stabilizers investigated included 
hydroxypropylmethylcellulose (HPMC), polyvinylpyrrolidone (PVP K30), 
sodium deoxycholate (NaDC), Pluronic F68, Pluronic F127, Tween 80, 
sodium lauryl sulphate (SLS), soya lecithin and miglyol (triglyceride). 
Structures of some of these are given in Figure 2.2. 
Once the stabilizers were identified for each drug, the effect of the three 
crystallization process conditions, temperature, agitation rate, and infusion 
rate, was investigated using a factorial design at two levels for each of the 
three drugs. The temperature of the crystallization vials was controlled at 
either 25C or 40C, the agitation rate at 600 rpm or 1200 rpm, and the 
infusion rate of the anti-solvent solution was set at 60 or 100 ml/minute. A set 
Stirring bar
Drug solution
Stabilizers solution
Precipitation TEM analysis
Nanocrystals
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of eight experiments shown in Table 4.1 was employed for nanosuspensions 
of the three drugs. 
To assess the scalability of the process, batch sizes of 10, 100 and 400 ml 
were manufactured for each of the drugs using the optimum formulation and 
process.  
 
Figure 2.2  Molecular structures of APIs, and some of the surfactants and polymers 
used in this study. 
 
 
 
 
 
  
HPMC
R = H, CH3, CH2CH(OH)CH3 
PVP
NaDC
Pluronic F127
Ibuprofen
Glyburide
Artemisinin
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Table 2.1. Full factorial design for the preparation of ibuprofen, glibenclamide and 
artemisinin nanosuspensions under controlled process variables. Temperature: (+ = 
high = 40 0C and - = low= 25 0C), Stirring rate:  (+ = high =1200rpm) and - = low = 
600rpm). Infusion rate: (+ = high = 100ml/minute and - = low = 50ml/minute) 
 
Batch No 
Mixing 
Temperature 
(°C) 
Infusion 
Rate(ml/minute) 
Stirring 
Rate(ml/minute) 
1 + + + 
2 - - - 
3 + - + 
4 + - - 
5 - + + 
6 - + - 
7 + + - 
8 - - + 
 
 
2.2.2.2 Particle Size Measurements 
The particle size of the nanocrystals was determined using at-line 
measurements with the Malvern Zetasizer Nano-Zs dynamic light scattering 
(DLS) instrument (Malvern Instruments, UK). The mean particle size was 
determined from three measurements. NanosphereTM (Catalogue no; 3060A, 
mean diameter 59.0nm±2.5) and duke standard TM (Catalogue no; 8050, 
diameter 500.0nm±0.02) were used to calibrate performance of the Zetasizer.  
2.2.2.3  Particle Morphology 
Evaluation by scanning electron microscopy (SEM) of raw ibuprofen, 
glibenclamide and artemisinin drug substances was carried out using a 
Quanta 400 SEM (FEI Company, Cambridge, UK) to produce 
photomicrographs at a range of magnifications. Sample preparation involved 
fixing of raw ibuprofen, glibenclamide, and artemisinin to a metal stub with 
the aid of double sided adhesive tape. The scanning electron microscopy 
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(SEM) instrument was calibrated with a gold grid supplied with the instrument. 
Sample preparation for transmission electron microscopy (TEM) involved 
deposition of a single drop of the nanosuspension onto a 200 mesh copper 
grid coated with Formvar/Carbon (code no S162) followed by drying at 
ambient temperature. The sample was then negatively stained using 2% 
magnesium uranyl acetate solution because of its low conductivity. 
Transmission electron microscopy (TEM) was then carried out by loading the 
sample on transmission electron microscope at 120KV.The TEM used was 
(JEM-1200EX, Japan Electron Optics Laboratory Corporation Japan). 
2.2.2.4 Determination of melting point and heat of fusion by 
DSC. 
Differential scanning calorimetery (DSC) of the unprocessed and processed 
glibenclamide, ibuprofen and artemisinin was carried out using the DSC 
module of the TA instruments Q2000 Series Thermal Analysis system (TA 
Instrument West (UK). Indium (99%, melting point 156.6) was used to 
calibrate the DSC and performance was confirmed using a zinc standard with 
a melting point of 419.50 °C. The unprocessed and processed samples of 
glibenclamide and artemisinin were then scanned under a stream of nitrogen 
gas at a flow rate of 50ml/minute from 25 – 200 °C. Whilst processed and 
unprocessed ibuprofen samples were scanned from 0°C to 110 °C, using 
heating rate 10 °C /min. All samples were analysed in triplicate.  
2.2.2.5  Powder x-ray Diffraction (PXRD) 
The crystallinity of the nanocrystals was assessed by powder X-ray 
diffraction (PXRD) (and DSC, see above) using dried powders recovered 
from the nanosuspensions by centrifugation at 14500 rpm for 60 minutes and 
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drying under ambient conditions. PXRD studies were carried out using a 
Bruker D-8 powder diffractometer (Bruker Kahlsruhl, Germany). For the 
nanocrystal samples we employed a silicon-well sample holder, whilst for the 
original raw drug material a plastic sample holder was used. Calibration of 
the PXRD was carried out using a corundum standard. The samples were 
scanned in triplicate over the range 5-50° 2θ at a rate of 1º 2θ/min using a 
copper Kα radiation source at a wavelength of 1.542 Å and with 1 mm slits. 
2.2.2.6  Stability Studies  
The stability of nanosuspensions was monitored for one month at the three 
different temperatures, 4°C, 25°C, and 40°C, to establish the extent of 
particle growth through agglomeration and Ostwald ripening.  Particle size 
measurements of the stored nanosuspensions were conducted at regular 
time intervals over the one month period (0, 5, 10, 15,20,25,30 days) using 
DLS. The drug content was also analyzed at regular intervals using a Waters 
2695 HPLC system connected to a UV detector. The Ultra II TM C18 5µm 
250×4.6mm column was used at a temperature of 30°C. The solvent system 
used as the mobile phase for glibenclamide assay consisted of monobasic 
ammonium phosphate (0.02M) and acetonitrile at a ratio of 45:55 v/v. The 
mobile phase for ibuprofen consisted of 50:50 v/v acetonitrile and water at 
PH 2.5 adjusted with orthophosphoric acid. The flow rate of the mobile phase 
was set at 1.5 ml/min and 1 ml/min for glibenclamide and ibuprofen 
respectively. The mobile phase used for artemisinin was 60/40 v/v 
acetonitrile and water at a flow rate of 1 ml/minute. The wavelength of the UV 
detector was set at 254 nm, 214 nm and 216 nm for glibenclamide, ibuprofen, 
and artemisinin, respectively. 
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2.2.2.7  Dissolution Rate Testing 
The dissolution rate of the glibenclamide nanocrystals was compared with a 
glibenclamide microsuspension (mean particle size ~5µm) prepared by 
crushing and sonication of a marketed 5mg glyburide tablet (Glibenclamide 
(UK name) 5mg tablets, batch no. 9A06HL, manufacturer Teva UK Ltd) in a 
liquid medium composed of 1% HPMC and 1%PVPK-30.  Nanosuspension 
dissolution was also compared to that of the intact marketed 5mg glyburide 
(glibenclamide) tablet.  Dissolution rate of the ibuprofen nanocrystals was 
compared with micronized ibuprofen powder of mean particle size ~9µm, and 
a 200mg ibuprofen marketed tablet (Ibuprofen 200mg tablets, Batch no. 
LL11845, manufacturer Wockhard Ltd UK). The dissolution rate of 
artemisinin nanocrystals was compared with micronized artemisinin powder 
of mean particle size ~2µm. The dissolution rates were monitored using the 
USP apparatus 2 (paddle method) at 75 rpm. The dissolution medium for 
glibenclamide was phosphate buffer pH= 7.5 whilst for ibuprofen it was 
phosphate buffer at pH 7.2. The dissolution rate of artemisinin nanocrystals 
was determined in distilled water at 200 rpm using the method reported in 
reference (Kakran et al., 2010).  
For all determinations the temperature was set to 37°C ± 0.3°C. 5mL aliquots 
were collected using a syringe filter (0.02 µm) at 0, 2, 6, 10, 15, 30, 45 and 
60 minutes after addition of the formulations to the dissolution vessels. We 
noted that the filter allowed nanocrystals below 20 nm to pass resulting in 
some overestimate of drug dissolution. The size of syringe filter has been 
employed previously by others for dissolution studies of nanosuspensions 
(Sylvestre et al., 2011, Shekunov et al., 2006, Pardeike et al., 2011, 
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Jünemann and Dressman, 2012). However, the expectation is that particles < 
20 nm size crystals are likely to dissolve almost immediately in the 
dissolution test. After each sampling time the dissolution media was 
replenished with 5ml of fresh dissolution medium. The aliquots were 
analyzed for the drug using a reverse phase high performance liquid 
chromatography (RP-HPLC) method, as detailed above. 
2.2.2.8  Effect of Supersaturation on Particle Size 
The effect of supersaturation on nanocrystal size was investigated by 
carrying out a series of preparations using the optimum formulation and 
process at different temperatures (5, 15, 25, 35 and 45°C) for which the 
supersaturation was estimated from determined solubilities of the drugs in 
the final vehicles. Use of temperature to vary the supersaturation rather than 
varying the concentration of the drug in the solute has the advantage of 
sampling a wider range of supersaturations, since the upper limit of solute 
concentration is fixed. Also, increasing the drug concentration would require 
associated changes in concentration of the stabilizers.  
The equilibrium solubility of glibenclamide, ibuprofen, and artemisinin in each 
of the final suspension vehicles was determined by stirring an excess of 
amount of the drug in a vial containing 10ml of the respective vehicle at the 
temperatures 15°C, 25°C, 35°C and 45°C (temperature control  2°C) and an 
agitation rate of 200 rpm for 48 hours. All the samples were filtered through 
0.22µm filter and analyzed using HPLC. 
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2.2.2.9 Identification of the Molecular Interactions at the 
Dominant Crystal Surfaces 
The crystal morphology of the three drugs was predicted using the molecular 
modelling software Materials Studio 4.1 based on the attachment energy 
model (Materials Studio software package). We employed the CVFF force 
field with force-field assigned charges (Maple et al., 1994). This force field 
has been found to be effective for a large number of drug materials, being 
able to reproduce the crystal structures to a better than 5% deviation in their 
lattice parameters (Shariare et al., 2012). The goal here was not to 
accurately predict the crystal morphology but rather to identify the major 
crystal surfaces that are likely to dominate the crystal morphology and then to 
explore the molecular interactions characterising these surfaces. The 
dominant crystal surfaces of the three drugs were examined visually with a 
view to rationalising the molecular interaction of the surface with crystal 
growth inhibitors/stabilizers. 
2.3 Results and Discussions 
2.3.1 Preparation of Ibuprofen, Glibenclamide and 
Artemisinin Nanosuspensions 
   
For all three drug molecules we were able to prepare stable nanocrystals 
using the simple anti-solvent precipitation technique, wherein the drug was 
dissolved in an appropriate solvent and then injected using a syringe into a 
stirred vial containing aqueous solution of growth inhibitors/stabilizers (the 
anti-solvent). The distinctiveness of the molecules revealed itself in the 
choice of the growth inhibitors/stabilizers and the ultimate nanocrystal size 
distribution obtained. For ibuprofen the effective growth inhibitors/stabilizers 
57 
 
were hydroxypropylmethylcellulose (HPMC 15cps) and Pluronic F127 (1% 
w/v concentration) (Table 2.2). The nanocrystals obtained had a particle size 
of 92 ± 2.5 nm and a polydispersity index of 0.15±0.01 (Figure 2.3 (b)). 
Glibenclamide nanocrystals required a combination of HPMC (15cps) and 
PVPK-30 (1%w/v) (Table 2.3) with the HPMC (15cps) + Pluronic F127 
combination being ineffective. The particle size and PDI values obtained for 
glibenclamide nanocrystals were 298nm ± 3.5 and 0.2 ± 0.02 respectively 
(Figure 2.3(a)). Artemisinin was more challenging and the surfactants and 
polymers employed for ibuprofen and glibenclamide were not found to be 
effective. The eventual optimum choice was sodium deoxycholate (NaDC) 
(0.2%w/v), Pluronic F127, and PVPK-30 (0.5%w/v) (Figure 2.4), which 
yielded nanocrystals of  size 400.0 ± 3.5 nm, which are larger than the size 
range obtained for ibuprofen and glibenclamide (Figure 2.3 (c)).  
To gain a better understanding of the re-precipitation process, we attempted 
to identify the critical process parameters using a full factorial design 
involving the variables stirring rate, temperature, and infusion rate, each at 
two levels (Table 2.5). Evaluation of the process parameters and interactions 
indicated that low temperature (25°C), high stirring rate (1200 rpm), and high 
infusion rate (100 ml/min) were necessary to achieve minimal particle size. 
Similar results have been reported previously (Lindfors, 2004). Each of these 
factors can increase the local supersaturation, which we believe is the main 
consequence in each case. For instance, high stirring and infusion rate 
enhance micro-mixing between the two phases, maintaining high local 
supersaturation (Matteucci et al., 2006). Lower temperature reduces the drug 
solubility, again enhancing supersaturation. The increased local 
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supersaturation is considered to increase the number of nuclei formed hence 
minimising the amount of solute available for subsequent crystal growth 
(Zhang et al., 2009).  
 
Table 2.2. Effect of different stabilisers on particle size of Ibuprofen nanocrystals. 
 
Stabilisers 
Particle Size (nm) ± SD 
Day 0 Day 5 Day 
10 
Day 
15 
Day 
20 
Day 
25 
Day 
30 
1% PLURONIC F-68 
292 
±3.5 
340 
±4.5 
375 
±2.5 
400 
±3.0 
460 
±5.0 
485 
±2.0 
550 
±5.0 
1% PVP + 1% HMPC(6cps) 
475 
±4.5 
502 
±3.2 
542 
±4.0 
578 
±2.5 
600 
±3.5 
625 
±2.0 
654 
±2.5 
0.5% HPMC (15cps)+ 0.5% 
PVP+ 0.2%SLS 
180 
±5.0 
200 
±4.0 
245 
±4.5 
300 
±5.0 
333 
±2.5 
340 
±2.0 
385 
±2.5 
1% HPMC (15)+ 1% PVP+ 
0.5%SLS 
160 
±3.5 
185 
±4.2 
190 
±4.0 
195 
±3.5 
225 
±3.0 
265 
±2.5 
285 
±2.0 
1% Pluronic F-68 +0.5%PVP 
+0.5%SLS 
396 
±2.5 
400 
±3.5 
415 
±4.0 
425 
±4.5 
440 
±4.0 
500 
±3.0 
525 
±3.5 
1% HPMC (15cps) 
+1%Pluronic F-127 
92 
±3.0 
95 
±2.5 
100 
±2.0 
102 
±3.0 
105 
±3.5 
108 
±2.0 
110 
±2.5 
1% PVP 
325 
±3.5 
350 
±4.5 
375 
±5.0 
400 
±3.5 
500 
±2.0 
525 
±2.5 
585 
±2.5 
1% HPMC(15cps) 
200 
±5.5 
225 
±4.5 
245 
±4.0 
285 
±3.5 
300 
±3.0 
310 
±3.0 
325 
±2.0 
1% Pluronic F-127 
320 
±4.5 
330 
±4.0 
340 
±4.0 
365 
±3.5 
385 
±3.0 
415 
±2.5 
425 
±2.5 
0.5%PVP+0.5%HPMC(15cps) 
550 
±5.2 
565 
±5.5 
585 
±5.0 
590 
±4.5 
610 
±4.0 
620 
±3.0 
630 
±3.0 
1.0%PVP+0.5%HPMC 
(15cps) 
630 
  ±6.0 
645 
  ±5.2 
660 
±4.0 
685 
±4.5 
702 
±3.5 
710 
±3.0 
725 
±3.5 
 
We explored the possibility of scaling up from the 3ml quantities employed for 
the precipitation studies and prepared batches of 10, 100, and 400 ml 
quantities. The nanocrystal sizes obtained from these batches were similar to 
those achieved in small scale experiments. Furthermore, stability and 
dissolution rates were also essentially unchanged. We do not see any 
significant challenges in scaling up beyond 400ml but the process will require 
a chemical engineering approach to maintain maximum mixing of fluids at the 
saturated solution/anti-solvent interface and efficient heat transfer involving 
the possible use of multiple nozzles. 
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Figure 2.3 Particle size distribution of (a) glibenclamide; (b) ibuprofen and (c) 
artemisinin 
Table 2.3. Effect of different stabilisers on particle size of Glibenclamide 
nanocrystals 
 
Stabilisers 
Particle Size (nm) ± SD 
Day 0 Day 5 Day 
10 
Day 
15 
Day 
20 
Day 
25 
Day 
30 
1% HPMC (15cps) 
400 
±2.5 
490 
±4.5 
546 
±3.5 
615 
±3.0 
700 
±4.0 
950 
±2.0 
1000 
±3.0 
1% HPMC (6cps) 
500 
±4.5 
600 
±5.2 
685 
±4.0 
780 
±3.5 
915 
±3.5 
1045 
±4.0 
1200 
±2.0 
0.5%PVPK-30 +0.5% 
HPMC (6cps) 
375 
±5.0 
400 
±5.5 
475 
±3.0 
502 
±2.5 
545 
±2.5 
675 
±3.0 
845 
±2.0 
0.5% HPMC (6cps)+ 0.5% 
PVPK-30+ 0.2%SLS 
340 
±3.5 
360 
±4.2 
385 
±4.0 
450 
±3.5 
500 
±3.0 
525 
±2.5 
580 
±2.0 
1% HPMC (6cps)+ 1% 
PVPK-30+ 0.5%SLS 
320 
±2.5 
330 
±3.5 
350 
±4.0 
425 
±4.5 
440 
±4.0 
500 
±3.0 
1605 
±3.0 
1% PVPK-30 
520 
±3.0 
575 
±2.5 
665 
±2.0 
789 
±3.0 
1000 
±3.5 
1500 
±2.0 
110 
±2.5 
0.5%PVPK-
30+0.5%HPMC(15cps) 
315 
±3.5 
335 
±4.5 
345 
±5.0 
360 
±3.5 
385 
±2.0 
400 
±2.5 
405 
±3.5 
1.0%PVPK-
30+0.5%HPMC(15cps) 
300 
±5.5 
310 
±4.5 
326 
±4.0 
340 
±3.5 
360 
±3.0 
370 
±3.0 
378 
±3.0 
1.0%PVPK-
30+1.0%HPMC(6cps) 
305 
±5.5 
325 
±4.0 
350 
±4.0 
365 
±4.5 
372 
±3.0 
385 
±3.5 
390 
±2.5 
1% HPMC (15cps) 
+1%PVPK-30+ .3%Miglyol 
290 
±5.2 
300 
±5.2 
320 
±4.2 
365 
±4.5 
375 
±4.0 
390 
±2.5 
400 
±3.0 
0.5% HPMC (15cps) + 
0.5% PVPK-30 +0.3% 
Miglyol 
300 
±6.5 
320 
±4.0 
340 
±3.5 
360 
±5.0 
370 
±4.0 
385 
±3.0 
415 
±2.5 
1%HPMC (6cps)+ 
1%PVPK-30+0.3% Miglyol 
305 
±4.0 
330 
±3.5 
350 
±5.0 
365 
±4.0 
375 
±3.0 
390 
±2.0 
400 
±3.0 
1%HPMC (15cps)+ 
1%PVPK-30 
298 
±3.5 
330 
±4.0 
326 
±3.0 
331 
±4.2 
333 
±2.5 
336 
±3.0 
338 
±3.5 
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Table 2.4. Effect of different stabilisers on particle size of artemisinin  nanocrystals 
 
 
Stabilisers 
Particle Size (nm) ± SD 
Day 
0 
Day 5 Day 
10 
Day 
15 
Day 20 Day 
25 
Day 
30 
0.2%Pluronic 
F127+0.2%PVPK-
30+0.1%NaDC 
570 
±2.0 
602 
±4.5 
645 
±3.5 
685 
±4.0 
715 
±5.0 
785 
±2.5 
815 
±3.0 
0.5%Pluronic 
F127+0.5%PVPK-
30+0.2%NaDC 
400 
±3.5 
412 
±3.2 
420 
±4.0 
434 
±4.5 
442 
±3.5 
450 
±3.0 
455 
±2.0 
0.5%HPMC+0.5%PVPK-
30+0.1%NaDC 
1000 
±5.0 
1140 
±5.5 
1300 
±3.0 
1420 
±4.0 
1700 
±2.5 
1825 
±3.0 
1980 
±2.0 
0.5%Pluronic 
F127+0.5%PVPK-
30+0.1%NaDC 
463 
±3.2 
488 
±4.2 
503 
±4.0 
515 
±3.5 
522 
±4.0 
530 
±2.5 
538 
±2.0 
0.2%Pluronic 
F127+0.5%PVPK-
30+0.2%NaDC 
508 
±2.5 
530 
±3.5 
544 
±5.0 
574 
±4.5 
590 
±4.0 
607 
±5.0 
614 
±3.0 
0.2%Pluronic 
F127+0.2%PVPK-
30+0.2%NaDC 
558 
±3.0 
597 
±2.5 
626 
±4.0 
685 
±3.0 
705 
±3.5 
750 
32.0 
785 
±2.5 
1%HPMC+1%PluronicF127 
1500 
±5.5 
1800 
±4.5 
2000 
±5.0 
2225 
±3.5 
2450 
±3.0 
2800 
±2.5 
3000 
±3.5 
0.5%Pluronic 
F127+0.2%PVPK-30+ 
0.2%NaDC 
515 
±6.0 
550 
±4.5 
600 
±4.0 
625 
±5.5 
675 
   ±3.0 
700 
±3.0 
715 
±3.0 
0.2%Pluronic 
F127+0.5%PVPK-
30+0.1%NaDC 
543 
±5.5 
566 
±4.0 
591 
±4.0 
610 
±4.5 
629 
±3.0 
637 
±3.5 
647 
±2.5 
1%HPMC+1%PVPK-
30+0.2%NaDC 
800 
±4.2 
900 
±5.2 
1200 
±4.2 
1360 
±4.5 
1500 
±4.0 
1800 
±2.5 
1905 
±3.0 
0.5%Pluronic 
F127+0.2%PVPK-
30+0.1%NaDC 
604 
±6.5 
625 
±4.0 
650 
±3.5 
685 
±5.0 
710 
±4.0 
725 
±3.0 
755 
±2.5 
1%Tween80+1%HPMC 
1800 
±3.0 
1950 
±3.5 
2100 
±5.0 
2200 
±4.0 
2375 
±3.0 
2400 
±2.0 
2465 
±3.0 
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Table 2.5. Effect of the process parameters on particle size of Ibuprofen, 
Glibenclamide and Artemisinin nanocrystals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.2 Morphology Studies 
All particles of raw glibenclamide sample were found to have a regular 
morphology when analysed at 400X magnification level. The average particle 
size was found 70 micron. Figure 2.4 (a) shows scanning electron 
micrographs of raw glibenclamide sample. TEM images of glibenclamide 
nanoparticles (Figure 2.4 (b)) were taken at 50K and the average particle 
size of the particle was found to be 0.2µm. Ibuprofen crystals were mostly in 
separate state from each other and some adjacent to one another and other 
clustered on each other (Figure 2.4 (c)) (Aly Nada, 2005). The images were 
more prominent at higher magnification (200X). Particle size measurements 
(118µm x 25.81µm) of bulk ibuprofen were taken at 200X magnification. 
Average 
effect of 
process 
parameters 
Level 
Used 
Average Particle Size (nm) 
Ibuprofen Glibenclamide Artemisinin 
A 
A 
+ 
- 
165±5.5 
94±3.5 
365±4.5 
298±5.5 
503±5.0 
405±3.5 
B 
B 
+ 
- 
95±6.0 
145±3.5 
302±4.5 
360±6.0 
395±4.0 
462±5.0 
C 
C 
+ 
- 
93±4.0 
204±3.0 
305±2.5 
412±4.5 
410±5.0 
520±2.5 
AB 
AB 
- + 
+ - 
96±6.0 
215±6.5 
300±4.0 
405±5.5 
400±3.5 
528±6.2 
BC 
BC 
++ 
- - 
100±3.0 
250±2.5 
310±2.5 
465±4.0 
398±6.5 
565±4.5 
AC 
AC 
- + 
   + - 
98±3.0 
275±4.5 
300±6.0 
460±4.5 
408±5.5 
580±3.5 
ABC 
ABC 
- + + 
+ - - 
98±2.0 
300±3.2 
295±2.5 
496±3.0 
400±5.4 
602±4.0 
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Image of bulk ibuprofen (Figure 2.4 (c)) shows the varying sizes of crystal 
present in the bulk ibuprofen sample. 
 
Figure 2.4 SEM and TEM images of unprocessed (a), processed (b) glibenclamide, 
unprocessed (c), processed (d) ibuprofen and unprocessed (e), processed (f) 
artemisinin particles. 
 
TEM images of ibuprofen were taken at 200K and showed that the particles 
were crystalline in nature with average particle size of 90nm (Figure 2.4(d)). 
Artemisinin samples analysed at 200X magnification level were found to have 
triclinic crystals (Figure 2.4 (e)). The average particle size was found to be 
(e) (f)
63 
 
300micron. TEM images of artemisinin were taken at 80K and the average 
particle size was below 400nm (Figure 2.4 (f)). Representative transmission 
electron microscope (TEM) images of the samples are shown Figure 2.4, 
which confirms particle size being in the nanometre range and being 
consistent with the dynamic light scattering determination.  
2.3.3 DSC and PXRD Studies 
For all three drugs, the nanocrystals obtained were found to be crystalline 
when characterized using a combination of differential scanning calorimetery 
(DSC) and powder X-ray diffraction (PXRD). With the DSC, a single sharp 
melting endotherm was observed for all samples including nanocrystalline 
and original powdered materials (Figures 2.5, 2.6 and 2.7). There was a 
slight reduction in the melting onset temperature (Tonset) and melting peak 
maximum for the nanocrystal samples relative to the unprocessed samples. 
The heat of fusion was also decreased for the nanocrystal samples (Table 
2.6). This behaviour has been observed previously being attributed to traces 
of the polymer(s) adsorbed on the surface of nanocrystals (Valleri et al., 2004, 
Bunjes et al., 2000). With respect to powder X-ray diffraction, the nanocrystal 
samples gave peaks in essentially identical positions to those of the original 
powders thus confirming the identity and crystallinity (Figure 2.8). The peaks 
were slightly broadened as expected due to particle-size broadening effects, 
which become important for small particle sizes. The marked variation in the 
peak intensity of the unprocessed samples is considered to be due to 
preferred orientation effects.  
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Figure 2.5 Representative DSC profiles of processed and unprocessed ibuprofen 
particles 
 
 
Figure 2.6 Representative DSC profiles of processed and unprocessed 
glibenclamide particles 
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Figure 2.7 Representative DSC profiles of processed and unprocessed artemsinin 
particles 
 
 
Table 2.6  DSC profile of unprocessed a processed samples of ibuprofen, 
glibenclamide and artemisinin 
Drug 
Melting 
point (°C) 
Heat of 
fusion (j/g) 
Raw 
ibuprofen 
74.09 ±1.5 151.80 ±1.2 
Ibuprofen 
nanocrystal 
70.00 ±1.0 123.50 ±2.0 
Raw 
glibenclamide 
174.75 ±2.0 100.00 ±1.0 
Glibenclamide 
nanocrystal 
172.00 ±1.2 89.00 ±1.4 
Raw 
artemisinin 
154.20±1.3 80.00 ±1.5 
Artemisinin 
nanocrystal 
150.00±1.6 64.00 ±2.2 
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Figure 2.8 Powder X-ray diffraction patterns of the nanocrystals and the original 
powdered drug for (a) ibuprofen, (b) glibenclamide, and (c) artemisinin. X-ray 
radiation source was copper Kα, =1.542 Å.  
(a)
(c)
(b)
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2.3.4 Stability Studies  
 The effect of different combinations of stabilizers on the particle size of 
nanocrystals of ibuprofen as a function of storage at 25°C is given Table 2.2. 
The effectiveness of the stabilizers as single components can be ranked as 
HPMC (15cp; 1% w/w) > Pluronic F127 (1% w/w) > Pluronic F68  PVP (1% 
w/w). Of the various combinations tested the combination of 1% HPMC(15cp) 
+ 1% Pluronic F127 is the most effective by far, yielding a very low particle 
size and high particle size stability  on storage.  The effect of stabilizers on 
the particle size for glibenclamide is shown in Figure 2.3. Single stabilizer 
components (1% HPMC (6cps), 1% HPMC (15cps) and 1% PVP), as with 
ibuprofen, yielded nanocrystals of a relatively low particle size but were not 
effective in maintaining and stabilizing the particle size on storage.  
Interestingly, a number of combinations of stabilisers are equally effective, 
including mixtures of HPMC+PVP and HPMC+PVPK-30. Inclusion of sodium 
lauryl sulphate or miglyol appears to have little effect. All these combinations 
yield stable nanosuspensions with a particle size of around 350-400 nm. The 
best combination is HPMC (15cps; 1% w/w) + PVPK-30 (1% w/w) which 
yields stable nanocrystals of size ~300 nm. The effect of stabilizers on the 
nanocrystal size and stability for artemisinin is shown in Figure 2.4. The data 
here are markedly different from those observed for ibuprofen or 
glibenclamide; the smallest attainable nanocrystal size just exceeding 400nm 
(which is much larger than the optimum particles sizes obtained for ibuprofen 
and glibenclamide).Particle size stability was in general terms poor with 
micron-sized crystals appearing in some of the nanosuspensions on storage. 
In this case, the polymer HPMC even in combination with other stabilizers 
68 
 
was essentially infective. A combination of PVP (0.5% w/w) + Pluronic F127 
(0.5% w/w) + sodium deoxycholate (0.2%w/w) gave the lowest particle size 
and best stability. 
The stability of the optimum formulations of the nanosuspensions was further 
assessed at 4, 25 & 40  C for up to 1 month. Ibuprofen, glibenclamide and 
artemisinin nanosuspensions were stable at 4 and 25  C for up to a month 
but showed an increase in particle size at 40C over the one month storage 
period. Particle growth observed at higher temperature is probably related to 
Ostwald ripening (Deng et al., 2010). Furthermore for HPMC based 
formulations, 40°C is close to the gel point of the polymer which might also 
affect its role as a stabilizer (Bajwa et al., 2009, Ford, 1999). The 
nanosuspensions were found to be physically and chemically stable at over 
the storage period of 1 month.  HPLC analysis showed that > 99.9% of the 
expected levels of glibenclamide, ibuprofen and artemisinin were recovered 
from the nanosuspensions, indicating that no significant loss or degradation 
of the drugs occurred during nanocrystal preparation or on storage.  
2.3.5 Dissolution Studies 
The dissolution rate of the suspended nanocrystals of glibenclamide, 
ibuprofen and artemisinin was compared to the micronized samples of the 
drug substances and marketed products and shown in(Figures 2.9, 2.10 and 
2.11). In all cases the dissolution rate of the nanocrystals was significantly 
faster than the micronized powder and the marketed products. This is 
encouraging even though we are aware that enhanced dissolution rates may 
not always translate into enhanced bioavailability. 
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Figure 2.9 Comparison of dissolution profiles of glibenclamide nanosuspension with 
microsuspension formulations and marketed tablets 
 
 
Figure 2.10 Comparison of dissolution profiles of ibuprofen nanosuspension with 
microsuspension formulations and marketed tablets 
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Figure 2.11. Comparison of the dissolution profiles of the artemisinin 
nanosuspension with microsuspension formulations. 
 
2.3.6 Effect of Supersaturation 
The two fundamental questions in using the precipitation method for 
preparing nanocrystals are (a)  what determines the (initial) nanocrystal size 
and (b) how can we stabilize the subsequent crystal growth and particle 
aggregation?  Possible determinants of the initial particle size include 
supersaturation, the nature of the stabilizers/inhibitors in the anti-solvent 
media and their molecular organization, and factors intrinsic to the molecule 
and how they govern the kinetics of nucleation. We have a general 
understanding of the effects of supersaturation. Higher supersaturation 
reduces the critical nucleus size, increasing the probability (and hence rate) 
of nucleation. This gives rise to the formation of an increased number of 
crystallites of a relatively small size, since much of the solute is consumed by 
the large number of emerging crystallites limiting the amount of solute 
0
20
40
60
80
100
120
0 10 20 30 40 50 60 70
A
v
e
ra
g
e
 %
 d
ru
g
 d
is
so
lv
e
d
Time (Minutes)
Artemisinin Nanosuspension (400nm)
Artemisinin Micronised powder (2.0micron)
71 
 
available for subsequent crystal growth. Is supersaturation the dominant 
determinant of nanocrystal size in these systems? Particle size as a function 
of supersaturation is plotted in Figure 2.12 for each of the three drug 
materials. (The raw solubility and supersaturation data are given in Table 2.7). 
If supersaturation is the dominant factor, one should expect all the data 
points to lie on a straight line with a negative gradient, characterizing the 
inverse relationship that higher supersaturations give rise to low particle size. 
Data for an individual drug molecule does indeed show such a relationship 
but there is no overall overlap of these data between the three molecules. 
Instead these data show systematic shifts in the particle size for a given 
supersaturation depending on the molecule. The lack of overlap of the data 
between the molecules suggests that supersaturation whilst being an 
important factor is not the dominant factor.  
For a given supersaturation the particle size of artemisinin nanocrystals is 
larger than that for glibenclamide, which in turn is larger than that for 
ibuprofen. The implication is that the rate of nucleation of artemisinin is 
relatively lower (as is the rate of nucleation of glibenclamide relative to 
ibuprofen), which might be due to an intrinsic factor of the molecule or the 
nucleation rate is retarded by the anti-solvent media containing the crystal 
growth inhibitors/stabilizers. The intrinsic factors determining nucleation 
include the rate of molecular diffusion of the molecule, which will dictate the 
kinetics of the initial phase separation to form clusters of the solute, and the 
ease or otherwise with which the molecules adopt the molecular orientation 
and lattice positions characterising the emerging crystal in spontaneous 
fluctuations. Given that rapid nucleation is expected to result in nanocrystals 
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of smaller dimensions, these considerations suggest that effective stabilizers 
for bottom-up nanocrystal preparation methods should at best have the ability 
to promote the rate of nucleation and at worst not retard it. Indeed, many of 
the effective stabilizers employed here and by others have surface activity 
whilst small molecule surfactants are also employed in nanocrystal 
precipitation, suggesting that these molecules may be playing a role in 
reducing the interfacial free energy for nucleation and hence enhancing the 
nucleation rate. 
 
Figure 2.12. Nanocrystal particle size as a function of supersaturation for ibuprofen, 
glibenclamide and artemisinin 
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Table 2.7 Solubility of ibuprofen, glibenclamide, and artemisinin in 10% anti-solvent 
phase as function of temperature, along with estimated supersaturation and the 
resulting nanocrystal particle size. 
Drugs 
Temperature 
/ °C 
Solubility  
/  µg/ml 
Supersaturation  
/  C/C* 
Average 
particle size  
/ nm 
Ibuprofen 
15 
25 
35 
45 
350.0±4.0 
415.0±2.5 
450.0±3.0 
510.0±1.5 
8.5±1.0 
7.2±1.2 
6.6±2.0 
5.8±1.5 
85.0±4.5 
92.0±2.5 
165.0±5.0 
195.0±4.0 
Glibenclami
de 
15 
25 
35 
45 
55.0±2.0 
85.0±2.5 
105.0±3.0 
125.0±2.2 
9.0±2.2 
5.8±2.7 
4.7±1.5 
4.0±1.0 
261.0±5.2 
298.0±3.0 
350.0±2.5 
380.0±4.0 
Artemisinin 
15 
25 
35 
45 
125.0±1.5 
205.0±2.0 
235.0±2.5 
300.0±2.1 
 12.5 ±2.8 
7.3 ±3.2 
6.3 ±3.0 
5.0±2.0 
373.0±5.5 
400.0±3.5 
433.0±4.2 
516.0±3.5 
 
2.3.7 Modelling Studies 
Given that each of the three drugs requires a different combination of crystal 
growth inhibitors/stabilizers to achieve the minimum crystal size and longer 
term stability to crystal growth, these results suggest that there is probably no 
generic set of inhibitors/stabilizers that yield stable, low particle-size 
nanocrystals. The specific nature of the molecule and/or exposed crystal 
surfaces appear to be critical in determining what stabilizers are likely to be 
effective. We therefore attempted to rationalise the choice of effective 
stabilizers for each of the drug substances by examining the intermolecular 
interactions on the dominant crystal faces for each drug and stabilizer 
molecules found to be effective. The crystal morphology for each drug was 
predicted using the attachment energy model which allowed us to identify the 
major faces. The predicted morphologies are intrinsic i.e. depend only on the 
internal intermolecular forces and do not consider how the solvent or 
stabilizers may modulate the morphology. The predicted major faces and the 
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associated percentage areas of the facets for each of the drug crystals are 
given in Table 2.8, while the morphologies and the structures of the dominant 
crystal faces are shown in Figures 2.13, 2.14, and  2.15. 
For ibuprofen the predicted morphology is a flat platelet with the faces (100) 
dominating the morphology (69%) (Figure 2.13). The next significant faces 
are the (011) and (002) with percentage facet areas of 14 and 11 % 
respectively. The dominant face (100) is terminated entirely by alkyl groups, 
as is one of the minor faces, (002) (11%). For ibuprofen, both PVP and 
Pluronic F68 individually were essentially ineffective, while HPMC and 
Pluronic F127 individually were marginally better, and the combination of 
HPMC+Pluronic F127 being markedly superior. The glibenclamide 
morphology is more 3-dimensional (Figure 2.18). The dominant faces in this 
case are (011) with 36%, (10-1) with 23%, and (110) with 17% of the total 
surface area. These faces are all largely polar in nature. The essential 
stabilizers appear to be HPMC + PVPK-30. The morphology for artemisinin is 
a flat prism with the dominant faces being (002) with 40%, (100) with 31%, 
and (011) with 9% of the surface area (Figure 2.15). All three faces largely 
expose alkyl groups, with the surfaces (002) and (100) also revealing some 
polar groups inter-dispersed in a dominantly non-polar surface. In this case 
the effective stabilizers are a combination of Pluronic F127, PVP-K and 
sodium deoxycholate. 
Apriori, one could argue that an effective stabilizer system should include an 
appropriate surfactant to lower the interfacial energy to nucleation, thus 
enhancing the nucleation rate, and other components that minimise crystal 
growth to favour nucleation and stabilize the crystallite surface to aggregation. 
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Considering the crystal surfaces and the molecular structures of the most 
effective stabilisers, there appears to be no apparent pattern as to the choice 
of stabilizers for a particular drug. A potential lead is that for ibuprofen and 
artemisinin, both of which have non-polar crystal surfaces, Pluronic F127 
appears to be more effective than Pluronic F68 in yielding stable, low 
particle-size nanocrystals. The Pluronics are tri-block polymers comprising a 
hydrophobic propylene oxide (PO) polymer block in the middle of two 
hydrophilic ethylene oxide (EO) polymer blocks. The respective structures of 
Pluronic F68 and Pluronic F127 are (EO)80(PO)27(EO)80 and 
(EO)101(PO)56(EO)101, suggesting the larger molecular weight and more 
hydrophobic polymer is more appropriate for crystals with non-polar surfaces. 
The difficulty in linking molecular level interactions between stabilizer 
molecules and crystal surfaces is not surprising given that these systems are 
highly complex, comprising multiple components and the dynamic nature of 
the precipitation process itself.  
 
Table 2.8 Dominant crystal surfaces predicted from crystal morphology prediction 
calculations for ibuprofen, glibenclamide, and artemisinin. 
Drug Face 
% Facet 
Area 
 100 65 
Ibuprofen 011 14 
 002 11 
 011 36 
Glibenclamide 10-1 23 
 110 17 
 020 41 
Artemisinin 110 34 
 011 18 
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Figure 2.13 Predicted crystal morphology for ibuprofen along with the dominant 
crystal surfaces. (a) (100) face with 65% of the surface area; (b) (011) face with 14% 
of the surface area; (c) (002) face with 11% of the surface area. 
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Figure 2.14  Predicted crystal morphology for glibenclamide along with the 
dominant crystal surfaces. (a) (011) face with 36% of the surface area; (b) (10-1) 
face with 23% of the surface area; (c) (110) face with 17% of the surface area. 
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Figure 2.15 Predicted crystal morphology for artemisinin along with the dominant 
crystal surfaces. (a) (020) face with 41% of the surface area; (b) (110) face with 34% 
of the surface area; (c) (011) face with 18% of the surface area. 
 
In summary this study demonstrated that a low energy precipitation method 
generally works for fabrication of nanocrystals of different molecules with 
marked increase in dissolution rate compared to the micronized and 
marketed products. Stable nanocrystals with uniform particle size were 
prepared for the three model compounds, glibenclamide, ibuprofen, and 
artemisinin, which are all practically insoluble in water and have diverse 
molecular structures and crystal packing. The choice of crystal growth 
inhibitors/stabilizers was found to be critical and specific for each drug. The 
effect of the process variables, temperature, stirring rate, and the solute 
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solution infusion rate into the anti-solvent, was rationalized in terms of how 
these factors influence the local supersaturation attained at the earliest 
stages of precipitation. The dissolution of the nanocrystals in aqueous media 
under physiological conditions was shown in all cases to occur almost 
instantaneously, being markedly more rapid than that observed for 
micronized suspensions of the model drugs and their marketed tablet 
formulations. Rationalization of the choice of optimum stabilizers in terms of 
molecular interaction with the exposed crystal surfaces proved to be difficult. 
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Chapter 3  
 
Nanocrystal Recovery Using Carrier 
Particles 
3.1 Introduction 
The ‗poorly solubles‘ problem is a significant issue for many marketed drugs 
and potential drug candidates. Indeed up to 40% of molecules in the 
development pipelines and approximately 60% of the molecules derived from 
high throughput screens exhibit markedly low aqueous solubility (Merisko-
Liversidge and Liversidge, 2008, Stegemann et al., 2007) The issue with 
poorly soluble drugs is that the low aqueous solubility can result in poor and 
erratic bioavailability. Low aqueous solubility can result from a low inclination 
of the molecule to be solvated by water and/or from a notable resistance of 
the crystal structure to dissolve owing to a high lattice energy (Kipp, 2004). 
For these molecules, consistent and enhanced bioavailability can be 
achieved if the dissolution rate can be sufficiently enhanced, or if the active 
substance is solubilised.  Approaches that can enhance dissolution include 
engineering stable amorphous or metastable solid forms of the drug, 
micronisation,(Charoenchaitrakool et al., 2000) solid dispersions (Serajuddin, 
1999), and the more recent addition, nanocrystals (Gao et al., 2012, Müller 
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and Keck, 2012, Muller and Akkar, 2004, Keck and Müller, 2006, Wang et al., 
2012, Müller et al., 2011, Masuda, 2011).  
Nanocrystals offer an immense surface area, an increased saturation 
solubility, and a decrease in the diffusional pathway adjacent to the 
nanocrystal surface, which all converge to substantially increase the rate of 
dissolution (Müller et al., 2011, Buckton and Beezer, 1992, Wu and 
Nancollas, 1998, Moeschwitzer and Mueller, 2006, C.M. Keck, 2010, Ponchel 
et al., 1997). The use of nanocrystals and nanosuspensions is fast becoming 
a platform technology, in particular in addressing the problem of poorly 
soluble (Muller, 1999, Müller and Keck, 2012). Although the technology is 
maturing, there are still important issues and limitations. A particular issue is 
the need and difficulty in recovering/isolating the nanocrystals in the dry state 
for incorporation, for instance, in solid dosage forms. Nanocrystals of drugs 
are generally produced in suspension and the solid must then isolated by 
removing the solvent. Current methods for isolating nanocrystals in the dry 
state include spray drying (Hu et al., 2010, Patravale and Kulkarni, 2004, 
Chaubal and Popescu, 2008, Liu et al., 2010, Mou et al., 2011, Basa et al., 
2008), freeze drying(de Waard et al., 2009, Choi et al., 2004, Beirowski et al., 
2011, Abdelwahed et al., 2006) and spray granulation(Bose et al., 2012, 
Keck and Müller, 2006, Abdelwahed et al., 2006, Kocbek et al., 2006). Spray 
drying can introduce instability owing to the heat and high energy involved 
the process (Freitas and Müller, 1998). Freeze drying is an expensive, time 
consuming process which can adversely affect the resulting particle size 
distribution (Abdelwahed et al., 2006). Additionally isolated nanocrystals 
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using nanosuspension as granulating fluid has exhibited decrease in 
dissolution rate (Basa et al., 2008). 
We report here a simple approach for recovering nanocrystals from a 
suspension using inert carrier particles. Whilst the concept of using carrier 
particles is not new (consider its widespread application in dry-powder inhaler 
formulations (Hooton et al., 2008, Hickey, 2005, HW Frijlink, 2004, Ian 
Ashurst, 2000, Prime et al., 1997, de Boer et al., 2012) and in ordered 
mixing(C. W. Yip & J. A. Hersey, 1976, Hersey, 1975, Yeung and Hersey, 
1979), to our knowledge this is the first open literature application of this 
approach for isolating nanocrystals from suspension. The isolated 
nanocrystal-carrier particles in powder form present the possibility of 
developing solid dosage forms such as tablets and capsules for oral 
administration with a marked potential for enhancement in dissolution rate. A 
key gain is the complete elimination of the problems of aggregation and 
Ostwald‘s ripening that plague nanocrystals in a liquid environment. The 
nanocrystal-carrier particles are shown to consistently reproduce the high 
dissolution rate of the original nanocrystal suspension. The methodology is 
robust and from the industry‘s perspective relatively low cost. Given that 
adsorption of the nanocrystals onto the carrier particle must depend on the 
particle size, crystallinity, and surface characteristics of the respective 
particles, we evaluated the adsorption efficiency for nanocrystals of two 
model drug compounds, ibuprofen and glibenclamide (Figure 3.1), produced 
by comminution, and in the case of glibenclamide also by simple precipitation. 
We have also attempted to rationalize the variation in adsorption efficiency 
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observed for the two compounds in terms of the molecular interactions at the 
crystal surfaces.  
 
Figure 3.1 Molecular structure of (a) glibenclamide and (b) ibuprofen (These 
structures have been created using (Marvin sketch) 
 
3.2 Materials and Methods 
3.2.1 Materials 
The chosen model drugs glibenclamide (Batch No. PPC/08/GLB/057) and 
ibuprofen (Batch No. 7050-1077) were purchased from Anzen Exports, 
Kolkata, India and Albemarle Corporation, USA, respectively. 
Hydroxypropylmethylcellulose (HPMC) of viscosity grades 6 cps (Batch No: 
8028213) and 15cps (Batch No. 7068037) were kindly provided by Shin-Etsu, 
Japan. Polyvinylpyrrolidone K-30 (PVP) (Batch No. 08297047GO) was 
purchased from BASF, Germany. Sodium lauryl sulphate (SLS), (Batch No. 
08421LE), sodium hydroxide (NaOH) (Batch No. S47417-479) and 
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monobasic potassium phosphate (MPP) (Batch No. SZE90330) were 
purchased from Sigma Aldrich, UK. Polyethylene glycol 400 (PEG-400) 
(Batch No. 0917861) and acetonitrile (Batch No. 0809411) were purchased 
from Fisher Scientific, UK. Dibasic calcium phosphate (DCP) (Batch No. 
A0280641) was purchased from Acros Organics, Belgium. 
3.2.2 Methods 
3.2.2.1 Preparation of Glibenclamide and Ibuprofen 
Nanocrystals by    Controlled Comminution   
   
Nanocrystals of glibenclamide and ibuprofen were prepared using the DENA 
DM100 size reduction system (Sulaiman, 2007). The DENA DM100 system 
comprises a fast rotating conical rotor constructed from a soft polymer, which 
sits inside a conical polymeric sleeve. Grinding media (0.2 mm yttrium 
reinforced zirconium beads) are housed inside indentations within the rotor 
which form a narrow gap between the outer sleeve and rotor. The high shear 
and turbulence generated within this narrow gap provide the potential for 
rupture and shearing of particles leading to ultrafine product in the sub-
micron size range. The suspension produced during processing is continually 
recycled through a stainless steel screen which retains the grinding media 
and prevents contamination of product. The drug material was presented for 
size reduction in the form of a stabilized aqueous suspension, with the 
dispersion media (150 ml) being composed of sodium lauryl sulphate (0.1% 
w/w), PVP-K30 (0.5 %w/w) and 6 cP grade HPMC (0.5 %w/w). The drug 
substance was mixed with the stabiliser solution give a 250 ml suspension 
containing 2.6 %w/w of the drug material. The resultant suspension was then 
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placed into the feedstock hopper of the size reduction system. The 
suspension was processed for 60 minutes by recycling through the size 
reduction chamber. In-process samples were taken at intervals of 5, 10, 15, 
30, 45 and 60 minutes with the particle size being measured by dynamic light 
scattering (DLS) using the Zetasizer Nano instrument (Malvern Instruments 
Ltd, UK).  
3.2.2.2 Preparation of Glibenclamide Nanosuspension Using   
Controlled Crystallization Method 
   
The nanoparticles of glibenclamide were fabricated by infusing 2.7ml of the 
stabilizer solution comprising of HPMC (15cps) (1% w/v) and PVP K-30 
(0.5 %w/w) at an infusion rate of 100ml/minute into 0.3 ml of drug solution 
(5mg/ml) dissolved in polyethylene glycol 400 (PEG-400). The solution was 
stirred in a 10ml vial using a magnetic stirrer at 1200rpm with the sample 
temperature maintained at 25°C. Five replicate batches were prepared to 
ascertain the variability in the process. The process was also replicated at 
scales of 10ml, 100ml and 400ml using identical process conditions.  
3.2.2.3 Particle Size Measurements 
Particle size of the nanocrystals and associated polydispersity index (PI) 
determinations were conducted in triplicate by dynamic light scattering 
(Zetasizer® NanoS, Malvern Instruments, UK), which measures the 
hydrodynamic diameter including the solvation layer around each particle 
(Aboofazeli et al., 2000).  
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3.2.2.4  PXRD Studies 
The crystallinity of the nanocrystals was assessed by powder X-ray 
diffraction (PXRD) (and DSC, see above) using dried powders recovered 
from the nanosuspensions by centrifugation at 14500 rpm for 60 minutes and 
drying under ambient conditions. PXRD studies were carried out using a 
Bruker D-8 powder diffractometer (Bruker Kahlsruhl, Germany). For the 
nanocrystal samples we employed a silicon-well sample holder, whilst for the 
original raw drug material a plastic sample holder was used. Calibration of 
the PXRD was carried out using a corundum standard. The samples were 
scanned in triplicate over the range 5-50° 2θ at a rate of 1º 2θ/min using a 
copper Kα radiation source at a wavelength of 1.542 Å and with 1 mm slits. 
3.2.2.5  Chemical Stability of the Nanocrystal Suspensions 
The glibenclamide and ibuprofen content in the respective nanosuspensions 
was determined using an HPLC system consisting of a Waters 2695 Model 
connected to a UV detector. For glibenclamide the UV detector wavelength 
was set at 254nm. The mobile phase solvent system comprised monobasic 
ammonium phosphate (0.02M) and acetonitrile at a ratio of (45/55 v/v). The 
flow rate of the mobile phase was set at 1.5ml/minute. An Ultra II TM C18 
5µm 250×4.6mm column was used which was maintained at a temperature 
of 30°C. For ibuprofen content the wavelength of the UV detector was set at 
214nm and a Vydac® 202TP C18 5µm, 4.6 × 250mm, column was employed, 
being maintained at a temperature of 30°C. The mobile phase consisted of a 
binary 50:50 v/v mixture of water and acetonitrile. The pH of mobile phase 
was 2.8 and the flow rate of the mobile phase was set at 1ml/minute. All the 
samples were analysed in triplicate. 
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3.2.2.6  Nanocrystal Particle Size Stability 
The particle size stability of glibenclamide and ibuprofen nanosuspensions 
was monitored regularly using DLS over a period of 1 month, with the 
nanosuspensions being stored at three different temperatures (4°C, 25°C 
and 40°C). These studies enabled an assessment of level of agglomeration 
and Ostwald ripening of the nanocrystals. 
3.2.2.7 Nanocrystal Adsorption on Carrier Particles 
The carrier particle material was dibasic calcium phosphate. The particle size 
analysis of dibasic calcium phosphate was carried out, using a laser 
diffraction particle size analyser (Sympatec HELOS and RODOS, Sympatec 
Instruments, UK). The adsorption efficiency of the carrier particles was 
investigated at range of carrier particle concentrations: 30 mg/ml, 60 mg/ml, 
90 mg/ml, 120 mg/ml, 150 mg/ml and 180 mg/ml. The dibasic calcium 
phosphate  was added to 10 ml of the nanosuspension samples and stirred 
for 5 minutes by a magnetic stirrer  at about 400 rpm at 25ºC, followed by 
filtration using a 0.4 micron filter paper. The filtered samples were dried at 
room temperature and subjected to analysis of active agent content by HPLC. 
To enable an objective comparison of adsorption efficiency, the 
glibenclamide nanosuspensions prepared by comminution were diluted to an 
equivalent concentration of the nanosuspensions prepared by controlled 
crystallization, giving a final concentration of 1.43mg/ml drug for both process 
variants. 
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3.2.2.8 Determination of Ibuprofen and Glibenclamide 
Contents Adsorbed to Dibasic Calcium Phosphate. 
 
HPLC analysis of the ibuprofen content in the nanocrystal-carrier powders 
was undertaken by weighing known quantities of the dried adsorbates then 
diluting with the mobile phase (55/45% v/v acetonitrile and water) to a volume 
of 100ml to give a nominal concentration of 20 µg/ml assuming that complete 
adsorption of drug had occurred. The resultant solution was sonicated and 
then centrifuged for half an hour at 14700rpm to cause the separation of 
bounded nanocrystals. The supernatant layer was then analysed in triplicate 
by HPLC. The injection volume for the HPLC during this analysis was 
maintained at 25 l. These steps were repeated for glibenclamide content in 
the adsorbates. However, dilution of the analytical samples was undertaken 
using the mobile phase 55/45%v/v ammonium phosphate (0.02M) and 
acetonitrile and an injection volume of 50 µl. 
3.2.2.9  Scanning Electron Microscopy (SEM) 
SEM images of the raw dibasic calcium phosphate carrier material, along 
with that of the nanocrystals of glibenclamide and ibuprofen adsorbed on the 
carrier particles were taken using a Quanta 400 SEM (FEI Company, 
Cambridge, UK). The SEM studies were carried out to investigate the 
adsorption of nanocrystals onto the surface of DCP. The samples were 
prepared by fixing the powder samples on to a metal stub using a double 
sided adhesive tape followed by gold coating. The instrument was calibrated 
using a gold grid obtained from the supplier. 
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3.2.2.10 Dissolution testing 
Dissolution studies were performed on nanosuspensions of glibenclamide 
and ibuprofen, the respective adsorbates on the carrier particles, and existing 
commercial preparations. Each test employed a dose equivalent to 5 mg of 
glibenclamide and 200 mg of ibuprofen. The USP dissolution apparatus II 
(USP, 2008) was employed with 900 ml of the dissolution medium (buffer at 
pH 7.2) at 37ºC and a paddle speed of 50rpm. Aliquots of 5 ml of the 
dissolution media were sampled using a syringe filter (0.2 µm) at 0, 2, 6, 10, 
15, 30, 45 and 60 minutes, the sample volume being replaced with an 
equivalent volume of fresh media. All the samples were analysed in triplicate 
using the HPLC method given above to quantify drug concentration. The % 
of the nominal dose of each drug released for each of the formulations at 
specific time intervals was then calculated. 
 
3.3  Results and Discussions 
3.3.1 Characterisation of Glibenclamide and Ibuprofen 
Nanosuspensions  
3.3.1.1 Particle Size Measurements Ibuprofen and 
Glibenclamide Nanosuspensions 
   
The systems being studied, nanosuspensions and nanocrystals adsorbed on 
carrier particles are clearly heterogeneous in nature. Therefore, one would 
expect variability in results which can make it hard to generalize findings.  In 
view of this it is essential to characterize the systems thoroughly, to control 
known factors, and cover the effect of some of broader variables. We have 
followed this philosophy here and have considered two distinct molecules for 
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the study and also utilized the two main (and disparate) approaches for 
preparing nanocrystals, namely top-down comminution and the bottom-up 
precipitation method. Dibasic calcium phosphate was chosen as the carrier 
particle material as it has a low aqueous solubility and has previously been 
reported as good inert carrier for adsorption of microparticles (Seth, 
1988).The results clearly reveal that the carrier particle approach to 
recovering nanocrystals from suspension is effective and robust. It is possible 
to recover/isolate up to 98% of the nanocrystals in the suspension, and the 
fast dissolution rate characterizing the nanosuspensions is reproduced by the 
nanocrystals adsorbed onto the carrier particles. 
We were able to prepare stable nanocrystals using both controlled 
comminution and precipitation. The effectiveness of the comminution 
approach using the DENA DM100 size reduction system has detailed earlier 
(Plakkot et al., 2011, Sulaiman, 2007). Here we briefly illustrate this by 
reference to Figure 3.2 which displays the particle size of the materials as 
function of processing time. It is apparent that a processing time of about 45 
minutes is sufficient to induce the maximum attainable reduction in particle 
size, after which the gain is minimal. After 60 minutes the respective particle 
size for glibenclamide and ibuprofen is 342 ± 3 (Figure 3.3) and 440 ± 5 nm 
(Figure 3.4). Average polydispersity index (PDI) values for both drug 
materials were <0.5 indicating narrow size distribution for 
nanosuspension(Deng et al., 2010) 
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Figure 3.2 Particle size distributions of glibenclamide (a) and ibuprofen (b) as a 
function of processing time in the DENA DM100 size reduction system 
 
Nanocrystals of glibenclamide prepared by controlled precipitation had an 
average particle size of approximately 300 ± 3 nm with low polydispersity 0.2 
± 0.02 (Figure 3.5), which is slightly lower than that attained by comminution, 
342. Similar particle size profiles were obtained when the process was 
scaled-up from 10 ml to 100 ml and 400 ml (Figure 3.6).  
 
 
Figure 3.3 Particle size distribution of milled glibenclamide 
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Figure 3.4 Particle size distribution of milled ibuprofen 
 
 
Figure 3.5 Particle size distribution for crystallised glibenclamide 
 
 
Figure 3.6 Particle size distribution for crystallised glibenclamide nanosuspensions 
at three different scales (10ml, 100ml and 400ml) 
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3.3.1.2 PXRD Studies 
With respect to powder X-ray diffraction, the nanocrystal samples gave peaks 
in essentially identical positions to those of the original powders thus 
confirming the identity and crystallinity (Figure 3.7). The smaller particles can 
cause broadening and disappearance of some peaks due to small angle 
reflection by the particles that shifts the peak intensity to lower level (Bunjes 
et al., 2000). 
 
Figure 3.7 PXRD patterns of unprocessed and processed (a) ibuprofen and (b) 
glibenclamide 
0             10                  20                 30                 40                 50      
2-Theta Scale 
Processed Ibuprofen
Unprocessed Ibuprofen
0                10                   20                    30                   40                  50      
2-Theta Scale 
Processed  Glibenclamide
(crystallised )
Processed  Glibenclamide
(size reduced)
Unprocessed  
Glibenclamide
(a)
(b)
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The marked variation in the peak intensity of the unprocessed samples is 
considered to be due to preferred orientation effects. 
3.3.1.3  Physical and Chemical Stability Studies.  
Physical stability of the nanocrystals is an important issue and nanocrystals 
in suspensions are prone to aggregation and Ostwald‘s ripening which can 
increase particle and also lead to sedimentation and caking. For both drug 
materials the particle size was found to be relatively stable for up to 30 days, 
with slight growth over the first 10 – 15 days (Figures 3.8 and 3.9).  
 
Figure 3.8 Particle size of nanocrystals of glibenclamide as a function of storage 
time at 25 C 
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Figure 3.9  Particle size of nanocrystals of ibuprofen, as a function of storage time 
at 25 C.  
 
HPLC assay results shown in Table 3.1 demonstrated that >90 % of the 
nominal drug content was recovered from nanosuspensions of both drugs, 
whilst for glibenclamide the degree of recovery was greater for the 
crystallized suspensions than for the formulations produced by size reduction. 
The slight reduction in drug content observed for the size reduced 
nanosuspensions for both drugs is probably related to retention of solids on 
grinding media and on the stainless steel screen which is designed to retain 
coarse particles and the grinding media within the size reduction chamber. 
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Table 3.1  Quantification of glibenclamide and ibuprofen nanosuspensions 
 
 
 
 
 
 
 
 
3.3.1.4  Adsorption Studies 
Table 3.2 shows HPLC results which demonstrates that greater levels of 
glibenclamide adsorption were observed at the highest concentrations of 
DCP ((X90= 44.85 µm), regardless of the method of fabrication 
(crystallization and comminution). At concentration 180mg/ml the maximum 
adsorption was found, where >95% of the drug nanocrystals were obtained 
from the filtrate (Figure 3.10). In this regard, it is probable that greater 
adsorption was derived from marked increase in the surface area of DCP 
available for adsorption at high concentration. DCP has previously been 
reported as good inert carrier for adsorption of microparticles (Seth, 1988). 
Milled nanocrystals however exhibited a slightly greater affinity for adsorption 
than the crystallised counterparts. A number of previous articles describing 
the impact of comminution have suggested that size reduction is often 
responsible for mechanical activation in which the crystalline surfaces  
Samples 
Drug 
concentration 
(mg/ml) in 
nanosuspension 
Percent nominal 
Glibenclamide 
nanosuspesion 
(size reduced) 
23.5.0± 1.5 90.30± 0.25 
Glibenclamide 
nanosuspesion 
(crystallized) 
0.49 ± 0.2 98.00±  0.5 
Ibuprofen 
nanosusepsnion 
(size reduced) 
23.0±2.0 91.00±2.0 
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Figure 3.10 The degree of isolation of glibenclamide and ibuprofen nanocrystals 
onto DCP achieved from both milled and crystallisation as a function of DCP 
concentration. 
 
become disordered with concomitant increases in surface free energy 
(Hüttenrauch et al., 1985, Roberts et al., 1994, Verma et al., 2009, Delogu, 
2005). It is this increase in surface energy caused by exposure to high 
energy during processing which is probably responsible for increased 
adhesion to the inert carrier (Annapragada and Adjei, 1996, 
Tangsathitkulchai, 2003, Hüttenrauch et al., 1985). At higher concentrations, 
this enhanced interaction for adsorption was however negligible (where only 
a 5% difference existed) with ample surface being available for particle 
adsorption at the highest concentrations of DCP and subsequent saturation 
of the carrier surface. The stirring and agitation allowed the nanocrystals to 
be mixed and adsorbed onto the DCP surface. 
The DCP adsorbates recovered after mixing with size reduced samples of 
ibuprofen and glibenclamide also demonstrated the relationship between the 
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concentration of the inert carrier, and the degree of recovery of drug 
nanocrystals (Tables 3.2 and 3.3). Nonetheless the results shown in Table 
3.2 also demonstrated that the relative affinity of glibenclamide for adsorption 
onto the surface of DCP particles was markedly greater than for ibuprofen, 
with only 90% being recovered for ibuprofen particles compared for the levels 
of 97% observed for size reduced glibenclamide samples. It is probable that 
this finding relates in part to differences in the molecular nature of the 
surfaces of nanoparticles constructed from the two drug compounds. 
Glibenclamide is a molecule which comprises two main functional groups, 
one being a carboxylic acid and the other an aromatic ring (Figure 3.1). The 
comparative adsorption tendencies of the drug to DCP have been shown in 
Figure 3.10. The structure of glibenclamide contains eight hydrogen 
acceptors and three hydrogen donors and contains moieties rich in both 
nitrogen and oxygen(Byrn et al., 1986) which provides potential for strong 
intermolecular interactions with the DCP substrate rich in phosphate groups 
and water of crystallization.  
What might be the essential factors for maximizing the adsorption efficiency 
and at the same time keeping the self-aggregation of the nanocrystals at a 
minimum? This problem is similar to that encountered in the design of 
formulations for dry-powder inhalers, where micron-sized drug particles are 
adsorbed onto a large carrier particle to deal with the cohesiveness and 
resulting poor flow of the micronized drug material (Lohrmann et al., 2007, 
Bunker et al., 2005, Adi et al., 2007, T. Srichana, 1998, De Boer et al., 2005).  
The two problems, however, are not identical. There are a number of 
distinctions. For the nanocrystal problem (i) the adsorption occurs in a liquid 
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medium, which has the potential to modulate the nanocrystal-carrier 
interaction; (ii) excessively strong adsorption of the nanocrystals onto the 
carrier particle is not an issue, since the detachment of the nanocrystals is 
not of interest; (iii) the nanocrystals in suspension are generally stabilized 
against aggregation and their surfaces will have significant amounts of 
adsorbed polymer and surfactants.  
For the drug-carrier problem in the dry-powder inhaler context, some of the 
important factors include hygroscopicity, surface roughness, particle size and 
shape, and surface energy of the respective particles, and drug-carrier 
adhesion (Saleem et al., 2008, Hooton et al., 2008, Traini et al., 2005, Islam 
et al., 2005, Srichana et al., 2000, T. Srichana, 1998, Dickhoff et al., 2006, 
Larhrib et al., 2003, Flament et al., 2004, Zeng et al., 2000, Podczeck, 1999, 
Price et al., 2002, Adi et al., 2008). Clearly, in the nanocrystal context, 
hygroscopy is not a factor since we are dealing with solid-solid interactions in 
a liquid medium. On the other hand, crystal particle size and shape and 
crystal surface characteristics are pertinent, the latter in particular influencing 
drug-carrier interaction. A particularly useful concept is the cohesive-
adhesive balance (CAB)(Begat et al., 2004, Begat et al., 2005, Hooton et al., 
2006, Jones et al., 2008) which characterizes the cohesion of the drug with 
itself relative to the adhesion of the drug particles to the carrier particles. A 
CAB ratio < 1 characterizes a situation where the drug‘s interaction with the 
carrier particle (adhesion) is stronger than that between the drug particles 
themselves (cohesion). To maximize the nanocrystal-carrier adsorption 
efficiency a high adhesive interaction between the nanocrystal and the carrier 
particle is essential. To keep the self-aggregation of the adsorbed 
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nanocrystals to a minimum so as to maintain the original surface for rapid 
dissolution, the requirement is low cohesion between the nanocrystals. 
Therefore, we need to aspire for a CAB ratio << 1 in developing an 
appropriate formulation of the nanocrystal suspension and/or in selecting an 
appropriate carrier particle. Low cohesion between nanocrystals is an 
essential requirement anyhow in developing stable nanosuspensions. The 
focus therefore shifts to maximizing the interaction between the nanocrystals 
and the carrier particles. An additional consideration is how the liquid medium 
in the nanosuspensions modulates the nanocrystal-particle interaction?. This 
cannot be predicted for a given system even in general terms, given the 
heterogeneous nature of nanosuspensions containing surfactant and/or 
polymer stabilizers. However, in principle a change in the nature of the liquid 
medium coupled with an appropriate choice of a carrier particle could 
facilitate adsorption of the nanocrystals onto the carrier due to hydrophobic-
type forces. For instance, if the nanocrystal material and the carrier particle 
were relatively hydrophobic, then in an aqueous medium the hydrophobic 
forces would actively promote the adsorption process (Israelachvili and 
Pashley, 1984, Ducker et al., 1994, Liang et al., 2007). Indeed these 
considerations suggest that a one-step process using the precipitation 
method in the presence of carrier particles could be an effective approach.    
We noted above that the adsorption efficiency for the two drugs prepared by 
comminution showed a small but a systematic difference, the recovery of 
glibenclamide nanocrystals being slightly higher at all concentrations of the 
carrier particles. Whilst the nanocrystal-carrier particle interaction is likely to 
be complex due to the presence of adsorbed stabilizers and the fact that it 
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occurs in a aqueous medium, we explored the possibility of rationalizing the 
differences in the adsorption efficiency on the basis of molecular interactions 
on the crystal surfaces of the two drug materials. Crystal morphology 
calculations were undertaken for the drug materials to identify the functional 
groups exposed at the dominant surfaces of crystals (Chapter 2 (Section 
2.2.2.9)). For ibuprofen the habit is dominated by the (100) face (65%) which 
is essentially non-polar (Figure 2.17). For glibenclamide the calculations 
revealed two major faces (10-1) (23%) and (011) (36%) both of which are 
polar in nature exposing SO, NH and CO groups (Figure 2.18). Focusing on 
the carrier, the major habit face for dibasic calcium phosphate is known to be 
face (010) is dominated by repeating units of the polar functional groups that 
include OH and PO4 (Dickens et al., 1972, MacLennan and Beevers, 1955, 
Louati et al., 2005, Sivakumar et al., 1998, Abbona et al., 1993).  
The dominant faces for the two major morphologies calculated for 
glibenclamide were characterized by polar functional groups with potential to 
form hydrogen bonds, which supports the strong adsorption to DCP observed 
in experimental studies. This type of interaction of DCP with ionic surfactants 
has also been reported previously (Wei et al., 2007).  It can therefore be 
summarized that ibuprofen with its predominance of non polar functional 
groups is likely to exhibit lower adsorption than glibenclamide which 
demonstrates greater potential for hydrogen bonding. 
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Table 3.2 Quantification of glibenclamide content on the surface of DCP. (*Assumes complete retention of drug on DCP surface) 
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% of the 
drug 
isolated± 
Standard 
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Drug contents 
isolated 
(µg/ml) 
% of the 
drug 
isolated± 
Standard 
deviation 
30 124.5 100 20 3.00 15.00±1.00 4.00 20.00±1.5 
60 246.9 100 20 4.10 20.5±2.25 5.60 28.00±2.0 
90 369.35 100 20 5.40 27.00±3.00 10.00 50.00±2.5 
120 491.8 100 20 10.00 50.00±1.50 16.00 80.00±1.2 
150 614.25 100 20 17.00 85.00±1.00 18.80 94.00±1.0 
180 736.7 100 20 18.40 92.00±1.25 19.50 97.5.00±0.50 
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Table 3.3 Quantification of DCP powder recovered after mixing with glibenclamide and ibuprofen nanosuspensions size reduced 
(*Assumes complete retention of drug   on DCP surface) 
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% of the 
drug 
isolated± 
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deviation 
Drug contents 
isolated 
(µg/ml) 
% of the 
drug 
isolated± 
Standard 
deviation 
30 124.5 100 20 3.00 15.00±1.00 4.00 20.00±1.5 
60 246.9 100 20 4.00 20.00±2.25 5.60 28.00±2.0 
90 369.35 100 20 5.00 25.00±3.00 10.00 50.00±2.5 
120 491.8 100 20 10.00 50.00±1.50 16.00 80.00±1.2 
150 614.25 100 20 16.40 82.00±1.00 18.80 94.00±1.0 
180 736.7 100 20 18.00 90.00±1.25 19.50 97.5.00±0.50 
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3.3.1.5 SEM Studies  
In addition to HPLC analysis, SEM micrographs of the pure DCP powders 
and DCP recovered from ibuprofen and glibenclamide nanosuspensions 
were generated (Figure 3.11)  
 
Figure 3.11 SEM micrographs of untreated DCP powder and DCP recovered from 
nanosuspensions; (a) = Untreated DCP powder; (b) = DCP recovered from 
Ibuprofen nanosuspension (milled); (c) = DCP recovered from Glibenclamide 
nanosuspension (milled) and (d) = DCP recovered from glibenclamide 
nanosuspension (crystallized). 
 
SEM micrographs of the DCP powder recovered from the nanosuspensions 
mixed with a concentration of 180mg/ml showed that nanocrystals were 
(a)
(d)
(b)
(c)
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adsorbed extensively on to the surface, which can be observed as small 
white deposits. However no deposits were observed on the surface of the 
pure DCP powders (Figure 3.11 (a)). Similarly SEM micrographs of DCP 
powder recovered from crystallized glibenclamide showed fewer nanocrystals 
deposits than the formulation produced using size reduced drug. (Figure 3.11 
(d)) 
3.3.1.6 Dissolution Studies 
The dissolution rates of the glibenclamide and ibuprofen nanosuspensions 
and the respective nanocrystals adsorbed on the carrier particles are 
compared in Figure 3.12, along with suspensions of the micronized drugs 
and marketed tablets. These data revealed the expected rapid dissolution for 
the nanosuspensions for both drug materials, with about 90% dissolving 
within the first 5 minutes or so. Remarkably the dissolution of the 
nanocrystals adsorbed on the carrier particles is also rapid, being only 5-10% 
lower in value at the 5-10 minute sampling points after which the difference 
becomes insignificant.  As expected, the dissolution rates of the suspensions 
of the micronized drugs and the respective tablet formulations are markedly 
lower.  
The results described in Figure 3.12 show that dissolution rate of 
glibenclamide (size reduced and crystallized) and ibuprofen 
nanosuspensions (size reduced) was a faster than observed for the 
microsuspension and marketed tablets. More than 90% of the glibenclamide 
nanosuspension dissolved in 5 minutes which has also been reported 
previously (Van Eerdenbrugh et al., 2008). Approximately 100% of the drug 
from nanosuspensions had already dissolved between 28-55 minutes. There 
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was observed slight reduction in dissolution rate for the adsorbed nanocrystal 
compared to the nanosuspensions of glibenclamide. However these 
formulations showed marked increase in dissolution rate compared to the 
respective glibenclamide microsuspension, marketed tablets and raw powder. 
In addition for ibuprofen nanosuspensions there was observed enhanced 
dissolution rate compared to the commercial products. The drug 
nanosuspensions and the adsorbed ibuprofen on DCP showed > 80% 
dissolution rate within 2 and 10 minutes respectively which is faster 
compared to the spray and freeze dried nanosuspensions (Van Eerdenbrugh 
et al., 2008). Remarkably the dissolution of the nanocrystals adsorbed on the 
carrier particles is also rapid, being only 5-10% lower in value at the 5-10 
minute sampling points after which the difference becomes insignificant. 
The lack of significant lowering of the dissolution rate for the adsorbed 
nanocrystals on the carrier particles (relative to the nanosuspensions) 
suggests that the adsorbed nanocrystals largely remain isolated from each 
with very little loss in surface area due to self-aggregation. Clearly this is an 
essential requirement for the proposed approach of isolating/recovering 
nanocrystals by means of carrier particles from a suspension.  
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Figure 3.12 Dissolution profiles of nanosuspensions, adsorbed nanocrystals on 
carried particles, suspensions of the micronized drug and marketed tablets of (a) 
glibenclamide, (b) ibuprofen. 
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In summary this study demonstrated that nanocrystals without significant 
decrease in surface area can be isolated from nanosuspensions using water 
insoluble large carrier particles.  We isolated nanocrystals of the two drugs 
(ibuprofen and glibenclamide) prepared by both comminution and 
crystallization. However it became evident that both carrier/drug surface 
morphology and the methods producing nanocrystals can affect the drug 
carrier interaction with subsequent isolation of the nanocrystals from 
nanosuspension. The drug surfaces with polar functional groups which form 
hydrogen bonding with carrier particles can lead to comparatively greater 
adsorption onto DCP. It was also observed that nanocrystals produced by 
crystallization have less affinity for the inert support material (DCP) compared 
to the size reduced nanocrystals. The greater tendency of size reduced 
nanocrystals to be adsorbed onto DCP surfaces can be because of the high 
surface free energy caused by mechanical activation. Our objective towards 
isolation of nanocrystals on DCP which have enhanced dissolution rate was 
also achieved because the isolated nanocrystals demonstrated marked 
dissolution rate compared to micronized and marketed tablets.  
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Chapter 4    
 
Coarse Grained Simulation of the Earliest 
Stages of Anti-Solvent Precipitation 
4.1 Introduction 
Nanocrystals are fast becoming a platform solution to address the issue of 
poor solubility associated with hydrophobic drugs, offering immense surface 
area which enhances the dissolution rate. An important set of methods for 
preparing nanocrystals are the bottom up approaches detailed in Section 
1.3.1, which include PCA, RESAS, SFL and EPAS. At the heart of bottom-up 
precipitation methods is crystal nucleation and growth, aspect of which we 
still do not entirely understand (Ruckenstein and Djikaev, 2005). The 
crystallisation process is central to a range of processes taking place in 
nature, pharmaceutical, food and chemical industries. In manufacturing, 
crystallization is employed both for purification and particle formation 
(Erdemir et al., 2009).  A number of products including dyes, explosive and 
materials used in photography are formed by crystallization processes. In 
addition, approximately more than 90% of active pharmaceutical ingredients 
(APIs) and excipients are in crystalline form and controlled crystallization is 
essential to engineering pharmaceutical particles (Morris et al., 2001, Valder 
and Merrifield, 1996). The key step in crystallisation is nucleation as this 
determines the characteristics of the final solid formed.  It is an important 
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step in generation of nanocrystals using anti solvent precipitation 
methodology. 
In the anti-solvent method for preparing nanocrystals, the organic solution 
containing the drug is mixed into an antisolvent containing surfactants and 
polymers. The nucleation rate  during mixing of the two phases depends on 
the level of supersaturation (LaMer and Dinegar, 1950). Nucleation is 
followed by growth of the particles by condensation which involves diffusion 
of molecules to the surface to be incorporated into the solid phase and 
coagulation (Weber and Thies, 2002).  
The particle size of nanocrystals depends on supersaturation and rate of 
nucleation, the higher the nucleation rate the smaller the particle size. During 
crystallisation, if the material can form a number of polymorphic forms, 
initially the metastable structure is formed with subsequent transformation to 
stable phase (Kashchiev, 2000). It is therefore imperative to understand the 
nucleation process and all other factors which influence this process, 
because proper understanding of this process can control the final product 
being crystallised (Schüth, 2001). We also need to understand the role of 
stabilisers in determining the resulting nanocrystal particle size. Whilst we 
have a good general understanding of how stabilisers can prevent particle 
growth and aggregation during top-down processes such as comminution 
and during storage, the role of stabiliser in determining the final particle size 
using precipitation methods remains an open question.  
To get a mechanistic understanding of the earliest stages of crystallisation 
we need to have an atomistic level resolution, which cannot yet be accessed 
using experimental techniques (Schüth et al., 2001). In view of this computer 
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simulation studies including Monte Carlo and molecular dynamic have been 
carried out to gain molecular level insights into the crystallization process 
(Esselink et al., 1994, Mandell et al., 1976, Swope and Andersen, 1990). 
Computer simulations however are still limited in terms of the time and length 
scales that can be accessed. Thus, if a process is relatively slow and has a 
random nature (as does the nucleation process) then it may be outside the 
scope of molecular simulation (Anwar and Zahn, 2011). In view of this we 
need to employ simpler models and one approach is to use a coarse grained 
approach (Marrink et al., 2004, Marrink et al., 2007). 
Coarse grained models use fewer particles to represent the molecules and 
hence are considerably more efficient in accessing longer timescales at the 
cost of chemical specificity. MARTINI force field is used to obtain an 
optimised and quality coarse grained model. This force filed initially 
introduced for lipids but now it has been employed for a range of other 
complex molecules including, amino acids, sterol, surfactants, proteins and 
polymers (Marrink et al., 2004, Marrink et al., 2007, Monticelli et al., 2008, 
Bedrov et al., 2006). MARTINI force field is based on a mapping system, 
which usually group together four heavy atoms as a single bead (4-1 
mapping). However for ring structures 3-1 or 2-1 mapping system is also 
employed.  Particles which are considered as interaction sites in this force 
field include polar, nonpolar, apolar and charged which can be subdivided 
into other types on the basis of hydrogen bonding capabilities. The subtypes 
include donor (d), acceptor (a) both (da) and none (0). In addition, the 
particles are also labelled on the basis of polarity which is from (1-5). Similar 
potential parameters are employed to describe the bonded and nonbonded 
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interactions between the particles in coarse grained modelling as used in 
atomistic modelling. The interaction strength is however different for different 
types of particles. For example, the LJ parameter (ε) ranges from (5.6 - 
2.0kJ/mol). The highest value (5.0kJ/mol) represents the interaction between 
the strong polar particles. Whereas the lower value (2.0kJ/mol) shows the 
interaction between polar and apolar particles. On the other hand, the LJ 
parameter ζ = 0.47nm is considered effective for all the normal particle 
except the ring structures. 
In present study we have investigated the early stages of antisolvent 
precipitation using coarse grained molecular simulation. In the current 
context the use of a coarse grained approach rather than atomistic models of 
specific chemicals is not an issue as the objective is to gain generic insight 
into what happens at a molecular level during anti-solvent precipitation. Thus, 
the interest is in what happens in general terms when poorly soluble 
molecules are precipitated, rather than what may happen for a particular 
system comprising, say, glibenclamide in ethanol using water containing PVP.  
 
4.2  Methodology 
4.2.1 Molecular Simulation of the Earliest Stages of 
Crystallization 
 
The starting system comprised two juxtaposed solution phases, an aqueous 
phase containing PVP in water, and an ethanol phase containing the drug in 
solution (Figure 4.1 (a)). This mimics the initial interaction at the interface as 
the drug solution is dispersed in the aqueous solution containing stabilizers 
during nanocrystal preparation.  
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The drug (solute), water, and ethanol molecules were represented by single 
particles (labelled S, W, and E respectively) interacting with a Lennard-Jones 
(LJ) potential. The PVP molecule comprised 14 monomer units and consisted 
of a backbone of linked LJ particles (labelled BB) with attached particles of 
slighter larger dimension representing the side chain sugar groups (labelled 
SC). The coarse grained model of PVP is shown in Figure 4.1 alongside the 
atomistic model for comparison. The coarse grained particles in the PVP 
backbone and side chains were connected to each other by harmonic bonds 
using the potential function  U(r)=0.5k(r-ro)
2. The bond parameters were 
taken from the Martini forcefield (Marrink et al., 2007). The equilibrium bond 
distance between backbone (BB) particles was set to ro=2.35Å and the force 
constant to k = 12.5 kJ mol-1Å-2. The equilibrium bond distance and force 
constant parameters for BBSC bonds were 4.3Å and k = 12.5 kJ mol-1 Å-2 
respectively. The 3-body angle interactions for the particles in the backbone 
were represented by U (θ) =0.5k (cosθ-cosθo)
 2 with k=25.0 kJ mol-1 and an 
equilibrium angle of 180.0, while for the side chains connected to the 
backbone we employed U(θ)=0.5k(θ-θo)
2 with k = 25.0 kJ mol-1 degree-2 and 
an equilibrium angle of 90. The cosine form is appropriate when the 
equilibrium angle 180.0 for which the harmonic is unstable. The interaction 
parameters of the various coarse grained particles are given in Table 4.1. 
The diameter (the LJ  parameter) of the LJ particles is generally fixed at 
0.47 nm, hence making our parameters in this respect consistent with the 
established Martini force field (Marrink et al., 2007). The LJ  have been 
parameterised to approximately correlate with the melting point of the 
substance or the chemical moieties being represented by the coarse grained 
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particle using the phase diagram of the LJ system (Agrawal and Kofke, 1995, 
Anwar and Boateng, 1998). Thus the models of the drug, water, and ethanol 
have the melting points 423 (150 C), 273 (0C), and 159 (-114 C) K 
respectively. The backbone particles of the PVP molecule were characterised 
by interaction parameters that gave a melting point of approximately 90K (-
183 C) for the monomer units (-CH2-CH2- equivalent) whilst pyrollidone 
particle representation had a stronger interaction reflecting a melting point of 
about 298K (25 C) for this moiety.  The masses of coarse grained (CG) 
particles of water, ethanol and solute particles were 72 amu. For the PVP 
model, the CG backbone particles (BB) mass was taken to be 32.0 amu 
representing a 2-to-1 coarse grained to atomistic mapping while the side 
chain particles (SC) had a mass of 72.0 amu. 
The MD simulations were carried out using DL-POLY2 (Smith et al., 2006) in 
the constant temperature constant pressure (NPT) ensemble. The 
temperature and pressure employed were 298K and 1bar respectively using 
the Hoover algorithm with the thermostat and barostat relaxation times set to 
1.0 ps and 10.0 ps respectively. The time step was 20 fs. The van der Waals 
interactions were truncated at 1.2 nm. The models were uncharged and 
consequently there were no charge-charge interactions. The system 
contained a total of 70000 molecules comprising 17500 drug molecules, 
17500 ethanol molecules, 34977 water molecules, and 23 PVP molecules. 
The simulation covered a period of 180 ns. 
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Figure 4.1 (a) Molecular structure of PVP, (b) coarse grained model of PVP, the 
green particles are referred to as BB (backbone) whilst the red particles are referred 
to as SC (side chain). 
Table 4.1 Lennard-Jones parameters for the coarse grained particles representing 
solute (S), ethanol (E), water (W) and the polymer PVP (BB-backbone particle; SC = 
side chain particle). 
Particle-Particle  
Interaction 
 / kJmol-1  / Å 
BBBB 1.0 4.7 
BBSC 1.9 4.7 
BBS 2.24 4.7 
BBW 1.81 4.7 
BBE 1.81 4.7 
SCSC 3.6 4.7 
SCS 4.5 4.7 
SCW 3.43 4.7 
SCE 3.43 4.7 
SS 5.0 4.7 
SW 2.0 4.7 
SE 3.50 4.7 
WW 3.28 4.7 
WE 3.28 4.7 
EE 3.28 4.7 
180°
90°
(a)
(b)
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4.3 Results and Discussion 
4.4 Molecular simulation of the Earliest Stages of 
Crystallization 
 
Snapshots of the molecular dynamics simulation of the earliest stages of 
precipitation are shown in Figures 4.2, 4.3 and 4.4. The starting system 
consists of two solutions, drug in ethanol and an aqueous solution containing 
the PVP molecules (Figure 4.2 (a)), juxtaposed to each other as might be 
when the volume element of the drug solution is brought into intimate contact 
with the anti-solvent media by mixing. Immediately the two solutions begin to 
mix as the water and the ethanol molecules diffuse across the original 
solvent boundaries (Figure 4.2 (b)). One might expect the water to diffuse 
into the solvent solution thereby reducing the interaction of the resulting 
mixed solution with the  
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Figure 4.2 Snapshots of the (a) molecular dynamics simulation trajectory for the 
juxtaposed volume elements of the solute solution and the anti-solvent; (b) snapshot 
reflecting the initial stages of dispersion of the solute solution into an anti-solvent. 
The solute is represented by red particles, water by grey particles, and solvent by 
green particles. 
 
solute molecules and causing them to aggregate and crystallise. The 
simulations however reveal a slightly different picture. As the two solutions 
begin to mix, in the main it is not the water molecules that diffuse into the 
solvent solution to reduce the solutesolvent interaction; rather the ethanol 
molecules diffuse out from the solute particles into the aqueous environment 
enabling the solute molecules to aggregate and eventually crystallise (Figure 
4.3 (a)). These events are intuitive: the affinity of water for the solute 
0.0ns 0.44ns
A B(a) (b)
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molecules is low and hence water would not be expected to enter in any 
significant way into a solute-rich region. 
 
Figure 4.3 Snapshot (a) shows more than 50% of ethanol particles (Green) mixed 
with water whereas snap shot (b) shows migrating of PVP molecules towards the 
interfaces. Water particles have been removed to show the diffusion of solute 
particles. 
 
 As for the crystallization process itself, we observe a two-stage process, 
aggregation of solute particles in a liquid-like mass and then nucleation, 
which is now an accepted mechanism for nucleation at high supersaturations 
(Anwar and Boateng, 1998, Bonnett et al., 2003, Zhang and Liu, 2009, 
Vekilov, 2004). As the solute molecules consolidate and crystallise we 
observe the migration of the PVP molecules to the crystal surfaces. Being 
PVP migrating  
to interface
(a) (b)
10ns 30ns
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large molecules the diffusion of the polymer molecules is relatively slow 
(Figure 4.3 (b) and Figure 4).  
 
Figure 4.4 Snapshots showing clustering and crystallization of drug particles with 
PVP particles approaching to the interfaces. Solvent and water particles have been 
removed to clearly show the crystallization of drug particles. 
 
This suggests that polymers in general, regardless of whether they have 
surface activity or not, are unlikely to play a significant role in promoting 
nucleation. The phase separation of the solute molecules from the solvent is 
a relatively fast process and polymer molecules which diffuse only slowly are 
unlikely to be involved at the rapidly-emerging solutesolvent interfaces. 
Furthermore, given that nucleation is likely to involve the two step 
mechanism, the important interface that limits nucleation will be between the 
liquid-like solute structure and the emerging nuclei. The polymer molecules 
(a) (b)
Crystalline 
regions
PVP migrating 
to the interface
150ns 180ns
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are likely to be within the aqueous volume element and hence would not be 
expected to be involved within liquid-like solute mass.  
One might consider (or infer from the above discussion) that the size of the 
nanocrystals must be dictated by the volume element of the solvent solution 
that finds itself isolated within the aqueous solution; the size of this volume 
element being dependent on the extent and nature of the mixing, which is an 
issue of bulk mass transfer. Such a consideration, however, cannot explain 
the observed dependence of nanocrystal size (for any given drug substance) 
on the attained supersaturation (Horn and Rieger, 2001). To explain this 
effect, the volume element of the solvent solution must phase separate into a 
number of smaller clusters, each then nucleating to yield a separate 
nanocrystal. Simply having many nucleation events within a large solute 
mass will not yield separate individual crystals but rather a single 
polycrystalline particle.  What might be the drive such a phase separation? At 
high supersaturations the driving force to nucleation becomes so high such 
that the barrier to nucleation is minimal and the system exhibits spinodal 
decomposition (Hilliard, 1970, Favvas and Mitropoulos, 2008), a phase 
separation process which is limited by diffusion and results in regular density 
fluctuations. In the current context, spinodal decomposition would mean 
separate solute clusters within the volume element. The size of these 
clusters will depend on both the extent of supersaturation and the diffusion 
coefficient of the solute. These considerations explain not only the 
dependence of nanocrystal size on attained supersaturation and the issue of 
a factor (diffusion coefficient) intrinsic to the molecule. Equally importantly, 
spinodal decomposition also explains why we are able to obtain nanocrystals 
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using only a magnetic stirrer rather than high-energy mixing techniques; 
spinodal decomposition causes the volume elements of solute in solvent 
attained by simple stirring to phase separate into smaller independent 
clusters. 
In summary this study provided physical insight into the formation of 
nanocrystals during anti-solvent crystallization. It explored the diffusion 
mechanism of solute, solvent and anti-solvent (water) molecules which lead 
to phase separation of the two solutions during mixing process. It became 
evident that the solute molecules here say glibenclamide are crystallized in 
organic solvent region during mixing of the solvent and antisolvent phases. 
This is because of the hydrophobic nature of the drug molecules which 
cannot accommodate the water molecules to be infused and the solvent 
molecules are diffused towards the water phase. In consequent to that the 
drug molecules begin to aggregate followed by nucleation and crystallization.  
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Chapter 5   
 
Phase Stability of Bulk and Nanocrystals 
of Glycine Using Molecular Simulation 
5.1 Introduction 
Polymorphism and unpredicted polymorphic phase transformations can 
present major difficulties and challenges in pharmaceutical development. 
Different polymorphic forms can exhibit markedly different mechanical and 
physicochemical properties that include crystal morphology, solubility, 
dissolution rate, tabletting behaviour, melting point, thermal conductivity and 
chemical stability (Brittain, 1999, Bernstein, 2002). In pharmaceutical 
development the selected polymorphic form of an API can often transform 
from one form to another under the employed tabletting pressure, or on 
storage depending on humidity and temperature causing problems in 
development (Carstensen, 1977, Morris et al., 2001, Lee et al., 2008). The 
control of polymorphism is therefore paramount to producing high quality 
pharmaceutical products (Singhal and Curatolo, 2004, Vippagunta et al., 
2001).  
Polymorphism is also an issue for nanocrystals. Like bulk crystals, 
nanocrystals too can exist in different polymorphic forms. However, the 
phase stability relationships that characterise bulk crystals need not 
characterise nanocrystals. Experimental evidence indicates that as particle 
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size is reduced the phase diagram may change and could lead to a phase 
which was unstable in the bulk crystal becoming thermodynamically more 
stable for nanocrystals (Ranade et al., 2002, McHale et al., 1997, Garvie, 
1978). Figure 5.1 (a) show the effect of particle size on phase stability of 
different polymorphs of TiO2 and schematic representation of the effect of 
size on phase stability as a function of temperature respectively (Figures 
5.1(b)).  
 
Figure 5.1 (a) Effect of particle size on stability of various phases of TiO2 as a 
function of particle size (Ranade et al., 2002) and (b) schematic representation of 
the effect of temperature (T) on phase stability of different phases of a crystal as a 
function of particle size. 
 
According to the Ostwald step rule, during nucleation the newly created first 
phase is a metastable phase which transforms subsequently to a stable 
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phase (Ostwald, 1897). This mechanism was qualified by Stranski and 
Totomanow (Stranski and Totomanow, 1933) , that the first phase formed is 
that for which the nucleation barrier is the lowest. The interplay of the bulk 
and interfacial free energy of the new phase are considered the key 
determinant for understanding the phase transformation steps until the 
thermodynamically stable phase is produced (D. Zahn, J. Anwar, Size-
Dependent Phase Stability of a Molecular Nanocrystal: a Proxy for 
Investigating the Early Stages of Crystallization, Chem. Eur. J. 2011, 17, 
11186 – 11192). These two quantities alter as a function of particle size of a 
crystal. Therefore the stability of a particular phase in bulk crystal form could 
be different from that in the nanocrystal form. Being able to prepare stable 
nanocrystals of a crystalline phase which otherwise would be unstable in bulk 
offer new opportunities both technically and commercially e.g. in the form of 
intellectual property. The present study employs molecular simulation to 
investigate the phase transformation behaviour between various forms of the 
model compound glycine in both bulk crystals and nanocrystals as a function 
of both temperature and pressure. Glycine was chosen as its crystallization 
behaviour, polymorphic forms and phase transformations are well 
characterised experimentally. 
 Glycine (NH2CH2COOH) is one the simplest amino acids and is widely used 
in a number of pharmaceuticals either by itself or as intermediate agent for 
synthesis of pharmaceutical compounds which include nucleic acids 
(Rabesiaka et al., 2010). The molecule exists in its zwitterionic (H3N+–CH2–
COO−) form both in the solid and in solution. It has three polymorphs α, β and 
γ at ambient temperature and pressure (Albrecht and Corey, 1939). Recently, 
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two other polymorphs of glycine (δ-glycine and ε-glycine) have been reported 
to exist at high pressure (Dawson et al., 2005). All these polymorphs exhibit 
different physical properties including densities, shapes, space group 
symmetries, solubility and bioavailability. At ambient temperature and 
pressure the order of thermodynamic stability between the main polymorphs 
is as γ > α > β (Sakai et al., 1992). A high temperature and pressure is 
required for phase transformation between the three polymorphs (Kvick et al., 
1980a, Ferrari et al., 2003, Iitaka, 1961, Boldyreva et al., 2003). β- polymorph 
is the least stable and is rapidly transformed either to α or γ forms in the 
presence of moisture at room temperature (Kvick et al., 1980a, Ferrari et al., 
2003).  The β-phase transforms to α-phase at temperature >373K (Iitaka, 
1961, Dang et al., 2009, Drebushchak et al., 2002b). The α phase can 
transform to the more stable γ- phase at around  443K (Park et al., 2003, 
IITAKA, 1954). 
Whilst the γ- phase is thermodynamically stable phase at ambient 
temperature and pressure, it is possible to crystallise other forms by varying 
the crystallisation conditions. The important factors affecting the choice of 
form that crystallises include nature of solvent, concentration of solution, 
mixing, agitation rate seeding and cooling rate (Myerson, 2002).  
All the three ambient temperature and pressure polymorphs of glycine are 
soluble in water and these can be recrystallised either by cooling or 
evoparation (Lin and Pepe, 1998). The α-phase with the space group (P21/n) 
can be obtained by cooling from a supersaturated aqueous solution. The 
cooling rate of the supersaturated aqueous solution needs to be controlled at 
a rate of 1K/30 minutes from 353K till room temperature.  The β phase with 
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space group (P21) was first crystallised from a mixture of water-alcohol 
solution (Iitaka, 1958). Crystallisation of glycine from a mixture of water 
ethanol at different ratios resulted in needle-like β-polymorph of glycine 
crystals (Weissbuch et al., 2005). A decrease in solubility of glycine in a 
mixture of water-alcohol becomes evident by high content of alcohol with a 
subsequent increase in solvated glycine monomers followed by precipitation 
β- polymorph of glycine. The γ-polymorph can be crystallized from 
supersaturated aqueous solution by evaporation or by acidification of the 
solution by acetic acid or by making the solution alkaline with ammonium 
hydroxide (Iitaka, 1958) (He et al., 2006).  
The α polymorph of glycine grown from supersaturated aqueous solution with 
bipyramidal crystal habit is composed of centrosymmetric bilayers of 
zwitterionic molecules (Figure 5.2) tailored by NH----O hydrogen bond 
interactions (Weissbuch et al., 2005).  
 
Figure 5.2 Molecular packing arrangement in the α form of glycine (The hydrogen, 
oxygen and nitrogen atoms are shown in gray, red and sky blue respectively). 
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The β glycine form comprises a single layered hydrogen bonded monomers 
units (Figure 5.3) (Iitaka, 1961) . Structurally γ polymorph is quite different to 
α and β. In the γ polymorph the molecules are linked to each other via 
hydrogen bonding involving nitrogen and carboxylic oxygen (N…. O), resulting 
in helical chains which are linked together by lateral hydrogen bonds (N…. O) 
with a consequent three dimensional lattice  (Boldyreva et al., 2003, Iitaka, 
1958) (Figure 5.4). 
 
Figure 5.3 Molecular packing arrangement the β form of glycine 
128 
 
 
Figure 5.4 Molecular packing arrangements in the γ form of glycine 
In contrast to α and β polymorphs the oxygen and nitrogen atoms are in the 
same direction. In the crystal lattice of γ-glycine every third molecule have 
the same conformation (Figure 5.4). At ambient temperature the torsion 
angles of zwitterions tailoring structure of the three polymorphs (α, β and γ) 
are different from each other which are (161.8°) (Jonsson and Kvick, 1972), 
(157.41°) (Drebushchak et al., 2002a) and (167.1°) (Kvick et al., 1980b).  
A wide range of studies have been conducted to investigate the existence of 
new polymorphs at high pressure (Dawson et al., 2005, Boldyreva, 2003, 
Boldyreva, 2007a, Moggach et al., 2008, Boldyreva, 2007b, Perlovich et al., 
2001). Two newly investigated high pressure polymorphs (δ-glycine and ε-
glycine) have been reported from compressing β and α-polymorphs using 
high pressure respectively. Among the three polymorphs (α, β and γ), α-
polymorph has been reported the most stable high pressure polymorph. 
Whereas transformation of β and γ occurs respectively to δ and ε-
polymorphs at 1.9GPa and 4.3GPa respectively (Dawson et al., 2005).  
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The present study reveals that α and γ glycine remains stable over the entire 
range of temperature (300K, 350K, 400K, 450K and 500K) and pressure 
(10kbar, 20kbar, 30kbar and 50kbar) respectively. In contrast the β phase 
transforms to the δ phase at a pressure >10kbar and temperature >400K 
respectively, confirming experimental results. The nanocrystals of the three 
polymorphs of glycine did not show any phase transformation as function 
temperature and remained stable.   
5.2 Methodology 
The molecular dynamics simulations of the three crystalline polymorphs (α, β 
and γ) of glycine (Figure 5.5)  were carried out in the constant stress NST 
ensemble with Parrinello–Rahman boundary conditions using the program 
DLPOLY (Smith et al., 2006) for up to 80ns using a time step of 2 fs. 
Simulations of nanocrystals of glycine molecules as a function of temperature 
were carried out in vacuum in the NVT ensemble. The simulation box 
contained 432 molecules (6×3×6 unit cells) for the α polymorph, 360 
molecules (6×5×6 unit cells) for β polymorph, and 450 (5x5x6 unit cells) for 
the γ polymorph of glycine.  
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Figure 5.5 Glycine molecule showing the atoms labelled according to atom types in 
the forcefield file. 
The force field used to describe glycine molecules comprised intramolecular 
terms (bonds, angles, and dihedrals), a Lennard-Jones term for the 
nonbonded interactions, and a Columbic interaction term. The force field 
parameters along with the atomic partial charges were from the AMBER 
forcefield (Sorin and Pande, 2005).  
Table 5.1 Partial atomic charges employed by glycine 
Atom 
Number 
Atom 
Type 
Charge/e 
1 O -0.7855 
2 O -0.7855 
3 N 0.1592 
4 C1 0.7231 
5 C2 -0.0461 
6 H1 0.1984 
7 H1 0.1984 
8 H1 0.1984 
9 H2 0.1984 
10 H2 0.1984 
 
The atom numbers along with the charges are show in Table 5.1. All bonds 
were constrained using the SHAKE algorithm (Table 5.2).  
Table 5.2Bond constraints employed for glycine 
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Bond type 
Bond 
Constraint 
(Å) 
1-4 1.2500 
2-4 1.2500 
3-5 1.4710 
3-6 1.0100 
3-7 1.0100 
3-8 1.0100 
4-5 1.5220 
5-9 1.0900 
5-10 1.0900 
 
The angle interactions for the atoms in the molecule were represented by a 
harmonic potential, U (θ) =0.5k (θ-θo)
 2 (Table 5.3). The dihedral angles in the 
structure were represented by a cosine form of potential, U (φ) = A [1 + cos 
(mφ − δ)] (Table 5.4).  
Table 5.3 Force field angle parameters employed for glycine 
Angles 
k (kJ mol-1 
degree-2) 
Value of 
angles 
(degree) 
5-3-6 50.00 109.50 
5-3-7 50.00 109.50 
5-3-8 50.00 109.50 
6-3-7 35.00 109.50 
6-3-8 35.00 109.50 
7-3-8 35.00 109.50 
1-4-2 80.00 126.00 
1-4-5 70.00 117.00 
2-4-5 70.00 117.00 
3-5-4 80.00 111.00 
3-5-9 50.00 109.00 
3-5-10 50.00 109.00 
4-5-9 50.00 109.00 
4-5-10 50.00 109.00 
9-5-10 35.00 109.00 
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Table 5.4 Dihedral angle force field parameters employed for glycine 
Dihedrals 
A 
(kcal/mol) 
δ 
(degree) 
m 
(multiplicity) 
9-5-4-1 0.00000 0.00 2.0 
9-5-4-2 0.00000 0.00 2.0 
3-5-4-1 0.00000 0.00 2.0 
3-5-4-2 0.00000 0.00 2.0 
10-5-4-1 0.00000 0.00 2.0 
10-5-4-2 0.00000 0.00 2.0 
8-3-5-9 1.40000 0.00 3.0 
8-3-5-4 1.40000 0.00 3.0 
8-3-5-10 1.40000 0.00 3.0 
7-3-5-9 1.40000 0.00 3.0 
7-3-5-4 1.40000 0.00 3.0 
8-3-5-10 1.40000 0.00 3.0 
7-3-5-9 1.40000 0.00 3.0 
7-3-5-4 1.40000 0.00 3.0 
7-3-5-10 1.40000 0.00 3.0 
6-3-5-9 1.40000 0.00 3.0 
6-3-5-4 1.40000 0.00 3.0 
6-3-5-10 1.40000 0.00 3.0 
 
The van der Waals interaction parameters of the different atoms are shown in 
Table 5.5. For the electrostatic interactions we employed smooth particle-
mesh Ewald with a precision of 1 × 10-5. The van der Waals and real space 
interaction cut offs for glycine bulk crystals was 1.2 nm. For the nanocrystals, 
the van der Waals and electrostatic interactions were both 4.0 nm (i.e. no 
truncation, covering all interactions), Ewald summation being inappropriate 
since we no longer have a periodic system.   
To investigate the effect of temperature on phase transformation between 
different polymorphs of the glycine polymorphs, simulations of three 
polymorphs of glycine in bulk and nanocrystals was carried at a range of 
temperature that included 300K, 350K, 400K, 450K and 500K using ambient 
pressure (0.001 kbar).  
 
133 
 
Table 5.5 Lennard-Jones force field parameters employed for glycine 
Atom-Atom 
Interaction 
 / kJmol-1  / Å 
O - O 0.210 2.959 
N - N 0.170 3.340 
C1-C1 0.086 3.400 
C2-C2 0.109 3.400 
H1- H1 0.016 1.069 
H2- H2 0.016 2.471 
N - O 0.189 3.150 
C1- O 0.134 3.179 
C1- N 0.120 3.370 
C2- O 0.151 3.179 
C2 -N 0.136 3.370 
C2- C1 0.097 3.400 
H1- O 0.057 2.015 
H1- N 0.051 2.205 
H1- C1 0.037 2.234 
H1- C2 0.041 2.234 
H2- O 0.057 2.716 
H2- N 0.051 2.906 
H2- C1 0.036 2.935 
H2-C2 0.041 2.935 
H2-H1 0.016 1.770 
 
In addition to assessing the phase transformation of the three polymorphs of 
glycine (bulk) as a function of pressure, simulations were also carried out a 
range of pressure (10kbar, 20kbar, 30kbar and 50kbar) and ambient 
temperature.  
 
5.3 Results and Discussions 
5.3.1 Test of force field parameters for glycine polymorphs 
The forcefield parameters for glycine were tested to ascertain whether they 
reproduce the crystal structures of three of the polymorphs of glycine, α, β 
and γ. The lattice parameters were averaged after short simulations (200ps) 
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of each of the three polymorphs at 50K and 298K in the constant stress NST 
ensemble. Should the simulated crystal structure diverge considerably from 
the starting experimental structures, then the force field would be considered 
to be inadequate. A sufficient force field should reproduce the lattice 
parameters (and the crystal packing) to better than 5% deviation from the 
experimental values for each of the lattice parameters. The simulations at the 
lower temperature of 50 K were carried out in case there is a phase 
transformation at ambient conditions. The MD simulations were also carried 
out for a short duration (200 ps) to enable the structures to relax to yield an 
equilibrated minimum energy structure but not to enable any phase 
transformation to take place. For all simulations the crystal structures 
underwent minor structural changes over a short period of time and then 
remained converged. The averaged lattice parameters from the MD 
simulations for the three phases at 50K and 298K are given in Table 5.6 
along with the experimental values. The percentage deviation is less than 4% 
for all lattice parameters.  
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This result verifies that the force field is good enough to reproduce the crystal 
structures and hence can be employed with confidence. 
 
Table 5.6 Comparison of averaged lattice parameters from crystal simulations at 
50K and 298K with experiment values at ambient temperature. 
Glycine 
polymorp
h 
Unit 
cell 
vector 
Experimental 
(Å) 
MD at 
50K 
(Å) 
MD at 
298K(Å) 
%Deviation 
50K 298K 
α-glyince 
a 30.63 29.75 30.64 2.87 -0.03 
b 35.97 37.13 37.25 -3.22 -3.55 
c 32.78 32.75 32.75 0.09 0.09 
β-glycine 
a 30.47 30.64 30.64 -0.55 -0.55 
b 30.96 31.86 31.86 2.90 2.90 
c 32.32 31.65 31.65 2.07 2.07 
γ-glycine 
a 35.19 34.04 34.51 3.26 1.93 
b 35.19 34.04 34.51 3.26 1.93 
c 32.89 32.95 33.03 -0.18 -0.42 
 
5.3.2 Characterisation of the Crystal Structure Using Radial 
Distribution Functions 
 
It is very difficult to identify the structure visually using molecular dynamics 
trajectories because the molecules are continuously vibrating. The radial pair 
distribution function (RDF) can be very useful in describing distance 
correlations between a pair of atoms (Leach, 1999). RDF calculations give 
the probability density that a selected atom will be found at a specified 
distance, and is calculated as an average over all selected atoms and over 
all configurations of the MD simulation trajectory, after the system has 
equilibrated.  
Glycine molecule is composed of ten atoms which include 2 x O, 5 x H, 1 x N 
and 2 x C which can result in a range of intermolecular pair interactions to 
describe the specific packing of atoms around each other in each polymorph. 
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We calculated all these interactions using the computer code dl_rdf  
(developed and distributed by J. Anwar, University of Bradford) with a view to 
identifying particular RDFs (for a given pair of atoms) to enable us to 
discriminate between the three polymorphs for glycine. 
RDFs calculations of different atomic pair interactions were carried out at 
300K for α, β and γ glycine. RDFs which categorically discriminate the three 
polymorphs from each other are (O2-O2, O2-H1, C1-H2, H2-H2, and H1-H2) 
(Figures 5.6). Given an unknown structure, one would carry the above 5 
RDFs to interpret the structure, focussing on intensity and distance at which 
the peaks occur.  
For example, RDFs peaks of (H2-H2) were observed at a distance 2.5Å for γ 
and α glycine respectively. For β glycine the first medium peak showing (H2-
H2) interaction was observed at distance 4Å followed by a relatively sharp 
peak at distance 5.3Å. A sharp C1-H2 (4-9) peak became evident for γ 
glycine at a distance 2.3Å followed by a tiny and medium peak for β and α 
glycine respectively. The peaks showing pair interaction C1-H2 (4-10) in α, β 
and γ phases appeared at 2.5Å, 4Å and 3.5Å respectively. The intensity of 
the peak representing β phase is found more intense compared to the other 
two phases.  The H1-H2 pair interaction peaks were observed at distance 3Å, 
4Å, and 5Å for β, α and γ glycine respectively. A sharp peak representing 
O2-O2 pair interaction in γ glycine appeared on 3Å followed by medium and 
tiny peaks of α and β respectively. The peaks representing O2-H1 interaction 
appeared at a distance 2Å for α and γ glycine. There was not observed any 
peak for β glycine at this distance. However two peaks at a distance 3Å and 
4Å were observed for β glycine. 
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Figure 5.6 RDFs of the selected pair interactions in α, β and γ glycine at 300K. 
 
5.3.3 Simulation of Bulk Crystals of Glycine Forms α, β and γ 
as a Function of Temperature 
The trajectories of simulations of the α, β and γ glycine for the entire range of 
temperatures (300K, 350K, 400K, 450K and 500K) were visualised. The α 
and γ glycine remained stable and no phase transformation was observed. 
The packing arrangement of the molecules in both of these phases was 
similar at 300K and 500K (Figure 5.7 and Figure 5.8).  
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Figure 5.7 Configurations of few molecules of α glycine at (a) 300K and (b) 500K 
 
The β glycine however showed a phase transformation above 400K. Figure 
5.9 shows the configurations of β glycine at 300K, 450K and 500K. The 
packing arrangement of nitrogen and oxygen in β glycine at 450K and 500K 
is different from the configuration at 300K. At 300K the oxygen (red) and 
nitrogen (blue) in each line of the crystal lattice point in the same direction. 
However at 450K and 500K one observes that each third molecule in each 
line of the crystal lattice is similar with the same alignment of nitrogen and 
oxygen atoms 
(a
)
(b
)
(a
)
(b
)
(a)
(b)
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Figure 5.8 Configurations of few molecules in γ glycine at (a) 300K and 500K 
This alteration does not exist in the initial configuration of the β glycine. This 
new phase obtained at 450K and 500K was compared to the configurations 
of γ and α glycine. However no similarity was found in the packing 
arrangement of the atoms among all these phases. Consequently we 
investigated whether the new form could be form δ which has been reported 
as a result of high pressure. The crystal structure data for form δ was 
downloaded from the Cambridge Structural Database (CSD, UK) (Allen, 
2002). The lattice parameters for the δ form are; a = 11.156Å, b = 5.8644Å 
and 5.3417Å and the angles are α = 90, β = 125.83 and γ = 90.0 and the 
structure packs in the space group is P21/a. The molecules were packed to 
yield a periodic crystal structure using the software Mercury (version 2.3) 
(CCDC, Cambridge, UK). The new structure obtained from the β form at 
450K and 500K was compared to the δ form and indeed confirmed to be 
more similar the δ form (Figure 5.10). In each layer of the crystal packing of 
the newly transformed phase obtained from β glycine the molecules have the 
(a)
(b)
Glycine Gamma configurations at (a) 10bar and (b) 20bar
(a)
(b)
Glycine Gamma configurations at (a) 10bar and (b) 20bar
(a)
(b)
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same alignment as δ form. The oxygen and nitrogen atoms are packed in the 
same patterns in both polymorphs which confirm the transformation of the β 
polymorph to the δ phase. However the rows in δ phase appear to be shifted 
relative to each other which do not occur in the transformations. This 
deviation suggests that transformation occurs but not to the exact δ phase. 
 
Figure 5.9 Configurations of β glycine at (a) 300K; (b) 450K and (c) 500K. Oxygen 
and nitrogen atoms are shown in red and blue respectively. The hydrogen atoms 
have been removed for clarity. 
(a) (b)
(c)
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Figure 5.10 Configurations of (a) δ glycine; (b) β glycine at 450K; (c) β glycine at 
500K; (d) β glycine at 20kbar and (e) β glycine at 50kbar. (The red sticks show 
oxygen and blue nitrogen atoms. The hydrogen atoms have been removed to clearly 
visualise the structure. 
(a) (b)
(c ) (d)
(e)
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5.3.4 RDFs of Selected Atomic Pairs in α, β and γ Glycine. 
RDFs of the selected atomic pairs including (O2-O2, C1-H2, O2-H1 and H2-
H2) for α and γ glycine calculated at 300K were compared with the the RDFs 
calculated at (350K, 400K, 450K and  500K)  which suggested no phase 
transformation occurred at higher temperature. Figures 5.11 and 5.13 show 
pair interaction peaks of α and γ glycine at 300K and 500K. There is little or 
no change in the location of the selected RDFs at 500K for both of the 
polymorphs (α and γ). The peaks intensity of the RDFs of the selected atomic 
pairs for both of these polymorphs was however bit reduced at higher 
temperature this is because of the expansion of the unit cells which cause 
the atoms to be located at rather large distance from each other. These 
results also verify the visual observation of the trajectories of α and γ at the 
entire range of temperature where we did not see any phase transformation 
(Figures 5.7 and 5.8).  
 
Figure 5.11 RDFs calculation of α, β and γ glycine at 300K and its comparison with 
the RDFs of α glycine calculated at 500K. 
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For β glycine the RDFs of the selected atomic pair interaction which include 
(O2-O2, O2-H1, C1-H2, H2-H2 and H1-H2) at 350K, 400K 450K and 500K 
(Figure 5.12) showed that a phase transformation occurred above 400K. The 
peaks representing the above mentioned pair interactions were found 
different at different distance at 450K and 500K compared to the counterparts 
at 300K. For example, the RDFs for the O2-H1 pair interaction revealed 
peaks at 2Å at 450K and 500K, which did not occur at 300K. Furthermore, 
the sharp peaks of O2-H1 interaction at 3.0Å, 4Å and 6.5Å at 300 K do not 
exist at 450K and 500K. Similarly the H2-H2 interaction peaks at 4Å, 4.5Å 
and 8.5Å are not observed at the higher temperatures. Additionally for the 
H2-H2 interaction a new relatively sharp peak is observed at 2.5Å at 450K 
and 500K. RDFs of other pair interactions also reveal a similar behaviour. 
This structural analysis of the β-phase confirms that the β-glycine is 
transformed to an altogether a new phase other than α and γ at 
temperature >400K, which visually could be confirmed (see earlier discussion) 
as the δ-phase.    
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Figure 5.12 RDFs of α, β and γ glycine at 300K and their comparison with the RDFs 
of the specified pair interactions of β glycine at 500K. 
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Figure 5.13 RDFs of specified atomic pairs interaction of α, β and γ glycine at 300K 
and their comparison with the same RDFs of γ glycine at 500K 
 
5.3.5 Potential Energy for α, β and γ Glycine 
Potential energy calculations for the three polymorphs of glycine were carried 
out at 300K, 350K, 400K, 450K and 500K respectively. The system potential 
energy relies on the packing of molecules or atoms within that structure. The 
three polymorphs of glycine have different potential energies because of the 
different arrangement of molecules within each polymorph. The potential 
energy of the system of a given phase decreases as the system temperature 
goes up. Assuming entropy change to be minimal, the potential energy 
should show a step change on phase transformation to a new phase. Figure 
5.14 shows that the potential energy for α, β and γ polymorphs was 
increased with the increase in temperature. The potential energies for α and 
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γ glycine were remained relatively constant during the entire time period of 
simulation (80ns). On the other hand, for β glycine both at 450K and 500K 
there was observed immediate decrease in the potential energy of a system. 
After 20ns and 50ns there was observed significant fluctuations at 450K and 
the system energy goes down which remained till end of the simulation. 
However at 500K the fluctuations in potential energy of the system became 
evident at 10ns and 30ns which remained decreased till end of the simulation 
(Figure 5.11(b)). In addition the potential energy/molecule calculations 
revealed that α phase is the most stable phase which has low potential 
energy compared to γ and β (Figure 5.15). The potential energies of α and γ 
constantly increased at high temperature. For the β glycine there was 
observed bit decline in the energy at 450K and 500 which we also observed 
in the system energy. To investigate the fluctuation in potential energy of the 
system the trajectories of β glycine were visualised and It became evident 
that at 450K and 500K the alignment of the nitrogen and oxygen atoms in 
molecules of β glycine tend to change in some rows immediately followed by 
a complete rotation of nitrogen and oxygen atoms above 20ns to be 
transformed to delta form and the configuration of the β glycine remained 
same till end of the simulation (80ns) (Figures 5.16 and 5.17).   
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Figure 5.14 Potential energies as a function of time at different temperatures for (a) 
α; (b) β and (c) γ glycine 
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Figure 5.15 Potential energy/molecule of the bulk phases of three polymorphs of 
glycine as a function of temperature 
 
 
Figure 5.16 Snap shots of β-glycine at (a) 0.0ns; (b) 0.40ns; (c) 20.0ns; (d) 55.0ns 
and (e) 80.0ns which show step wise phase transformation. The close view shows 
the alignment of the atoms that begins to change immediately and spreaded 
towards other lines in the lattice. The structures shown in ―d‖ and ―e‖ are similar 
(From simulation at 450K). 
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Figure 5.17 Snap shots of β-glycine at (a) 0.0ns; (b) 0.17ns; (c) 10.0ns; (d) 30.0ns 
and (e) 80.0ns which show step wise phase transformation. The close view shows 
the alignment of the atoms that begins to change immediately and spreaded 
towards other lines in the in the lattice. The structures shown in ―d‖ and ―e‖ are 
similar (From simulation at 500K). 
 
5.3.6 Lattice Parameters of α, β and γ Glycine. 
The variation in lattice parameters i.e. cell dimensions and angles and cell 
volume was examined as a function of temperature for the three polymorphs, 
α, β and γ. The data is shown in Tables 5.7 and plotted in Figures 5.8  
There was not observed any significant increase in the cell axis of unit cell of 
α glycine at the specified range of temperature. Additionally, the cell angles 
for α glycine also remained unchanged at higher temperature. There was 
observed an increase in the unit cell volume of α glycine at temperature > 
300K which is because of thermal motion of molecules (Table 5.7).   
(a) (b)
(c)
(e)(d)
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Table 5.7 Comparison of experimental and calculated lattice parameters of α 
glycine at different temperature which were averaged over the molecular dynamics 
simulation trajectory. 
Temperature 
(K) 
Unit cell vector (Å), angles (α, β, γ (degree)) and volume 
(Å)3 
a b c α β γ 
Volume 
(Å)3 
300K 5.02 12.41 5.47 90.0 118.00 90.0 310.00 
350K 5.04 12.45 5.46 90.0 118.00 90.0 312.00 
400K 5.05 12.47 5.47 90.0 118.00 90.0 313.00 
450K 5.06 12.50 5.48 90.0 118.00 90.0 315.00 
500K 5.09 12.53 5.49 90.0 118.00 90.0 317.00 
Experimental 5.10 11.97 5.46 90.0 111.74 90.0 310.13 
 
 
Figure 5.18 Unit cell parameters of α glycine as a function of temperature 
 
For β glycine the cell axis (b and c) were increased at 400K, 450K and 500K 
(Table 5.8 and Figure 5.19). There was also observed an increase in β angle 
of unit cell of β glycine.  The unit cell volume of β glycine increased at 350K 
and 400K but this phase did not remain stable at temperature >400K and the 
unit cell volume decreased with consequent new more stabilised phase (δ 
form) (Table 5.8).   
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Table 5.8 Comparison of experimental and calculated lattice parameters of β 
glycine at different temperature which were averaged over the molecular dynamics 
simulation trajectory. 
Temperature (K) 
Unit cell vector (Å), angles (α, β, γ (degree)) and 
volume (Å)3 
a b c α β γ 
Volume 
(Å)3 
300K 5.11 6.52 5.28 90.0 115.00 90.0 159.00 
350K 5.11 6.52 5.29 90.0 115.00 90.0 160.00 
400K 5.11 6.67 5.35 90.0 115.00 90.0 164.00 
450K 5.11 6.64 5.46 90.0 116.00 90.0 157.00 
500K 5.12 6.68 5.46 90.0 116.00 90.0 158.00 
Experimental 5.07 6.19 5.38 90.0 113.35 90.0 155.54 
 
 
Figure 5.19 Unit cell parameters of β glycine as a function of temperature 
 
On the other hand there was not observed any expansion in the cell axis (a, 
b and c) for γ glycine at higher temperature (Table5.9 and Figure 5.20). 
Whilst the cell angles remained unchanged (Table 5.12). Also there was 
observed expansion in unit cell volume of γ glycine at increased temperature 
(Table 5.11).  The cell parameters calculation for the three polymorphs at the 
specified range of temperature suggests that α and γ polymorphs remained 
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stable and did not transform to any other polymorph at higher temperature. 
However the β glcycine is transformed to a new polymorph when the 
temperature is increased >400K which has also been confirmed by RDFs 
and visual observation. 
Table 5.9 Comparison of experimental and calculated lattice parameters of γ  
glycine at different temperature which were averaged over the molecular dynamics 
simulation trajectory. 
 
Temperature (K) 
Unit cell vector (Å), angles (α, β, γ (degree)) and 
volume (Å)3 
a b c α β γ 
Volume 
(Å)3 
300K 6.90 6.90 5.50 90.0 90.0 120.0 227.00 
350K 6.91 6.92 5.50 90.0 90.0 120.0 229.00 
400K 6.94 6.94 5.50 90.0 90.0 120.0 230.00 
450K 6.97 6.97 5.50 90.0 90.0 120.0 232.00 
500K 6.98 6.98 5.50 90.0 90.0 120.0 234.00 
Experimental 7.03 7.03 5.48 90.0 90.0 120.0 235.12 
 
 
Figure 5.20 Cell parameters of γ glycine as a function of temperature 
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5.3.7 Simulation of Nanocrystals of α, β and γ Glycine as a 
Function of Temperature 
Selected snapshots of the nanocrystals for each of the forms are given in 
Figure 5.21. It was observed from visualisation of trajectories of the 
nanocrystal form of α, β and γ glycine that all the three phases retained their 
polymorphic forms over the entire range of temperature studied (300K-500K). 
However it was found that the crystals tend to lose their shapes and the 
edges of the crystals are deformed and become curved. As the temperature 
was increased the edges of the crystals became more curved and at 500K 
the crystals adopt the shape of a sphere. The reason for deformation the 
edges of a crystal at high temperature is because the system attempts to 
reduce the surface free energy to adopt the shape with lowest surface to 
volume ratio i.e. a sphere which is considered thermodynamically more 
stable because of the low surface free energy. The β phase of glycine was 
found more spherical with round edges compared to the α and γ phases.  
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Figure 5.21 Configurations of glycine (a) α  glycine at 300K; (b) α glycine at 500K; 
(c) β glycine at 300K ; (d) β glycine at 500K; (e) γ glycine at 300K ; (f) γ glycine at 
500K 
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Glycine Alpha Nano configurations at (a) 300K  and (b) 500K
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Glycine Beta Nano configuration at (a) 300K  and (b) 500K
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5.3.8 RDFs and Potential Energy Calculations for 
Nanocrystals of α, β and γ Glycine.  
RDFs calculations of the selected atomic pairs including (H2-H2, O2-N, O2-
H1 and O1-O1) of nanocrystals of three of the polymorphs of glycine (α, β 
and γ) showed that all the three phases were stable at the entire range of 
temperature (300K, 350K, 400K, 450K and 500K). These RDFs of the three 
polymorphs of glycine calculated at 300K, 350K, 400K, 450K and 500K were 
compared to look at the phase transition. No change in these RDFs was 
however observed for all the three polymorphs. RDFs of the pair interactions 
at 300K and 500K are shown in (Figures 5.22, 5.23 and 5.24) and there was 
not observed any change in the distance of the peaks at higher temperature. 
These results suggest that all the three polymorphs in nanocrystals phase 
remained stable at higher temperature. Similarly, the potential energies at 
300K, 350K, 400K, 450K and 500K as a function of time increased with the 
temperature but remained equilibrated during the entire simulation time (80ns) 
which suggest no phase transformation occurred at the selected range of 
temperature (Figure 5.12). Figure 5.26 shows the potential energy/molecule 
of nanocrystal form of three of the polymorphs. It was observed that the β 
phase which we found the least stable in bulk form and transformed to δ 
phase becomes stable in nanocrystal form. This is possibly because of the 
surface free energy which may favour this particular phase. However there 
was not observed any step change in the energy showing phase 
transformation. There has been reported that the surface free energy 
become important when the particle size is reduced and the phase which is 
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unstable in bulk could be stable in nanocrystal phase (Zahn and Anwar, 
2011). 
 
 
Figure 5.22 RDFs of selected pair interaction of α, β and γ glycine (300K) and their 
comparison with the RDFs for α glycine calculated at 500K 
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Figure 5.23 RDFs calculation of α, β and γ glycine (300K) and their comparison with 
the RDFs for β glycine calculated at 500K. 
 
 
 
 
 
 
 
 
 
 
 
 
0
10
20
30
40
50
60
70
0 10 20 30 40 50
g 
(r
)
r (Angstrom)
α(10,10)
β(10,10)
γ(10,10)
β500(10,10)
O1-O1
0
50
100
150
200
250
300
350
0 10 20 30 40 50
g
 (
r)
r (Angstrom)
α(2,3)
β(2,3)
γ(2,3)
β500(2,3)
O2 -N
0
10
20
30
40
50
60
70
80
0 10 20 30 40 50
g
 (
r)
r (Angstrom)
α(1,1)
β(1,1)
γ(1,1)
β500(1,1)
H2 –H2
0
20
40
60
80
100
120
140
0 10 20 30 40 50
g
 (
r)
r (Angstrom)
α(2,8)
β(2,8)
γ(2,8)
β500(2,8)
O2 –H1
158 
 
 
 
Figure 5.24 RDFs calculation of α, β and γ glycine (300K) and their comparison with 
the RDFs for γ glycine calculated at 500K. 
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Figure 5.25 Potential energy of (a) α glycine; (b) β glycine; and (d) γ glycine as a 
function of time at different temperature 
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Figure 5.26 Potential energy/molecule of nanocrystal forms of three polymorphs of 
glycine as a function of temperature. 
 
5.3.9 Simulation of Bulk Phases of Glycine (α, β and γ) as a 
Function of Pressure. 
The trajectories of α, β and γ glycine at elevated pressures were visualised 
for the entire range of pressure (10kbar, 20kbar, 30kbar and 50kbar). The α 
and γ phases showed little or no change in the packing arrangement of 
molecules at high pressures investigated. The crystal lattice of α glycine was 
little distorted at 50 kbar (Figure 5.27), whilst γ glycine showed no distortion 
(Figure 5.28). In contrast, the β phase showed a phase transformation at 
20kbar. Figure 5.29 shows snapshots from the trajectories of β phase at 10 
kbar and 20 kbar. These clearly show the different alignment of nitrogen and 
oxygen. Every third molecule in each line from left to right in the configuration 
of β phase obtained at 20kbar has the same alignment/conformation, 
whereas no such arrangement was observed in the configuration obtained at 
10Kbar. Closer examination of the new phase revealed that the structure is 
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β-δ has transformation also been reported at 19kbar (Dawson et al., 2005). 
There was not observed any difference in the structures obtained at 20kbar 
and 50kbar (Figure 5.7).  
 
 
Figure 5.27 Configurations of few molecules in crystal packing of α glycine at (a) 
10kbar; (b) 20kbar and (c) 50kbar. (The nitrogen and oxygen atoms are shown in 
red and dark blue respectively, whereas the hydrogen atoms have been removed to 
clearly see the phase transformation 
(a)
(b)
(c)
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Figure 5.28 Configurations of few molecules in crystal packing of γ glycine at (a) 
10kbar; (b) 20kbar and (c) 50kbar 
 
 
Figure 5.29 Configurations of β glycine at (a) 10kbar and 20kbar. The red and blue 
sticks show oxygen and nitrogen atoms respectively whereas the hydrogen atoms 
have been removed to visualise clearly the phase transformation. 
(b)
(a)
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5.3.10  RDFs of the Selected Atomic Pairs in α, β and γ  
      Glycine  
 
RDFs of the atomic pairs including (C1-H2, O2-H1, O2-O2, H2-H2 and O1-
H1) which discriminate the three polymorphs from each other were 
determined for equilibrium configurations at 10kbar, 20kbar, 30kbar and 
50kbar. These RDFs were compared with the RDFs calculated for three of 
the polymorphs (α, β and γ) at ambient conditions (300K and .001katm). For 
α and γ glycine, the RDFs (show in Figures 5.30 and 5.31 respectively) 
remained unchanged at high pressure, confirming the visual analysis that no 
phase transformation occurred at the pressures investigated for these 
phases.  
 
Figure 5.30 RDFs calculation of the specified pair interactions for α, β and γ glycine 
at ambient conditions and their comparison with the α glycine at high pressure. (10, 
20 and 50 show the employed pressure) 
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All the pair interactions peaks for α and γ glycine appeared on the same 
distance at high pressure. The peaks intensity for the α glycine at 50kbar was 
however bit reduced which could be probably caused by the small distortion 
of the crystal structure (Figure 5.27). It has also been observed 
experimentally that a very high pressure is required for phase transformation 
of these two polymorphs (Dawson et al., 2005).  
 
Figure 5.31 RDFs calculation of the specified pair interactions for α, β and γ glycine 
at ambient conditions and their comparison with the γ glycine at high pressure.( 
10,20 and 50 show the employed pressure) 
For β glycine, however, the RDFs of pair interactions H2-H2, C1-H2, O1-H1 
and O2-H1, which clearly discriminate the three polymorphs from each other 
were found to different at 20 kbar compared with β polymorph at ambient 
pressure and at 10 kbar (Figure 5.32). This suggests that β polymorph has 
been transformed to a new polymorph at a pressure (> 10Kbar). For β 
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glycine, the peaks intensity of the RDFs for specified atomic pairs interaction 
were increased (Fig 5.33) at 50 kbar, which could be probably caused by the 
compression of the lattice with subsequent increase of the specified atoms 
around each other. In addition at high pressure the density of atoms around 
each other increases because of the less freedom for molecules to vibrate.  
 
Figure 5.32 RDFs calculation of the specified pair interactions for α, β and γ glycine 
at ambient conditions and their comparison with the β glycine at high pressure.(10 
and 20 are the employed pressure) 
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Figure 5.33 Comparison of the RDFs of the specified pair interactions for β glycine 
calculated at 20kbar and 50kbar 
 
5.3.11  Lattice Parameters   
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pressure because the atomic pair interactions remained the the same as 
calculated at 10kbar (Figures 5.30 and 5.31). The structure of α glycine 
seems bit distorted at high pressure (Figure 5.27) and there was also 
observed much variations in cell angles at 30kbar and 50kbar (Table 5.10). 
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The unit cell angles of γ did not change at higher pressure (Table 5.10).  For 
β glycine the axis ―a‖ and ―b‖ were reduced as a results of pressure > 10kbar 
whereas the ―c‖ axis was increased (Table 5.10 and Figure 5.34 (b)).  The β 
angle of unit cell of β polymorph increased at 20kbar, 30kbar and 50kbar 
respectively. The other two angles including α and γ remained unchanged at 
a pressure range (10kbar – 50kbar). These variations in lattice parameters at 
high pressure for β polymorphs justify the phase transformation in this 
particular polymorph which has been confirmed both visually and by RDFs 
calculations of the specified atomic pair interactions. 
 
Table 5.10 Comparison of the lattice parameters of glycine (α, β and γ) at different 
pressure which were averaged over the molecular dynamics simulation trajectory.  
Polymorphs Pressure 
(kbar) 
Unit cell vector (Å), angles (α, β, γ (degrees)) 
and volume (Å)3 
a b c α β γ 
volume 
(Å)3 
α-Glycine 
10 5.01 12.47 5.12 90.0 110.0 90.0 300.00 
20 4.99 12.18 5.02 90.0 110.0 90.0 292.00 
30 4.97 11.65 5.15 92.6 109.0 84.3 282.00 
50 4.92 11.49 5.13 92.7 110.0 83.9 272.00 
β-Glycine 
10 5.28 6.37 5.20 90.0 110.0 90.0 153.00 
20 4.94 6.12 5.43 90.0 110.0 90.0 147.00 
30 4.93 6.00 5.41 90.0 109.0 84.3 144.00 
50 4.92 5.85 5.34 90.0 110.0 83.9 138.00 
γ-Glycine 
10 6.80 6.81 5.48 90.0 90.0 120.0 221.00 
20 6.75 6.78 5.45 90.0 90.0 120.0 216.00 
30 6.70 6.70 5.44 90.0 90.0 120.0 212.00 
50 6.62 6.62 5.40 90.0 90.0 120.0 206.00 
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Figure 5.34 Unit cell parameters of (a) α; (b) β and (c) γ glycine as a function of 
pressure 
 
In conclusion the forcefield parameters for glycine were found to be good 
enough to reproduce the crystal structures of the various crystalline forms of 
glycine.  The molecular dynamics simulations were able to reproduce the 
stability of the α and β forms as function of temperature and pressure over 
the range (300K-500K) and (10kbar-50kbar). Further, the simulations were 
also were able to reproduce the phase transformation of the β pahse to the δ 
phase at high temperatures and pressure, being entirely consistent with 
experiment. The observed delta phase that occurs after the transformation of 
the beta phase, however, does not have the exact structure of delta phase 
but shows a slight variation. 
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The bulk and nanocrystals forms of different polymorphs of a crystal can 
behave differently at high pressure and temperature. In the case of glycine 
we observed that stability order for bulk crystals of the three polymorphs is  
α > γ > β. In contrast for the nanocrystal forms however the stability ranking 
was changed to β > α > γ. At high temperature and pressure there was 
observed little expansion and reduction respectively in unit cells of α and γ 
forms of bulk crystal of glycine. However the arrangement of atoms in the 
crystal packing remained unchanged. Visual observation, potential energy 
and RDFs calculation confirmed β – δ phase transformation at high 
temperature and pressure. This study illustrates the power of molecular 
dynamics simulations to investigate phase transformation in crystals, even 
particularly challenging system that contains hydrogen-bonding networks.   
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Chapter 6  
 
Concluding Remarks and Future 
Perspective 
 
Greater than 40% of drugs derived through high-throughput screening 
demonstrate low aqueous solubility. Amongst the range of formulation 
approaches employed to address this key issue, crystalline nanocrystals and 
nanosuspensions are rapidly becoming a platform solution, although several 
challenges including stabilisation and control of particle size distribution for 
nanosuspensions and scale up issues still need to be addressed. 
Nanocrystals are rapidly becoming a platform technology due to the immense 
surface area that they present. Methods for nanocrystal production can be 
categorized as top down or bottom-up and include milling, high pressure 
homogenisation, and precipitation. Each of these methods can have specific 
issues which may include high energy input, long processing times and 
uncontrolled particle growth. The intention of this study was to revisit the 
simplest approach of re-precipitation and to identify the critical parameters, 
including the effect of different stabilisers as well as process conditions. We 
utilised a combined approach of both experiments and molecular modelling 
and simulation, not only to determine the optimum parameters but also to 
gain mechanistic insight.  
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The uptake of the bottom-up re-precipitation approach to producing 
nanocrystals appears to be limited. From a technical perspective a perceived 
limitation of the approach is that the method is not applicable to a wide range 
of molecules. We have carried a systematic study on three distinct molecules, 
ibuprofen, glibenclamide and artemsinin, and have shown that stable 
nanocrystals with uniform size can be prepared in for all three drugs using 
simple anti-solvent precipitation. The technical challenge appears to be the 
identification of appropriate stabilizers, which depend on the choice of drug 
molecule. Also investigated were the effects of the process variables, 
temperature, stirring rate, and infusion rate. Each of these variables is 
considered to affect the local supersaturation attained during the anti-solvent 
precipitation process. Indeed the local supersaturation has been observed to 
be an important factor in determining the nanocrystal particle size, with 
higher local supersaturations yielding smaller nanocrystals. We attempted to 
rationalise the choice of optimum stabilizers in terms of molecular 
interactions between crystal surfaces and the stabilizer molecules but were 
unable to make headway. Overall, this comprehensive study demonstrates 
that conventional crystallisation technology represents an effective approach 
for preparing nanocrystals in the range 200400 nm. 
Recovery of nanocrystals in the solid form from nanosuspensions is also a 
technical challenge. The goal is to recover the nanocrystals in the dry form 
which when incorporated in a solid dosage form can yield the near original 
nanocrystal characteristics e.g. dissolution rate. We have developed a 
method described in Chapter 3 that utilises large single crystals of di-calcium 
phosphate (DCP) as carrier particles for adsorbing nanocrystals from 
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nanosuspension. This study demonstrated that drug nanocrystals produced 
by both size reduction and crystallisation can be efficiently isolated on a solid 
support material (DCP). Both comminuted and crystallised glibenclamide 
showed an affinity for DCP, whereas nanocrystals produced by comminution 
showed greater affinity for the carrier, probably owing to greater surface 
energy induced by mechanical activation. Molecular modelling linked to 
experimental data indicated that polar functional groups with tendencies to 
form hydrogen bonds were responsible for adsorption on to the carrier 
particle surfaces. Adsorbed nanoparticles showed marked improvements in 
dissolution rate compared to original API, micronised suspensions, and 
marketed products. Differences in dissolution rate for the adsorbed 
nanoparticles obtained by two different approaches (milled and crystallized) 
were negligible. The carrier particles with the adsorbed nanocrystals can 
potentially be transformed to other solid dosage forms including tablets, 
capsules and pellets. 
Whilst the technology of nanocrystal production is advancing at a rapid pace, 
we still do not understand the mechanisms that determine the particle size 
and stability in bottom up processes such a precipitation. There are a range 
of bottom up methods which have been mentioned in Section 1.3.1 that 
produce nanocrystal by precipitation of the drug molecules from mixing of the 
solvent anti solvent. Crystallisation of the drug molecules occurs by 
nucleation which is the key step to controlling the particle size distribution 
and size of the crystal. It is therefore imperative to understand this early 
stage of antisolvent crystallisation. As this process takes place at atomistic 
level which is difficult to be visualised using experimental approaches 
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(Schüth et al., 2001). Computer simulation approaches such as Monte Carlo 
and molecular dynamics simulations have been used to investigate this 
process but are limited by the random nature of the nucleation process. In 
view of this the earliest stages of the anti-solvent precipitation process were 
explored by means of coarse grained molecular dynamics simulation, rather 
than atomistic simulations which require large cpu resource for an extended 
period. These coarse grained simulations reveal that the water molecules do 
not infiltrate the solvent phase containing the drug to any significant extent 
and therefore do not initiate the aggregation of the solute particles as might 
be expected. At a molecular level this would mean initial infiltration of water 
into the solute solution (unlikely given that water has little affinity for the 
solute particles) and then evacuation of the water as the solute aggregates, 
which would not be efficient. Instead the simulations reveal that the solvent 
molecules move towards the water leaving the solute molecules to aggregate 
which is then followed by nucleation. An important issue is whether the 
volume element created by the mixing process determines the final size of 
the nanocrystal. Given that the local supersaturation is an important factor, 
we argue that spinodal decomposition causes the individual volume elements 
to phase separate into individual clusters yielding nanocrystals of a size 
smaller than that of the volume element. This would explain why nanocrystals 
can arise from simple mixing processes. 
We then proceeded to investigate the phase stability of nanocrystals. More 
than 90% of the APIs in different pharmaceutical dosage forms are in the 
solid form. This solid might be amorphous or crystalline. The crystalline forms 
of API can exist in a number of polymorphic forms which have different 
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physicochemical characteristics resulting in different dissolution rate and 
bioavailability (Singhal and Curatolo, 2004) .  Therefore, it is important to 
select an appropriate polymorph for a specific dosage form which yields the 
desired dissolution rate and bioavailability. An important issue is phase 
stability and the possibility of phase transformation. For example the failure of 
ritonavir in dissolution tests happened because of a transformation to a new 
polymorph which has a low solubility (Bauer et al., 2001).  Phase stability is 
an important issue also for nanocrystals, for which the stable phase may be 
different from that in the bulk phase, hence offering new opportunities, both 
technical and commercial.  In view of this the aim of the study detailed in 
Chapter 5 was to investigate the phase stability and thermodynamics of both 
bulk crystals and their nanocrystal counterparts. For this study we 
investigated crystalline forms of glycine as a model as they are well 
characterised.  The simulations of the crystalline forms were performed as a 
function of temperature and pressure on bulk and nanocrystals of three 
phases (α, β and γ) of glycine. This study showed that α and γ phases 
remained stable at the entire range of temperature (300K, 350K, 400K, 450K 
and 500K) and pressure (10 lbar, 20 kbar, 30 kbar and 50 kbar). With respect 
to the β phase, the simulations as a function of evaluated temperature and 
increased pressure produced a new phase (δ form) which has also been 
reported experimentally (Dawson et al., 2005).  The packing and 
arrangements of molecules in the new phase obtained from simulation of β 
glycine as a function of temperature and pressure were found similar to the 
published δ phase. Additionally, at elevated temperature and pressure the 
potential energy and RDFs calculations of the specified atomic pairs which 
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categorically discriminate the three polymorphs from each other confirmed 
the transformation of β phase to new phase (δ). The simulation of the 
nanocrystals of the three phases of glycine as a function of temperature 
showed that all the phases remained stable at the entire range of 
temperature (300K, 350K, 400K, 450K and 500K). Whereas at this 
temperature range and increased pressure the β polymorph in bulk phase 
showed transformation to δ phase above 400K and 10Kbar respectively. This 
suggested that the crystals behave differently when the particle size is 
reduced because of the surface free energy. This study reveals that crystal-
crystal phase transformations can be predicted for hydrogen-bonded systems. 
Mechanisms of transformation using molecular simulations could prove to be 
useful in devising strategies for controlling crystal-crystal phase 
transformations. 
In summary the studies comprising the thesis reveal that stable nanocrystals 
in ideal pharmaceutical range < 500nm of hydrophobic API molecules can be 
produced by simple controlled crystallisation method. The selection of 
suitable stabilisers (polymers and surfactants) and process conditions are 
critical for producing stable nanocrystals on large scale. This study also 
presented a novel idea for recovering nanocrystals from nanosuspensions 
using large crystal of pharmaceutically acceptable career particles. This 
method is more economical and efficient compared to other methods which 
have been employed to dry nanosuspensions and include spray drying, 
freeze drying and spray granulation. The recovery of drug nanocrystal from 
suspension using inert support materials can be affected both by morphology 
of drug/carrier and methods producing drug nanocrystals.  
176 
 
The coarse grained simulation studies provided molecular insight into the 
mechanism of formation of nanocrystals by simple mixing process which 
determines that the size of the nanocrystal is smaller than the phase 
separation of the volume elements caused by spinodal decomposition.  
Molecular simulation studies also showed that phase stability of nanocrystals 
depends on crystal size and at nanoscale because of the different 
thermodynamics attributes and the phase becomes stable which was 
unstable at bulk form. This study can be employed to predict the issue of 
polymorphism in hydrogen bonded systems.  
6.1 Future Perspectives 
The key issues associated with nanocrystals produced by bottom up method 
which still require mechanistic understanding include stability, process scale 
up, the early stages of nanocrystal formation, and in vivo studies. The simple 
method of crystallisation that we developed for producing drug nanocrystals 
would need to be scaled up to test for reproducing drug nanocrystals at large 
scale. It is still a challenge to understand the early stages of nanocrystal 
formation in polymeric liquor and how the polymers/surfactants inhibit the 
crystal growth to rationalising the suitable stabilisers. Further coarse grained 
simulations could be employed to address this issue. For example the 
mechanism of crystal growth inhibition by the polymers could be modelled by 
introducing a large crystal in a solution which contains drug and polymer 
particles.   As there are many studies of preparation of nanocrystals using a 
variety of methods and how well they perform in in-vitro dissolution tests, 
there are very few studies investigating the bioavailability of nanocrystals in-
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vivo. Clearly in-vivo studies of the prepared nanocrystals and marketed 
formulations to compare their bioavailability are required.   
Solid dosage forms are considered the most attractive, acceptable and 
widely used among all other dosage forms. Solid dosage forms including 
tablets and capsules which contain drug nanocrystal can be prepared from 
the isolated nanocrystals on carrier particles with subsequent solid state 
characterisation and in-vivo studies. Further to the effect of process and drug 
surfaces on isolation of nanocrystal from solution, the impact of size of carrier 
particle needs also to be investigated for recovery of nanocrystals. 
Phase stability in nanocrystals is also a key challenge. Molecular simulation 
can be employed to carry out free energy calculations as a function of 
particle size to see how the phase diagram changes in going from bulk 
crystals to nanocrystals. The stability of a phase depends on competition 
between bulk and free energies. It is therefore important to determine that at 
what scale the surface free energy becomes significant to give favour to the 
particular phase. Free energy calculations investigating the size dependent 
phase stability of inorganic nanocrystals including TiO2, ZrO2 and Al2O3 
(Ranade et al., 2002) illustrate what is required. . 
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